
<html lang="en"     class="pb-page"  data-request-id="48734ed5-fd9b-4f24-bc59-a23b82985ec5"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;wgroup:string:ACHS website Group;website:website:acspubs;pageGroup:string:Publication Pages;article:article:10.1021/acs.jmedchem.9b02008;subPage:string:Full Text;issue:issue:10.1021/jmcmar.2020.63.issue-11"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="citation_journal_title" content="Journal of Medicinal Chemistry" /></meta><meta name="dc.Title" content="Design and Synthesis of a Trifunctional Molecular System “Programmed” to Block Epidermal Growth Factor Receptor Tyrosine Kinase, Induce High Levels of DNA Damage, and Inhibit the DNA Repair Enzyme (Poly(ADP-ribose) Polymerase) in Prostate Cancer Cells" /></meta><meta name="dc.Creator" content="Julie  Schmitt" /></meta><meta name="dc.Creator" content="Shanlong  Huang" /></meta><meta name="dc.Creator" content="Elliot  Goodfellow" /></meta><meta name="dc.Creator" content="Christopher  Williams" /></meta><meta name="dc.Creator" content="Bertrand J.  Jean-Claude" /></meta><meta name="dc.Description" content="Resistance to chemotherapy in advanced cancers can be mediated by different factors such as epidermal growth factor receptor (EGFR) overexpression and DNA repair enzymes. Therefore, current standar..." /></meta><meta name="Description" content="Resistance to chemotherapy in advanced cancers can be mediated by different factors such as epidermal growth factor receptor (EGFR) overexpression and DNA repair enzymes. Therefore, current standar..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="June 2, 2020" /></meta><meta name="dc.Type" content="research-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.9b02008" /></meta><meta name="dc.Language" content="en" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="Copyright © 2020 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.9b02008" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.9b02008" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.9b02008" /></link>
        
    
    

<title>Design and Synthesis of a Trifunctional Molecular System “Programmed” to Block Epidermal Growth Factor Receptor Tyrosine Kinase, Induce High Levels of DNA Damage, and Inhibit the DNA Repair Enzyme (Poly(ADP-ribose) Polymerase) in Prostate Cancer Cells | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.9b02008" /></meta><meta property="og:title" content="Design and Synthesis of a Trifunctional Molecular System “Programmed” to Block Epidermal Growth Factor Receptor Tyrosine Kinase, Induce High Levels of DNA Damage, and Inhibit the DNA Repair Enzyme (Poly(ADP-ribose) Polymerase) in Prostate Cancer Cells" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b02008/20200604/images/large/jm9b02008_0012.jpeg" /></meta><meta property="og:description" content="Resistance to chemotherapy in advanced cancers can be mediated by different factors such as epidermal growth factor receptor (EGFR) overexpression and DNA repair enzymes. Therefore, current standards of care usually involve combinations of multiple treatments. Here, to reduce the adverse effects of multiple drug combinations and improve outcome, we proposed a single drug approach to block multiple overlapping effects that characterize chemoresistance. Thus, we designed a new linker that allows assembly of multiple functions (e.g., inhibition of EGFR phosphorylation, induction of DNA lesions, and blockade of their repair) into a single molecule. This led to the successful synthesis of a novel and potent combi-molecule JS230. Here, we demonstrated that in resistant prostate cancer cells overexpressing EGFR, it was capable of (a) inhibiting EGFR in a dose-dependent manner, (b) damaging DNA, and (c) sustaining the damage by inhibiting the DNA repair protein poly(ADP-ribose) polymerase (PARP). The triple mechanism of action of JS230 cumulated into growth inhibitory potency superior to that of classical two- or three-drug combinations." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.9b02008"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.9b02008">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-14/achre4.2021.54.issue-14/20210720/achre4.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-29/aamick.2021.13.issue-29/20210728/aamick.2021.13.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-14/acncdm.2021.12.issue-14/20210721/acncdm.2021.12.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-7/amlcef.2021.3.issue-7/20210705/amlcef.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-29/acsodf.2021.6.issue-29/20210727/acsodf.2021.6.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-29/ascecg.2021.9.issue-29/20210726/ascecg.2021.9.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-29/ancham.2021.93.issue-29/20210727/ancham.2021.93.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-29/bichaw.2021.60.issue-29/20210727/bichaw.2021.60.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-27/cgeabj.2021.99.issue-27/20210726-01/cgeabj.2021.99.issue-27.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-7/cgdefu.2021.21.issue-7/20210707/cgdefu.2021.21.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-14/esthag.2021.55.issue-14/20210720/esthag.2021.55.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-29/iecred.2021.60.issue-29/20210728/iecred.2021.60.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-14/inocaj.2021.60.issue-14/20210719/inocaj.2021.60.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-29/jafcau.2021.69.issue-29/20210728/jafcau.2021.69.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-29/jacsat.2021.143.issue-29/20210728/jacsat.2021.143.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-7/jamsef.2021.32.issue-7/20210707/jamsef.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-29/langd5.2021.37.issue-29/20210727/langd5.2021.37.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-7/mpohbp.2021.18.issue-7/20210705/mpohbp.2021.18.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.9b02008&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.9b02008&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.9b02008&amp;href=/doi/10.1021/acs.jmedchem.9b02008" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2020</span><span class="cit-fg-volume">, 63</span><span class="cit-fg-issue">, 11</span><span class="cit-fg-pageRange">, 5752-5762</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/63/11" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/acs.jmedchem.9b02016" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Article</span><a href="/doi/10.1021/acs.jmedchem.9b02100" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Design and Synthesis of a Trifunctional Molecular System “Programmed” to Block Epidermal Growth Factor Receptor Tyrosine Kinase, Induce High Levels of DNA Damage, and Inhibit the DNA Repair Enzyme (Poly(ADP-ribose) Polymerase) in Prostate Cancer Cells</span></h1><ul class="loa"><li><span><span class="hlFld-ContribAuthor">Julie Schmitt</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Julie Schmitt</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Cancer Drug Research Laboratory, Department of Medicine, The Research Institute of the McGill University Health Center/Glen Hospital, Montreal, QC H4A 3J1, Canada</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Julie++Schmitt">Julie Schmitt</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-1990-1429" title="Orcid link">http://orcid.org/0000-0002-1990-1429</a></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Shanlong Huang</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Shanlong Huang</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Cancer Drug Research Laboratory, Department of Medicine, The Research Institute of the McGill University Health Center/Glen Hospital, Montreal, QC H4A 3J1, Canada</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Shanlong++Huang">Shanlong Huang</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Elliot Goodfellow</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Elliot Goodfellow</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Cancer Drug Research Laboratory, Department of Medicine, The Research Institute of the McGill University Health Center/Glen Hospital, Montreal, QC H4A 3J1, Canada</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Elliot++Goodfellow">Elliot Goodfellow</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Christopher Williams</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Christopher Williams</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Scientific Support, Chemical Computing Group Inc., Montreal, QC H3A 2R7, Canada</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Christopher++Williams">Christopher Williams</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0001-5428-2742" title="Orcid link">http://orcid.org/0000-0001-5428-2742</a></div></div></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor">Bertrand J. Jean-Claude</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Bertrand J. Jean-Claude</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Cancer Drug Research Laboratory, Department of Medicine, The Research Institute of the McGill University Health Center/Glen Hospital, Montreal, QC H4A 3J1, Canada</div></div><span class="conrtib-corresp"><strong>*</strong>E-mail: <a href="/cdn-cgi/l/email-protection#1e7c7b6c6a6c7f707a7430547b7f70337d727f6b7a7b5e737d79777272307d7f"><span class="__cf_email__" data-cfemail="a9cbccdbdddbc8c7cdc387e3ccc8c784cac5c8dccdcce9c4cacec0c5c587cac8">[email protected]</span></a></span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Bertrand+J.++Jean-Claude">Bertrand J. Jean-Claude</a></span></div></div></span></li><span class="comma-separator"></span></ul><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.9b02008&amp;href=/doi/10.1021%2Facs.jmedchem.9b02008" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2020</span></span><span class="cit-volume">, 63</span><span class="cit-issue">, 11</span><span class="cit-pageRange">, 5752–5762</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">June 2, 2020</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>6 December 2019</li><li><span class="item_label"><b>Published</b> online</span>2 June 2020</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 11 June 2020</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.9b02008" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.9b02008</a></div><div class="article_header-article-copyright"><strong>Copyright © 2020 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D5752%26pageCount%3D11%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DJulie%2BSchmitt%252C%2BShanlong%2BHuang%252C%2BElliot%2BGoodfellow%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D63%26issueNum%3D11%26contentID%3Dacs.jmedchem.9b02008%26title%3DDesign%2Band%2BSynthesis%2Bof%2Ba%2BTrifunctional%2BMolecular%2BSystem%2B%25E2%2580%259CProgrammed%25E2%2580%259D%2Bto%2BBlock%2BEpidermal%2BGrowth%2BFactor%2BReceptor%2BTyrosine%2BKinase%252C%2BInduce%2BHigh%2BLevels%2Bof%2BDNA%2BDamage%252C%2Band%2BInhibit%2Bthe%2BDNA%2BRepair%2BEnzyme%2B%2528Poly%2528ADP-ribose%2529%2BPolymerase%2529%2Bin%2BProstate%2BCancer%2BCells%26numPages%3D11%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D5762%26publicationDate%3DJune%2B2020">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.9b02008"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">1276</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">1</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.9b02008" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Design and Synthesis of a Trifunctional Molecular System “Programmed” to Block Epidermal Growth Factor Receptor Tyrosine Kinase, Induce High Levels of DNA Damage, and Inhibit the DNA Repair Enzyme (Poly(ADP-ribose) Polymerase) in Prostate Cancer Cells&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Julie&quot;,&quot;last_name&quot;:&quot;Schmitt&quot;},{&quot;first_name&quot;:&quot;Shanlong&quot;,&quot;last_name&quot;:&quot;Huang&quot;},{&quot;first_name&quot;:&quot;Elliot&quot;,&quot;last_name&quot;:&quot;Goodfellow&quot;},{&quot;first_name&quot;:&quot;Christopher&quot;,&quot;last_name&quot;:&quot;Williams&quot;},{&quot;first_name&quot;:&quot;Bertrand&quot;,&quot;last_name&quot;:&quot;J. Jean-Claude&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2020&quot;,&quot;month&quot;:&quot;06&quot;,&quot;day&quot;:&quot;02&quot;,&quot;issue&quot;:&quot;11&quot;,&quot;volume&quot;:&quot;63&quot;,&quot;pages&quot;:&quot;5752-5762&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.9b02008&quot;},&quot;abstract&quot;:&quot;Resistance to chemotherapy in advanced cancers can be mediated by different factors such as epidermal growth factor receptor (EGFR) overexpression and DNA repair enzymes. Therefore, current standards of care usually involve combinations of multiple treatments. Here, to reduce the adverse effects of multiple drug combinations and improve outcome, we proposed a single drug approach to block multiple overlapping effects that characterize chemoresistance. Thus, we designed a new linker that allows assembly of multiple functions (e.g., inhibition of EGFR phosphorylation, induction of DNA lesions, and blockade of their repair) into a single molecule. This led to the successful synthesis of a novel and potent combi-molecule JS230. Here, we demonstrated that in resistant prostate cancer cells overexpressing EGFR, it was capable of (a) inhibiting EGFR in a dose-dependent manner, (b) damaging DNA, and (c) sustaining the damage by inhibiting the DNA repair protein poly(ADP-ribose) polymerase (PARP). The triple mechanism&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.9b02008&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.9b02008" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.9b02008&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.9b02008" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.9b02008&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.9b02008" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.9b02008&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.9b02008&amp;href=/doi/10.1021/acs.jmedchem.9b02008" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.9b02008" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.9b02008" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (5 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.9b02008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.9b02008%26sid%3Dliteratum%253Aachs%26pmid%3D32484346%26genre%3Darticle%26aulast%3DSchmitt%26date%3D2020%26atitle%3DDesign%2Band%2BSynthesis%2Bof%2Ba%2BTrifunctional%2BMolecular%2BSystem%2B%25E2%2580%259CProgrammed%25E2%2580%259D%2Bto%2BBlock%2BEpidermal%2BGrowth%2BFactor%2BReceptor%2BTyrosine%2BKinase%252C%2BInduce%2BHigh%2BLevels%2Bof%2BDNA%2BDamage%252C%2Band%2BInhibit%2Bthe%2BDNA%2BRepair%2BEnzyme%2B%2528Poly%2528ADP-ribose%2529%2BPolymerase%2529%2Bin%2BProstate%2BCancer%2BCells%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D63%26issue%3D11%26spage%3D5752%26epage%3D5762%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (2)</span><span class="article_header-suppInfo-arrow">»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=292524" title="Peptides and proteins">Peptides and proteins</a>,</li><li><a href="/action/doSearch?ConceptID=291439" title="Genetics">Genetics</a>,</li><li><a href="/action/doSearch?ConceptID=291350" title="Assays">Assays</a>,</li><li><a href="/action/doSearch?ConceptID=290896" title="Cells">Cells</a>,</li><li><a href="/action/doSearch?ConceptID=291793" title="Inhibition">Inhibition</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/63/11" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/jmcmar.2020.63.issue-11/20200611/jmcmar.2020.63.issue-11.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="_i1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b02008/20200604/images/medium/jm9b02008_0012.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b02008/20200604/images/large/jm9b02008_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b02008&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">Resistance to chemotherapy in advanced cancers can be mediated by different factors such as epidermal growth factor receptor (EGFR) overexpression and DNA repair enzymes. Therefore, current standards of care usually involve combinations of multiple treatments. Here, to reduce the adverse effects of multiple drug combinations and improve outcome, we proposed a single drug approach to block multiple overlapping effects that characterize chemoresistance. Thus, we designed a new linker that allows assembly of multiple functions (e.g., inhibition of EGFR phosphorylation, induction of DNA lesions, and blockade of their repair) into a single molecule. This led to the successful synthesis of a novel and potent combi-molecule <b>JS230</b>. Here, we demonstrated that in resistant prostate cancer cells overexpressing EGFR, it was capable of (a) inhibiting EGFR in a dose-dependent manner, (b) damaging DNA, and (c) sustaining the damage by inhibiting the DNA repair protein poly(ADP-ribose) polymerase (PARP). The triple mechanism of action of <b>JS230</b> cumulated into growth inhibitory potency superior to that of classical two- or three-drug combinations.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_04418" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_04418" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">In the clinic, there are currently several different types of chemotherapeutic agents, each of which is classified according to their mechanism of action.<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> Alkylating agents, for example, are designed to react directly with the DNA of cancer cells, thereby causing genomic instability and triggering cell death.<a onclick="showRef(event, 'ref2'); return false;" href="javascript:void(0);" class="ref ref2">(2)</a> However, their clinical use is limited due to significant side effects such as systemic toxicity, lack of selectivity, and resistance mediated by DNA repair proteins.<a onclick="showRef(event, 'ref3'); return false;" href="javascript:void(0);" class="ref ref3">(3)</a> Poly(ADP-ribose) polymerase (PARP) is one such protein that is known to be a key player in base excision repair (BER).<a onclick="showRef(event, 'ref4'); return false;" href="javascript:void(0);" class="ref ref4">(4)</a> When DNA is damaged, PARP is recruited and through poly(ADP-ribosylation), it PARylates and attracts multiple DNA repair proteins to the damage site. It represents an important repair mechanism of alkylating adducts, and it is known as the ultimate DNA repair pathway in cells with BRCA1/2 mutations.<a onclick="showRef(event, 'ref5'); return false;" href="javascript:void(0);" class="ref ref5">(5)</a> Its blockade with clinical PARP inhibitors (e.g., olaparib) leads to the selective death of BRCA1/2 mutant tumor cells.<a onclick="showRef(event, 'ref6'); return false;" href="javascript:void(0);" class="ref ref6">(6)</a> Interestingly, we and others showed that PARP inhibition generally sensitized cells to DNA damaging agents in resistant tumor cells, regardless of the BRCA1/2 status.<a onclick="showRef(event, 'ref7 ref8 ref9'); return false;" href="javascript:void(0);" class="ref ref7 ref8 ref9">(7−9)</a> On the other hand, overexpression of several cell surface receptor tyrosine kinases is associated with increased DNA repair activity and activation of antiapoptotic signaling: two events that further enhance resistance to DNA damaging agents.<a onclick="showRef(event, 'ref10'); return false;" href="javascript:void(0);" class="ref ref10">(10)</a> One such receptor, epidermal growth factor receptor (EGFR), is overexpressed in many tumors, including lung, brain, colon, and prostate cancers, and is often associated with poor prognosis.<a onclick="showRef(event, 'ref11 ref12'); return false;" href="javascript:void(0);" class="ref ref11 ref12">(11,12)</a> The inhibition of EGFR leads to the downregulation of key players in BER and sensitizes cells to alkylating agents and ionizing radiation.<a onclick="showRef(event, 'ref10'); return false;" href="javascript:void(0);" class="ref ref10">(10)</a> Despite the overlapping role of receptors, DNA repair enzymes, and other adverse compensatory signaling responses associated with chemotherapy resistance, cancer drug discovery is primarily directed at designing monofunctional molecules. In the past, to circumvent the effect of receptor-mediated signaling on DNA damage, we designed several single molecules, termed “combi-molecules”, capable of damaging DNA and blocking EGFR according to a strategy termed “combi-targeting”.<a onclick="showRef(event, 'ref13 ref14'); return false;" href="javascript:void(0);" class="ref ref13 ref14">(13,14)</a> We categorized these combi-molecules, generalized as I<sub>1</sub>–I<sub>2</sub> in <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>, into three different types according to their mechanism of action. As depicted in <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>, type I combi-molecules are designed to block target T<sub>1</sub> (e.g., EGFR) as an intact molecule and to be hydrolyzed into I<sub>1</sub> (an EGFR inhibitor) + I<sub>2</sub> (a DNA damaging species) capable to target T<sub>1</sub> (EGFR) and T<sub>2</sub> (DNA), respectively. Type II systems can block target T<sub>1</sub> and T<sub>2</sub> without requirement for hydrolytic cleavage. Finally, type III combi-molecules behave similarly to type I regarding their ability to be hydrolyzed into I<sub>1</sub> + I<sub>2</sub> and as type II with their ability to be dual-targeted to T<sub>1</sub> and T<sub>2</sub>. This was recently demonstrated with <b>AL776</b>, a combi-molecule designed to target EGFR (T<sub>1</sub>) and Src (T<sub>2</sub>).<a onclick="showRef(event, 'ref15'); return false;" href="javascript:void(0);" class="ref ref15">(15)</a></div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b02008/20200604/images/medium/jm9b02008_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b02008/20200604/images/large/jm9b02008_0001.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Prototypes of type I, type II, and type III targeting molecules.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b02008/20200604/images/large/jm9b02008_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b02008&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Recently, with the purpose of selectively sensitizing resistant O6-methylguanine DNA methyl transferase (MGMT)-expressing cells co-expressing EGFR to the DNA alkylating drug temozolomide, we designed <b>MR30</b>, a binary type II combi-molecule, and demonstrated its ability to block EGFR and deplete MGMT.<a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">(16)</a> However, this system was not able to induce a triple-targeting functions as an intact combi-molecule as it required an exogenous source of DNA damage to be active against resistant cells. To circumvent this problem, here, we advanced our concept toward the design of the first ternary system (I<sub>1</sub>–I<sub>2</sub>–I<sub>3</sub>) to contain an EGFR-targeting leading edge (I<sub>1</sub>), a masked DNA damaging function (I<sub>2</sub>), and more importantly, a DNA repair inhibitory (PARP) moiety (I<sub>3</sub>), which is added to block the repair of the types of DNA lesions that the system is designed to induce (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>).</div><figure id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b02008/20200604/images/medium/jm9b02008_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b02008/20200604/images/large/jm9b02008_0003.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. <b>JS230</b>, a “trifunctional combi-molecule” designed as a new “chimeric structure” to mimic the combined effect of blocking EGFR signaling pathways (gefitinib-like), damaging DNA (busulfan-like), and preventing DNA repair by inhibiting PARP (olaparib-like).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b02008/20200604/images/large/jm9b02008_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b02008&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">With the prediction of a type III combi-molecule, <b>JS230</b> was designed to contain an aminoquinazoline warhead targeted to EGFR (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>, purple-colored moiety) to which was appended an alkyl sulfonate linker (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>, blue-colored moiety). This permitted the extension of an arm toward the scaffold of olaparib, which is targeted to PARP (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>, orange-colored moiety) through a unique click product (or triazole) linker. Although more recent generations of EGFR inhibitors (e.g., osimertinib) showed unique potency against resistant EGFR mutants, we chose to establish our model with the first-generation quinazoline inhibitor scaffold due to its small size that allowed us to limit the bulkiness of the ternary system, thereby avoiding risk of poor cell penetrability.<a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">(17)</a> Thus, this proof of concept was primarily directed at vectorization of the combi-molecule to selectively target tumors overexpressing EGFR. Herein, we assessed the capability of <b>JS230</b> to modulate its targets T<sub>1</sub> (EGFR), T<sub>2</sub> (DNA), and T<sub>3</sub> (PARP) and compared its mechanisms of action with those of corresponding clinical drugs and combinations.</div></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i3">Results and Discussion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_03434" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_03434" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec2_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i4" class="anchor-spacer"></div><h3 class="article-section__title" id="_i4"> Chemistry</h3><div class="NLM_p"><b>JS230</b> was synthesized from a convergent strategy using a 1,3-dipolar cycloaddition or “click” chemistry reaction between alkyne <b>5</b> and azide <b>6</b> (<a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>). Compounds <b>5</b> (quinazoline scaffold) and <b>6</b> (olaparib scaffold) were carefully chosen as fragments that could maintain binding affinity for their respective targets. <i>In silico</i> studies were used to determine if the quinazoline and olaparib moieties of <b>JS230</b> could bind to their corresponding active sites (i.e., EGFR or PARP) without steric clashes. Molecular modeling showed that both the linker/olaparib and the linker/quinazoline portion of <b>JS230</b> had no binding hindrances to their respective site (see the Supporting Information, <a href="/doi/suppl/10.1021/acs.jmedchem.9b02008/suppl_file/jm9b02008_si_001.pdf" class="ext-link">Figures S18 and S19</a>). Finally, the DNA damaging part used for this “triplex combi-molecule” is a novel first-in-class mimic of busulfan, a clinical alkyl sulfonate agent (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>).<a onclick="showRef(event, 'ref18'); return false;" href="javascript:void(0);" class="ref ref18">(18)</a> The sulfonate ester linkage was selected as a good leaving group that renders the intact molecule sensitive to attack by purine nucleophilic centers (e.g., the N<sup>7</sup> position of the guanine). The quinazoline scaffold was obtained as depicted in <a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>, starting from the commercially available 5-fluoro-2-nitrobenzonitrile treated with 2-(methylamino)ethanol in DMSO in the presence of Cs<sub>2</sub>CO<sub>3</sub> to give <b>1</b>. The nitro group of <b>1</b> was reduced in an iron-catalyzed reaction to afford <b>2</b>. Compound <b>2</b> was subsequently condensed with DMF acetal to give amidine <b>3</b>, which was cyclized in the presence of 3-bromoaniline under reflux in acetic acid to generate a mixture of acetylated and hydroxylated compounds. Separation of the mixture using silica gel column chromatography led to compound <b>4</b> as a pure yellow solid. Compound <b>4</b> was reacted with but-3-yne-1-sulfonyl chloride in pyridine, and the residue was purified by silica gel column chromatography to afford <b>5</b>. Azide <b>6</b> was obtained in one step from 4-(4-fluoro-3-(piperazine-1-carbonyl)benzyl)phthalazin-1(2<i>H</i>)-one. Lastly, the click reaction was performed in DMF with CuSO<sub>4</sub>·5H<sub>2</sub>O and sodium ascorbate as catalysts. After the reaction was stirred overnight, purification of the pure triplex combi-molecule <b>JS230</b> gave a yellow powder in 45% yield. Its structure was confirmed by <sup>1</sup>H NMR, <sup>13</sup>C NMR, and high-resolution mass spectrometry, and its purity was determined to be >95% by reversed-phase HPLC under two different solvent conditions.</div><figure id="sch1" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b02008/20200604/images/medium/jm9b02008_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b02008/20200604/images/large/jm9b02008_0011.jpeg" id="gr11" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthetic Scheme of <b>JS230</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b02008/20200604/images/large/jm9b02008_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b02008&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) Cs<sub>2</sub>CO<sub>3</sub>, DMSO, 100 °C, on, 91%; (b) Fe, AcOH, EtOH/H<sub>2</sub>O, 100 °C, 2 h, 98%; (c) DMF dimethylacetal, 110 °C, 1.5 h, 64%; (d) 3-bromoaniline, AcOH, 110 °C, 1 h, 36%; (e) sulfonyl chloride, pyridine, 20 min, 84%; (f) piperazine, 4-azidobutyric acid, HOBt, EDCI, Et<sub>3</sub>N, DMF, 0 °C, on, 72%; and (g) CuSO<sub>4</sub>·5H<sub>2</sub>O, Na ascorbate, DMF, on, rt, 45%.</p></p></figure></div><div id="sec2_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i6" class="anchor-spacer"></div><h3 class="article-section__title" id="_i6"> In Vitro Alkylation</h3><div class="NLM_p">The DNA-based reactivity of <b>JS230</b> was assessed in vitro using a direct chemical reaction with 2′-deoxyguanosine (dG) under physiological conditions according to a protocol by Haapala et al.<a onclick="showRef(event, 'ref19'); return false;" href="javascript:void(0);" class="ref ref19">(19)</a> (see the Supporting Information, <a href="/doi/suppl/10.1021/acs.jmedchem.9b02008/suppl_file/jm9b02008_si_001.pdf" class="ext-link">Figure S20</a>). DNA damaging agents like busulfan and nitrogen mustards are known to react mainly with the N<sup>7</sup> position of guanine in DNA.<a onclick="showRef(event, 'ref20 ref21'); return false;" href="javascript:void(0);" class="ref ref20 ref21">(20,21)</a> As depicted in <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>, hydrolytic product <b>4</b> was detected in the reaction mixture, as previously described.<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a> Although an aziridinium ion formation cannot be monitored, we surmise that compound <b>4</b> results from the hydrolysis of the latter intermediate I<sub>1</sub>–I<sub>2</sub>, as previously reported for nitrogen mustards.<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a> By contrast, the clinical alkylating drug busulfan is known to alkylate DNA through direct nucleophilic substitution (S<sub>N</sub>2). Importantly, we observed the guanine-alkylated adduct <b>8</b>, indicating that <b>JS230</b> has DNA alkylating potential. We emphasize that only a fraction of <b>JS230</b> may be able to alkylate DNA since the major product found in the reaction was compound <b>4</b>, an EGFR inhibitor (IC<sub>50</sub> = 0.145 μM; see the Supporting Information, <a href="/doi/suppl/10.1021/acs.jmedchem.9b02008/suppl_file/jm9b02008_si_001.pdf" class="ext-link">Figure S34</a>). We also observed the depurination of dG, which, as previously reported, may be due to the hydrolability of the anomeric C–N<sup>9</sup> bond of guanine following alkylation of its 7-position.<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a> Further, we embarked onto a systematic target analysis involving an enzyme assay to demonstrate its ability to block EGFR (target T<sub>1</sub>) as an intact structure, damage DNA (target T<sub>2</sub>), and inhibit PARP (target T<sub>3</sub>) in whole cells. The triple-targeted effects of <b>JS230</b> were dissected in a panel of prostate cancer cells (22Rv1, PC3, and DU145), selected on the basis of their EGFR overexpression and resistance to the PARP inhibitor olaparib.</div><figure id="fig3" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b02008/20200604/images/medium/jm9b02008_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b02008/20200604/images/large/jm9b02008_0004.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Hypothetical mechanism of action of <b>JS230</b> based on the products identified by LC–MS analysis. I<sub>1</sub>–I<sub>2</sub>–I<sub>3</sub> as an intact molecule can block target T<sub>1</sub> (EGFR) and T<sub>3</sub> (PARP) while being allowed to form a transient aziridinium ion that can further block target T<sub>1</sub> (EGFR) and damage T<sub>2</sub> (DNA), while I<sub>3</sub> remains capable of inhibiting T<sub>3</sub> (PARP). Compounds <b>4</b>, <b>7</b>, and <b>8</b> have been identified by LC–MS analysis.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b02008/20200604/images/large/jm9b02008_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b02008&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i7" class="anchor-spacer"></div><h3 class="article-section__title" id="_i7"> Target 1 (T<sub>1</sub>): Downregulation of EGFR-Activated Pathways</h3><div class="NLM_p">As an indirect evidence of the EGFR-targeting properties of <b>JS230</b>, we first analyzed its ability to block EGFR phosphorylation in an EGF-stimulated whole cell phosphorylation assay. Indeed, <b>JS230</b> showed the inhibition of EGFR phosphorylation in a dose-dependent manner, with 34 to 45% inhibition at concentrations as low as 1 μM (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>) in PC3 and 22Rv1 prostate cancer cells, respectively. Moreover, this is equally translated into the downregulation of ERK and AKT signaling in these cells, indicating that kinases downstream from EGFR also have a reduction in their functionality.<a onclick="showRef(event, 'ref25'); return false;" href="javascript:void(0);" class="ref ref25">(25)</a> These results are indicative that treatment with <b>JS230</b> causes a reduction in processes involved in cell growth (EGFR), cell cycle progression (ERK), and evasion of apoptosis (AKT). To verify whether <b>JS230</b> was capable of blocking EGFR phosphorylation and its downstream signaling cascades via direct EGFR inhibition, we subsequently used an isolated enzyme assay to measure its affinity toward the ATP binding pocket of EGFR. The results showed that despite its size, it retained strong EGFR inhibitory potency (IC<sub>50</sub> = 0.3262 ± 0.0594 μM), suggesting that the inhibition of phosphorylation in cells occured via direct binding to the kinase domain of EGFR. Lastly, to confirm that the molecule was selective for EGFR, we used a cell-based selectivity assay, consisting of an isogenic pair of cells (NIH-3T3 and NIH-3T3 transfected with EGFR). The results showed that <b>JS230</b> exhibited 7-fold selectivity toward the NIH-3T3-EGFR transfectant cells (<i>P</i> < 0.0001; <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>), confirming that it is indeed targeted toward EGFR-overexpressing cells. These experiments provide strong evidence that the EGFR-targeting properties of <b>JS230</b> are maintained and it can selectively target and inhibit EGFR-mediated signaling.</div><figure id="fig4" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b02008/20200604/images/medium/jm9b02008_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b02008/20200604/images/large/jm9b02008_0005.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Inhibition of EGFR signaling by <b>JS230</b> and clinical drugs in PC3 and 22Rv1 cell lines. The cells were treated with differing concentrations (μM) of all compounds for 2 h and subsequently followed by EGF (50 ng/mL) stimulation for 30 min.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b02008/20200604/images/large/jm9b02008_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b02008&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="fig5" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b02008/20200604/images/medium/jm9b02008_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b02008/20200604/images/large/jm9b02008_0006.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. IC<sub>50</sub> of <b>JS230</b> compared against clinical EGFR inhibitor gefitinib on cell lines NIH-3T3 (EGFR wild-type) and NIH-3T3-EGFR (EGFR transfectant). Selectivity of 7-fold is observed for the combi-molecule <b>JS230</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b02008/20200604/images/large/jm9b02008_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b02008&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i8" class="anchor-spacer"></div><h3 class="article-section__title" id="_i8"> Target 2 (T<sub>2</sub>): Induction of DNA Damage</h3><div class="NLM_p">Using an alkaline comet assay to assess DNA damage on PC3 and 22Rv1, we demonstrated that the triplex combi-molecule was able to induce DNA damage in whole cells in a dose-dependent manner (<a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a> and see the Supporting Information, <a href="/doi/suppl/10.1021/acs.jmedchem.9b02008/suppl_file/jm9b02008_si_001.pdf" class="ext-link">Figure S22</a>), which is consistent with the alkylating potency of the alkyl sulfonyl group observed in the chemical reaction with 2′-deoxyguanosine (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>). Importantly, the DNA damaging potential of <b>JS230</b> was 3- to 6-fold more potent than that of the strong bis-sulfonate drug busulfan. Further evidence of the DNA damaging potential of <b>JS230</b> was given by the induction of γ-H2AX phosphorylation, a marker of DNA double-strand breaks (<a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a>). Finally, DNA repair kinetics showed that the levels of DNA damage induced by <b>JS230</b>, in contrast to those by busulfan and corresponding combinations, are not only sustained 24 h post-treatment but also showed a significant increase (<i>P</i> < 0.0001). This strongly indicates that <b>JS230</b> is capable of targeting and damaging DNA as well as inducing sustained levels of DNA damage.</div><figure id="fig6" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b02008/20200604/images/medium/jm9b02008_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b02008/20200604/images/large/jm9b02008_0007.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Assessment of DNA damage using the alkaline comet assay. The results indicate that DNA damage is not only sustained but enhanced 24 h post-treatment with respect to a drug incubation of 2 h. <b>JS230</b> has been compared to single drugs (G, gefitinib; O, olaparib; and B, busulfan) and their equimolar double or triple combinations.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b02008/20200604/images/large/jm9b02008_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b02008&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="fig7" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b02008/20200604/images/medium/jm9b02008_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b02008/20200604/images/large/jm9b02008_0008.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Detection of γ-H2AX phosphorylation and PAR levels induced in PC3 and 22Rv1 cells (48 h post-treatment).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b02008/20200604/images/large/jm9b02008_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b02008&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i9" class="anchor-spacer"></div><h3 class="article-section__title" id="_i9"> Target 3 (T<sub>3</sub>): PARP Inhibition</h3><div class="NLM_p">To assess the ability of <b>JS230</b> to block PARP in whole cells, we used western blot to determine the inhibition of poly(ADP-ribose) (PAR) polymerization in two prostate cancer cell lines (<a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a>). The results showed that <b>JS230</b> could strongly inhibit PARP-induced PARylation in a manner similar to olaparib. Further evidence of its PARP inhibitory potency was acquired using a growth inhibition assay in a pair of isogenic cells, differing solely in their BRCA status (VC8, BRCA mutant and VC8-BRCA, BRCA transfectant; <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a>). Importantly, <b>JS230</b> was 4-fold selective for the BRCA mutant (<i>P</i> < 0.0001), indicating its ability to modulate PARP activity in these cells. Finally, the increase in DNA lesions as a function of time observed in <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a> may well be secondary to the sustained inhibitory effects of PARP function or perhaps a tandem silencing of EGFR-mediated signaling and base excision repair. Indeed, we have already demonstrated that the blockade of EGFR signaling by a dual EGFR-DNA-targeting combi-molecule was associated with the downregulation of the base excision repair (BER) protein X-ray repair cross-complementing group 1 (XRCC1) and delayed DNA repair.<a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a> The direct inhibition of PARP, another key player of BER, may lead to the observed sustained levels of DNA lesions induced by <b>JS230</b> in the cells. The results strongly support the notion that <b>JS230</b> is capable of modulating the PARP function.</div><figure id="fig8" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b02008/20200604/images/medium/jm9b02008_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b02008/20200604/images/large/jm9b02008_0009.jpeg" id="gr8" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. IC<sub>50</sub> of <b>JS230</b> compared against clinical PARP inhibitor olaparib on cell lines VC8 (BRCA mutant) and VC8-BRCA (BRCA transfectant). Selectivity of 3-fold is observed for the combi-molecule <b>JS230</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b02008/20200604/images/large/jm9b02008_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b02008&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i10" class="anchor-spacer"></div><h3 class="article-section__title" id="_i10"> Growth Inhibitory Potency</h3><div class="NLM_p">To analyze the growth inhibitory potency associated with the triple effect, we compared <b>JS230</b> with the single clinical drugs shown in <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>, i.e., gefitinib (clinical EGFR inhibitor), olaparib (clinical PARP inhibitor), busulfan (clinical DNA alkylating agent), and their various equimolar combinations using the sulforhodamine B growth inhibition assay in EGFR-overexpressing and olaparib-resistant prostate cancer cells.<a onclick="showRef(event, 'ref26 ref27'); return false;" href="javascript:void(0);" class="ref ref26 ref27">(26,27)</a> The IC<sub>50</sub> values are shown in <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>, and a comparison with triple drug combinations is illustrated in <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">9</a></a>.</div><figure id="fig9" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b02008/20200604/images/medium/jm9b02008_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b02008/20200604/images/large/jm9b02008_0010.jpeg" id="gr9" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 9. Response of <b>JS230</b> in a cell-based growth inhibition assay using a panel of prostate cancer cell lines. <b>JS230</b> shows a similar growth inhibition profile as the triple combination of clinical drugs in DU145, whereas in PC3 and 22Rv1, <b>JS230</b> is significantly more potent.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b02008/20200604/images/large/jm9b02008_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b02008&amp;id=fig9"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. IC<sub>50</sub> Values (μM) of <b>JS230</b>, Clinical Controls, and Equimolar Combinations</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="char" char="±" /></col><col align="char" char="±" /></col><col align="char" char="±" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="3" align="center" char="±">IC<sub>50</sub> (μM)<a class="ref internalNav" href="#t1fn1" aria-label="a">a</a></th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compounds</th><th class="colsep0 rowsep0" align="center" char="±">22Rv1</th><th class="colsep0 rowsep0" align="center" char="±">PC3</th><th class="colsep0 rowsep0" align="center" char="±">DU145</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">gefitinib</td><td class="colsep0 rowsep0" align="char" char="±">14.0 ± 0.1</td><td class="colsep0 rowsep0" align="char" char="±">5.3 ± 0.4</td><td class="colsep0 rowsep0" align="char" char="±">7.3 ± 0.1</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">olaparib</td><td class="colsep0 rowsep0" align="char" char="±">33.8 ± 1.3</td><td class="colsep0 rowsep0" align="char" char="±">20.6 ± 1.2</td><td class="colsep0 rowsep0" align="char" char="±">17.7 ± 0.7</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">busulfan</td><td class="colsep0 rowsep0" align="char" char="±">24.3 ± 1.2</td><td class="colsep0 rowsep0" align="char" char="±">36.2 ± 1.1</td><td class="colsep0 rowsep0" align="char" char="±">25.8 ± 0.2</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">busulfan + gefitinib</td><td class="colsep0 rowsep0" align="char" char="±">18.3 ± 0.1</td><td class="colsep0 rowsep0" align="char" char="±">11.1 ± 0.7</td><td class="colsep0 rowsep0" align="char" char="±">13.3 ± 0.7</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">olaparib + gefitinib</td><td class="colsep0 rowsep0" align="char" char="±">20.1 ± 0.5</td><td class="colsep0 rowsep0" align="char" char="±">6.5 ± 0.5</td><td class="colsep0 rowsep0" align="char" char="±">9.0 ± 0.2</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">olaparib + busulfan</td><td class="colsep0 rowsep0" align="char" char="±">16.7 ± 0.8</td><td class="colsep0 rowsep0" align="char" char="±">19.2 ± 1.2</td><td class="colsep0 rowsep0" align="char" char="±">19.7 ± 0.5</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">gefitinib + olaparib + busulfan</td><td class="colsep0 rowsep0" align="char" char="±">15.5 ± 1.1</td><td class="colsep0 rowsep0" align="char" char="±">7.9 ± 0.3</td><td class="colsep0 rowsep0" align="char" char="±">5.6 ± 0.4</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>JS230</b></td><td class="colsep0 rowsep0" align="char" char="±">1.9 ± 0.6</td><td class="colsep0 rowsep0" align="char" char="±">3.0 ± 0.8</td><td class="colsep0 rowsep0" align="char" char="±">3.2 ± 0.8</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t1fn1"><div class="footnote" id="t1fn1"><sup><sup>a</sup></sup><p class="last">Values indicate the average of three independent experiments.</p></div></div></div><div class="NLM_p last">Taken together, the results showed that the triplex combi-molecule-targeting approach induced a statistically significant enhancement in growth inhibitory potency in 22Rv1 and PC3 prostate cancer cells when compared with their clinical counterparts and corresponding combinations. Notably, <b>JS230</b> exhibited 2- to 8-fold stronger activity than the three-drug combination, cogently displaying the superior benefit of the combi-molecule delivery system. Moreover, particularly in 22Rv1, <b>JS230</b> is able to completely abrogate the resistance associated with gefitinib and olaparib as single agents or when combined.</div></div><div id="sec2_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i12" class="anchor-spacer"></div><h3 class="article-section__title" id="_i12"> Intracellular Localization</h3><div class="NLM_p">To confirm the hypothesis that <b>JS230</b> indeed enters the cell as an intact molecule, a time-course analysis of its level inside cells was performed. Analysis by LC–MS revealed that <b>JS230</b> achieves its highest cellular concentration within 1 h and retains its intact structure for at least 6 h (<a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">10</a></a>A). This confirms that <b>JS230</b> is indeed stable within the cellular milieu and mainly enters the cells as an intact molecule that can deliver its three moieties. To further deconvolute the superior potency of <b>JS230</b> when compared with its corresponding three-drug combinations, we equally analyzed its cellular distribution. Fortuitously, the innate fluorescence properties of the quinazoline scaffold allowed us to visualize the combi-molecule in whole cells without the requirement for additional conjugation. As shown in <a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">10</a></a>B, <b>JS230</b> is preferentially distributed in the perinuclear region 2 h after treatment. This is in agreement with previous observations by our group, indicating that EGFR-DNA-targeting molecules abundantly localize in the perinuclear region from which they may diffuse to the nucleus to induce significant DNA damage.<a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a></div><figure id="fig10" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Figure 10</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b02008/20200604/images/medium/jm9b02008_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b02008/20200604/images/large/jm9b02008_0002.jpeg" id="gr10" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 10. (A) Time-course analysis of the level of intact <b>JS230</b> in the prostate cancer cell line 22Rv1. (B) Confocal microscopy of <b>JS230</b> at 10 μM in prostate cancer cell line 22Rv1 (2 h post-treatment).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b02008/20200604/images/large/jm9b02008_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b02008&amp;id=fig10"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">It is important to note that while <b>JS230</b> was abundantly distributed in the perinuclear region, there are two lines of indirect evidence of its nuclear localization: (a) its strong DNA damaging properties require a nucleophilic attack by DNA bases and (b) its ability to inhibit PARP, a nuclear enzyme. Therefore, the intact molecule or its corresponding reactive species must have nuclear localization.</div></div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i13">Conclusions</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_01383" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_01383" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p last">In summary, this study conclusively demonstrated, for the first time, the feasibility of a trifunctional molecule designed to behave as a dual EGFR-PARP-targeting (T<sub>1</sub> and T<sub>3</sub>) inhibitor while inflicting high levels of DNA damage (T<sub>2</sub>). The resulting single molecule I<sub>1</sub>–I<sub>2</sub>–I<sub>3</sub> was significantly more potent (8-fold) than the combination of the clinical drugs represented as I<sub>1</sub> + I<sub>2</sub> + I<sub>3</sub> possibly due to its subcellular localization and triple-targeted mechanism of action brought about by its unique scaffold. This approach may inspire the design of a new generation of molecules capable of addressing the tumor heterogeneity and the target multiplicity of advanced cancers in the context of reversing chemoresistance.</div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i14">Experimental Section</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_36581" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_36581" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec4_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i15" class="anchor-spacer"></div><h3 class="article-section__title" id="_i15"> Materials and Methods</h3><div class="NLM_p last">All chemicals were of the highest purity. Commercially available ones were used without further purification. Purification by column chromatography was performed with silica gel 60 (230–400 mesh) (MilliporeSigma) with solvent mixtures specified for each compound where applicable. NMR spectra were recorded using either Bruker 400 or 600 MHz spectrometers. Chemical shifts are reported as parts per million (ppm) and referenced according to the residual solvent peak, and coupling constants (<i>J</i>) are reported in hertz (Hz). Where assignments of <sup>1</sup>H NMR spectra are given, they have been unambiguously established via COSY and heteronuclear single quantum correlation experiments. Mass spectra were obtained by using an Amazon spectrometer (ES-MS) and a QTOF Impact II instrument with internal calibration. The purity for the final compound <b>JS230</b> was determined to be >95% by reversed-phase HPLC under two different solvent conditions.</div></div><div id="sec4_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i16" class="anchor-spacer"></div><h3 class="article-section__title" id="_i16"> Synthesis of Compound <b>1</b></h3><div class="NLM_p last">5-Fluoro-2-nitrobenzonitrile (1 equiv, 100 mg, 602 μmol), 2-(methylamino)ethanol (1.20 equiv, 55 mg, 723 μmol), and Cs<sub>2</sub>CO<sub>3</sub> (1.20 equiv, 235 mg, 723 μmol) were combined in DMSO (2 mL), and the reaction mixture was stirred at 100 °C overnight. The solution was cooled to rt, EtOAc (50 mL) was added, and the organic layer was washed with a saturated NaHCO<sub>3</sub> solution (3 × 15 mL) and a brine solution (1 × 15 mL). The organic layer was dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and evaporated to dryness. The residue was purified by silica gel column chromatography (DCM/MeOH 3%) to afford compound <b>1</b> as an orange solid in 91% yield (121 mg). <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 400 MHz, 298 K): δ 8.16 (d, <i>J</i> = 9.7 Hz, 1H, H<sub>2</sub>), 7.31 (d, <i>J</i> = 2.9 Hz, 1H, H<sub>3</sub>), 7.04 (dd, <i>J</i><sub>1</sub> = 9.7 Hz, <i>J</i><sub>2</sub> = 2.9 Hz, 1H, H<sub>1</sub>), 4.82–4.85 (m, 1H, H<sub>6</sub>), 3.60–3.61 (m, 4H, H<sub>4</sub>-H<sub>5</sub>), 3.12 (s, 3H, H<sub>7</sub>) ppm. <sup>13</sup>C NMR (DMSO-<i>d</i><sub>6</sub>, 100 MHz, 298 K): δ 127.79, 117.57, 113.90, 108.92, 58.18, 54.06 ppm. ES-MS (ESI) <i>m/z</i> (%): 244.01 (100) [M + Na]<sup>+</sup>.</div></div><div id="sec4_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i17" class="anchor-spacer"></div><h3 class="article-section__title" id="_i17"> Synthesis of Compound <b>2</b></h3><div class="NLM_p last">Compound <b>1</b> (1 equiv, 121 mg, 547 μmol) was suspended in aqueous EtOH (7 mL)/water (3 mL). Iron (6.4 equiv, 196 mg, 3.51 mmol) and CH<sub>3</sub>COOH (14 equiv, 438 μL, 7.66 mmol) were added, and the reaction was stirred at 100 °C for 2 h. The solution was cooled to rt, and EtOH was evaporated under reduced pressure. EtOAc (10 mL) and a saturated NaHCO<sub>3</sub> solution (10 mL) were added. The aqueous phase was extracted with EtOAc (3 × 10 mL), and the combined organic layer was dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and evaporated to dryness. The good product was obtained as an orange solid in 98% yield (103 mg) and was used without any further purification. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 400 MHz, 298 K): δ 6.93 (dd, <i>J</i><sub>1</sub> = 9.0 Hz, <i>J</i><sub>2</sub> = 2.9 Hz, 1H, H<sub>1</sub>), 6.73 (d, <i>J</i> = 9.0 Hz, 1H, H<sub>2</sub>), 6.66 (d, <i>J</i> = 2.7 Hz, 1H, H<sub>4</sub>), 5.29 (br s, 2H, H<sub>3</sub>), 4.59 (br s, 1H, H<sub>7</sub>), 3.48 (t, <i>J</i> = 6.2 Hz, 2H, H<sub>6</sub>), 3.22 (t, <i>J</i> = 6.2 Hz, 2H, H<sub>5</sub>), 2.79 (s, 3H, H<sub>8</sub>) ppm. <sup>13</sup>C NMR (DMSO-<i>d</i><sub>6</sub>, 100 MHz, 298 K): δ 143.28, 141.09, 121.36, 118.69, 117.03, 114.11, 94.41, 58.09, 55.34 ppm. ES-MS (ESI) <i>m/z</i> (%): 192.03 (100) [M + H]<sup>+</sup>.</div></div><div id="sec4_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i18" class="anchor-spacer"></div><h3 class="article-section__title" id="_i18"> Synthesis of Compound <b>3</b></h3><div class="NLM_p last">Compound <b>2</b> (103 mg, 539 μmol) was suspended in DMF dimethylacetal (2 mL), and the reaction was stirred at 110 °C for 1.5 h. DMF dimethylacetal was then evaporated, and the product was purified by silica gel column chromatography and eluted with a gradient (DCM/MeOH 1–4%) to afford compound <b>3</b> as a yellow solid in 64% yield (85 mg). <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 400 MHz, 298 K): δ 7.79 (s, 1H, H<sub>3</sub>), 6.99 (d, <i>J</i> = 8.9 Hz, 1H, H<sub>2</sub>), 6.92 (dd, <i>J</i><sub>1</sub> = 9.2 Hz, <i>J</i><sub>2</sub> = 3.1 Hz, 1H, H<sub>1</sub>), 6.81 (d, <i>J</i> = 2.9 Hz, 1H, H<sub>6</sub>), 4.64 (t, <i>J</i> = 5.5 Hz, 1H, H<sub>9</sub>), 3.51 (q, <i>J</i> = 6.2 Hz, 2H, H<sub>8</sub>), 3.33 (t, <i>J</i> = 6.0 Hz, 2H, H<sub>7</sub>), 3.01 (s, 3H, H<sub>4</sub> or H<sub>5</sub>), 2.93 (s, 3H, H<sub>4</sub> or H<sub>5</sub>), 2.88 (s, 3H, H<sub>10</sub>) ppm. <sup>13</sup>C NMR (DMSO-<i>d</i><sub>6</sub>, 100 MHz, 298 K): δ 153.48, 144.57, 144.46, 119.67, 119.22, 118.38, 114.38, 106.00, 58.06, 54.53 ppm. ES-MS (ESI) <i>m/z</i> (%): 247.10 (100) [M + H]<sup>+</sup>.</div></div><div id="sec4_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i19" class="anchor-spacer"></div><h3 class="article-section__title" id="_i19"> Synthesis of Compound <b>4</b></h3><div class="NLM_p last">Compound <b>3</b> (1 equiv, 601 mg, 2.44 mmol) and 3-bromoaniline (1.1 equiv, 292 μL, 2.68 mmol) were solubilized in CH<sub>3</sub>COOH (3.5 mL), and the reaction was stirred at 115 °C for 1 h. The solvent was evaporated, and the product was purified by silica gel column chromatography and eluted with a gradient (DCM/MeOH 1–4%) to afford compound <b>4</b> as a yellow solid in 36% yield (326 mg). <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 400 MHz, 298 K): δ 9.48 (s, 1H, H<sub>4</sub>), 8.39 (s, 1H, H<sub>3</sub>), 8.14 (t, <i>J</i> = 1.8 Hz, 1H, H<sub>5</sub>), 7.90 (d, <i>J</i> = 8.2 Hz, 1H, H<sub>8</sub>), 7.63 (d, <i>J</i> = 9.3 Hz, 1H, H<sub>2</sub>), 7.50 (dd, <i>J</i><sub>1</sub> = 9.2 Hz, <i>J</i><sub>2</sub> = 2.4 Hz, 1H, H<sub>1</sub>), 7.35 (t, <i>J</i> = 8.1 Hz, 1H, H<sub>7</sub>), 7.31 (d, <i>J</i> = 2.4 Hz, 1H, H<sub>9</sub>), 7.28 (d, <i>J</i> = 7.8 Hz, 1H, H<sub>6</sub>), 4.72 (t, <i>J</i> = 4.9 Hz, 1H, H<sub>12</sub>), 3.57–3.63 (m, 4H, H<sub>10</sub>, H<sub>11</sub>), 3.11 (s, 3H, H<sub>13</sub>) ppm. <sup>13</sup>C NMR (DMSO-<i>d</i><sub>6</sub>, 150 MHz, 298 K): δ 155.74, 149.81, 147.86, 142.17, 141.37, 130.25, 128.56, 125.53, 124.17, 121.36, 121.08, 120.80, 116.27, 99.38, 58.27, 54.12. ppm. HRMS (ESI) <i>m/z</i>: [M + H]<sup>+</sup> calcd for C<sub>17</sub>H<sub>17</sub>BrN<sub>4</sub>O<sub>1</sub>, 373.0665; found, 373.0658.</div></div><div id="sec4_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i20" class="anchor-spacer"></div><h3 class="article-section__title" id="_i20"> Synthesis of Compound <b>5</b></h3><div class="NLM_p last">Compound <b>4</b> (1 equiv, 50 mg, 0.134 mmol) was solubilized in dry pyridine (1 mL) under argon. Then, but-3-yne-1-sulfonyl chloride (1.05 equiv, 0.141 mmol, 21 mg) was added dropwise, and the reaction mixture stirred at rt for 20 min. The solvent was evaporated, and the residue was purified by silica gel column chromatography and eluted with a mixture of 5% MeOH in DCM to afford compound <b>5</b> as a yellow solid in 84% yield (<i>m</i> = 55 mg, 0.112 mmol). <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 400 MHz, 298 K): δ 9.50 (s, 1H, H<sub>4</sub>), 8.43 (s, 1H, H<sub>3</sub>), 8.15 (t, <i>J</i> = 1.9 Hz, 1H, H<sub>5</sub>), 7.90 (d, <i>J</i> = 8.1 Hz, 1H, H<sub>8</sub>), 7.67 (d, <i>J</i> = 9.3 Hz, 1H, H<sub>2</sub>), 7.54 (dd, <i>J</i><sub>1</sub> = 9.3 Hz, <i>J</i><sub>2</sub> = 2.6 Hz, 1H, H<sub>1</sub>), 7.39 (d, <i>J</i> = 2.7 Hz, 1H, H<sub>9</sub>), 7.36 (t, <i>J</i> = 8.1 Hz, 1H, H<sub>7</sub>), 7.28 (d, <i>J</i> = 8.0 Hz, 1H, H<sub>6</sub>), 4.43 (t, <i>J</i> = 5.3 Hz, 1H, H<sub>11</sub>), 3.90 (t, <i>J</i> = 5.3 Hz, 2H, H<sub>10</sub>), 3.53 (t, <i>J</i> = 7.3 Hz, 2H, H<sub>12</sub>), 3.13 (s, 3H, H<sub>13</sub>), 2.96 (t, <i>J</i> = 2.7 Hz, 1H, H<sub>15</sub>), 2.56 (td, <i>J</i><sub>1</sub> = 7.3 Hz, <i>J</i><sub>2</sub> = 2.7 Hz, 1H, H<sub>14</sub>) ppm. <sup>13</sup>C NMR (DMSO-<i>d</i><sub>6</sub>, 150 MHz, 298 K): δ 158.56, 149.08, 147.76, 139.50, 131.06, 128.98, 127.44, 122.89, 123.56, 122.50, 121.63, 115.69, 101.74, 80.77, 73.41, 68.41, 55.38, 50.84, 47.74, 31.16, 13.84 ppm. HRMS (ESI) <i>m/z</i>: [M + H]<sup>+</sup> calcd for C<sub>21</sub>H<sub>21</sub>BrN<sub>4</sub>O<sub>3</sub>S, 489.0591; found, 489.0591.</div></div><div id="sec4_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i21" class="anchor-spacer"></div><h3 class="article-section__title" id="_i21"> Synthesis of Compound <b>6</b></h3><div class="NLM_p last">4-(4-Fluoro-3-(piperazine-1-carbonyl)benzyl)phthalazin-1(2<i>H</i>)-one (1 equiv, 300 mg, 0.82 mmol), 4-azidobutyric acid (1.1 equiv, 116 mg, 0.90 mmol), and HOBt (1;1 equiv, 0.98 mmol, 122 mg) were solubilized in dry DMF (4 mL) under argon. Et<sub>3</sub>N (2 equiv, 1.64 mmol, 230 μL) was added, and the reaction mixture was cooled to 0 °C with an ice bath before EDCI (1.1 equiv, 0.90 mmol, 196 μL) was added dropwise. The solution was stirred at rt overnight. The solvent was evaporated, and the residue was purified by silica gel column chromatography and eluted with a mobile phase of 3% MeOH in DCM. Compound <b>6</b> was obtained as a white-off solid in 72% yield (<i>m</i> = 265 mg, 0.555 mmol). <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 400 MHz, 298 K): δ 12.59 (s, 1H, H<sub>12</sub>), 8.27 (d, <i>J</i> = 7.7 Hz, 1H, H<sub>16</sub>), 7.96 (d, <i>J</i> = 7.9 Hz, 1H, H<sub>13</sub>), 7.89 (t, <i>J</i> = 7.5 Hz, 1H, H<sub>14</sub>), 7.83 (t, <i>J</i> = 7.8 Hz, 1H, H<sub>15</sub>), 7.44 (br s, 1H, H<sub>10</sub>), 7.36 (br s, 1H, H<sub>8</sub>), 7.24 (t, <i>J</i> = 8.9 Hz, 1H, H<sub>9</sub>), 4.33 (s, 2H, H<sub>11</sub>), 3.64 (br s, 1H, piperazine), 3.58 (br s, 1H, piperazine), 3.52 (br s, 2H, piperazine), 3.35 (br s, 4H, piperazine + H<sub>1</sub>), 3.19 (br s, 1H, piperazine), 3.15 (br s, 1H, piperazine), 2.42 (t, <i>J</i> = 7.1 Hz, 1H, H<sub>3</sub>), 2.35 (t, <i>J</i> = 7.1 Hz, 1H, H<sub>3</sub>), 1.72–1.79 ( m, 2H, H<sub>2</sub>) ppm. <sup>13</sup>C NMR (DMSO-<i>d</i><sub>6</sub>, 150 MHz, 298 K): δ 169.99, 164.01, 159.34, 157.5, 155.10, 144.78, 134.79, 133.45, 131.75, 131.67, 131.51, 129.04, 128.91, 128.88, 127.87, 126.03, 125.41, 123.63, 123.47, 115.99, 115.77, 50.21, 46.49, 46.20, 44.79, 44.36, 41.51, 41.17, 40.59, 36.39, 29.10, 23.94 ppm. HRMS (ESI) <i>m/z</i>: [M + H]<sup>+</sup> calcd for C<sub>24</sub>H<sub>24</sub>FN<sub>7</sub>O<sub>3</sub>, 478.1997; found, 478.1995.</div></div><div id="sec4_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i22" class="anchor-spacer"></div><h3 class="article-section__title" id="_i22"> Synthesis of <b>JS230</b></h3><div class="NLM_p last">Compound <b>5</b> (1 equiv, 0.102 mmol, 50 mg) and compound <b>6</b> (1.1 equiv, 0.112 mmol, 54 mg) were solubilized in dry DMF (2.5 mL) under argon. Then, CuSO<sub>4</sub>·5H<sub>2</sub>O (1.25 equiv, 0.127 mmol, 32 mg) and Na ascorbate (3 equiv, 0.306 mmol, 60 mg) were added in once. The reaction mixture was then stirred at rt overnight. Water (15 mL) and DCM (30 mL) were added, and the organic layer was washed twice with water (2 × 15 mL) and then brine (15 mL). The organic layer was dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and evaporated to dryness. The residue was purified by silica gel column chromatography and eluted using a gradient of MeOH in DCM (5, 7, and then 10%) to afford the final product <b>JS230</b> as a yellow solid in 45% yield (<i>m</i> = 44 mg, 0. 046 mmol). <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 600 MHz, 298 K): δ 12.59 (s, 1H, H<sub>27</sub>), 9.49 (s, 1H, H<sub>4</sub>), 8.42 (s, 1H, H<sub>3</sub>), 8.26 (d, <i>J</i> = 7.7 Hz, 1H, H<sub>31</sub>), 8.13 (s, 1H, H<sub>5</sub>), 7.95 (t, <i>J</i> = 8.2 Hz, 1H, H<sub>29</sub>), 7.89–7.81 (m, 4H, H<sub>8</sub>, H<sub>15</sub>, H<sub>28</sub>, H<sub>30</sub>), 7.64–7.67 (m, 1H, H<sub>2</sub>), 7.51–7.54 (m, 1H, H<sub>1</sub>), 7.43–7.45 (m, 1H, H<sub>24</sub>), 7.33–7.37 (m, 3H, H<sub>7</sub>, H<sub>9</sub>, H<sub>25</sub>), 7.28 (d, <i>J</i> = 7.6 Hz, 1H, H<sub>6</sub>), 7.23 (t, <i>J</i> = 9.0 Hz, 1H, H<sub>23</sub>), 4.39–4.42 (m, 2H, H<sub>11</sub>), 4.32 (s, 2H, H<sub>26</sub>), 4.27–4.31 (m, 2H, H<sub>18</sub>), 3.84–3.87 (m, 2H, H<sub>10</sub>), 3.61–3.67 (m, 2H, H<sub>12</sub>), 3.62 (br s, 1H, piperazine), 3.57 (br s, 1H, piperazine), 3.51 (br s, 1H, piperazine), 3.44 (br s, 1H, piperazine), 3.37 (br s, 1H, piperazine), 3.27 (br s, 1H, piperazine), 3.16 (br s, 2H, piperazine), 3.11 (d, 3H, H<sub>13</sub>), 2.98–3.01 (m, 2H, H<sub>14</sub>), 2.32 (t, <i>J</i> = 6.9 Hz, 1H, H<sub>18</sub>), 2.26 (t, <i>J</i> = 6.8 Hz, 1H, H<sub>18</sub>), 1.96–1.99 (m, 2H, H<sub>17</sub>) ppm. <sup>13</sup>C NMR (DMSO-<i>d</i><sub>6</sub>, 150 MHz, 298 K): δ 169.72, 164.03, 163.95, 159.35, 157.16, 155.88, 155.48, 150.23, 147.18, 144.79, 142.88, 142.45, 141.22, 134.80, 133.45, 131.76, 131.71, 131.53, 130.28, 129.04, 128.88, 128.69, 127.87, 126.05, 125.66, 125.42, 124.24, 123.56, 122.46, 121.39, 121.10, 120.85, 116.14, 115.97, 115.82, 100.19, 67.78, 54.89, 50.51, 48.76, 48.01, 46.43, 44.72, 44.29, 41.46, 41.17, 40.59, 36.40, 28.81, 25.44, 25.37, 19.79 ppm. HRMS (ESI) <i>m/z</i>: [M + H]<sup>+</sup> calcd for C<sub>45</sub>H<sub>45</sub>FBrN<sub>11</sub>O<sub>6</sub>S, 966.2515; found, 966.2523. HPLC analysis: retention time = 5.972 min; peak area, 96.19%; eluent A, H<sub>2</sub>O; eluent B, MeOH; gradient (90:10 → 10:90) over 8 min with a flow rate of 1 mL/min and detection at 254 nm; column temperature, rt. HPLC analysis: retention time = 5.410 min; peak area, 95.59%; eluent A, H<sub>2</sub>O; eluent B, CH<sub>3</sub>CN; gradient (90:10 → 10:90) over 8 min with a flow rate of 1 mL/min and detection at 254 nm; column temperature, rt.</div></div><div id="sec4_9" class="NLM_sec NLM_sec_level_2"><div id="ac_i23" class="anchor-spacer"></div><h3 class="article-section__title" id="_i23"> In Vitro Alkylation of 2′-Deoxyguanosine by <b>JS230</b> and Reaction Analysis by LC–MS</h3><div class="NLM_p last">The protocol was adapted from a publication by Haapala et al.<a onclick="showRef(event, 'ref19'); return false;" href="javascript:void(0);" class="ref ref19">(19)</a><b>JS230</b> (0.1 mM) was allowed to react with 2′-deoxyguanosine (2.9 mM) in a non-nucleophilic buffer at pH 6.8 (0.2 M cacodylic acid, 50% base). The reaction mixture was incubated at 37 °C for 24 h, and reaction progression was monitored by LC–MS. LC–MS grade solvents, acetonitrile, formic acid, and water were obtained from EMD Millipore. Ammonium acetate was obtained from VWR. Analyses were performed at the Drug Discovery Platform within the Research Institute of the McGill University Health Centre on an ESI-QTOF-MS system (Impact II, Bruker, Billerica, MA) coupled with an HPLC system (1290 Infinity, Agilent). Analyses were performed on a reversed-phase InertSustain AQ-C18 column (100 × 2.1 mm, 3 μm) from GL Sciences Inc. Mobile phases consisted of 50 mM ammonium acetate in water with 0.1% formic acid (eluent A) and acetonitrile with 0.1% formic acid (eluent B). The following gradient elution method was used: 5% B from 0 to 1 min, 5–60% B from 1 to 12 min, a 60% B plateau for 12 to 16 min, 60–80% B from 16 to 20 min, and an 80% B plateau for 3 min before returning to initial conditions, which were maintained for 2 min. The column temperature was set at 25 °C, and the flow rate was 0.4 mL/min. The samples were kept in an autosampler at 4 °C. The ESI source was operated in the positive ion mode. The operating parameters of the mass spectrometer were as follows: positive spray voltage, 4000 V; dry temperature, 250 °C; dry gas flow, 10 L/min; and nebulizer, 3 bar. The data were collected in an auto MS/MS mode with a mass range from 50 to 3000 <i>m/z</i>. The instrument was calibrated using ESI-L low concentration tuning mix solution (Agilent).</div></div><div id="sec4_10" class="NLM_sec NLM_sec_level_2"><div id="ac_i24" class="anchor-spacer"></div><h3 class="article-section__title" id="_i24"> Sample Preparation</h3><div class="NLM_p last">The samples were injected directly to the LC–MS system. Blank samples were run before and after each sample.</div></div><div id="sec4_11" class="NLM_sec NLM_sec_level_2"><div id="ac_i25" class="anchor-spacer"></div><h3 class="article-section__title" id="_i25"> Cell Lines</h3><div class="NLM_p last">PC3, DU145, and 22Rv1 were purchased from ATCC (Manassas, VA, USA). NIH-3T3 wild-type and NIH-3T3-EGFR cells were a generous donation from Dr. Moulay Alaoui-Jamali (Lady Davis Institute, Jewish General Hospital, McGill University, Montreal, Quebec, Canada). VC8 and VC8-BRCA cells were kindly donated by Dr. Bernd Kaina (Institute of Toxicology, Mainz, Germany). PC3, DU145, and 22Rv1 cells were maintained in RPMI media. NIH-3T3 wild-type, NIH-3T3-EGFR, VC8, and VC8-BRCA cell lines were maintained in DMEM media. All media formulations consisted of 10% fetal bovine serum (FBS), 10 mM HEPES, and antibiotics (gentamicin, amphotericin B, and ciprofloxacin) (Wisent Inc. St-Bruno, QC, Canada). All cells were incubated in a humidified incubator with 5% CO<sub>2</sub> at 37 °C.</div></div><div id="sec4_12" class="NLM_sec NLM_sec_level_2"><div id="ac_i26" class="anchor-spacer"></div><h3 class="article-section__title" id="_i26"> In Vitro SRB Growth Inhibition Assay</h3><div class="NLM_p last">The inhibition of cell growth was examined by the SRB assay, as previously described in ref <a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">(28)</a>. Briefly, cells were seeded in 96-well plates using a volume of 100 μL and treated with 100 μL of drug at various doses for 5 days. Cells were then fixed using 50 μL of 50% w/v trichloroacetic acid (Alfa Aesar, Tewksbury, MA, USA) and subsequently washed with water 2 h after incubation at 4 °C. Once dried, plates were stained with a 0.4% sulforhodamine B (SRB; Alfa Aesar, Tewksbury, MA, USA) solution and incubated for 1 h prior to rinsing excess dye with 1% acetic acid (Alfa Aesar, Tewksbury, MA, USA). The colored pigment was dissolved using a 10 mM solution of Tris base (Fisher Scientific Company, Ottawa, Ontario, Canada), and optical density was measured at 490 nm using an ELx808 BioTek microplate reader (S/N: 234710). Growth inhibition rates and IC<sub>50</sub> values were analyzed by GraphPad Prism 6 (GraphPad Software, Inc., San Diego, CA, USA). The results represent the average of at least three independent experiments in triplicate.</div></div><div id="sec4_13" class="NLM_sec NLM_sec_level_2"><div id="ac_i27" class="anchor-spacer"></div><h3 class="article-section__title" id="_i27"> In Vitro Kinase Assay</h3><div class="NLM_p last">The EGFR kinase assay was performed, as previously described in ref <a onclick="showRef(event, 'ref29'); return false;" href="javascript:void(0);" class="ref ref29">(29)</a>. Briefly, the kinase assay was conducted in 96-well plates coated with PGT (poly(<span class="smallcaps smallerCapital">l</span>-glutamic acid-<span class="smallcaps smallerCapital">l</span>-tyrosine), 4:1, Sigma-Aldrich, MO, USA) diluted in PBS and incubated at 37 °C for 2 days. The excess PGT was removed, and 10 μL of drug diluted in PBV buffer (50 mM HEPES, 125 mM NaCl, 24 mM MgCl<sub>2</sub>, and 0.1 mM sodium orthovanadate) at various doses was added to each well. The kinase reaction was carried out using 7.5 μL/well of EGFR at 0.1 mg/mL concentration (SignalChem, Richmond, Canada), 20 μL/well of ATP (Alfa Aesar, Tewksbury, MA, USA) at 50 μM, and 2.1 μL/well of EGF at 100 μg/mL (Sigma-Aldrich, MO, USA), all diluted in PBV buffer. The phosphorylated substrate was examined by the addition of 50 μL/well of HRP-conjugated antiphosphotyrosine antibody (Santa Cruz Biotechnology, Dallas, TX, USA) at 0.2 μg/mL and incubated in the dark for 25 min. The signal was developed by adding the tetramethylbenzidine (TMB) peroxidase substrate and peroxidase solution (Kirkegaard & Perry Laboratories, Gaithersburg, MA, USA) in a 1:1 ratio, and the reaction was stopped using 50 μL/well of H<sub>2</sub>SO<sub>4</sub> at 0.09 M after 15 min of incubation in the dark at room temperature. The colored substrate was detected at 450 nm by an ELx808 BioTek microplate reader (S/N: 234710). IC<sub>50</sub> values were analyzed using GraphPad Prism 6 (GraphPad Software, Inc., San Diego, CA, USA). The results represent the means of two individual experiments performed in duplicate.</div></div><div id="sec4_14" class="NLM_sec NLM_sec_level_2"><div id="ac_i28" class="anchor-spacer"></div><h3 class="article-section__title" id="_i28"> Alkaline Comet Assay for DNA Damage Quantification</h3><div class="NLM_p last">Cells were seeded in 6-well plates at a density of 500,000 cells/well and left to attach overnight. Cells were then treated with drugs at 12.5 μM for either 2 or 24 h, and the cells were harvested using conventional methods. The cells were pelleted at 340 g for 5 min, and the supernatant was removed. The cells were washed with 1 mL of PBS before centrifugation under the conditions previously stated. The supernatants were removed, and each sample was resuspended once more in PBS prior to creating a 1:10 solution of cell suspension and 0.75% low melting point agarose (Fisher Scientific Company, Ottawa, Ontario, Canada). This mixture (200 μL) was then cast on a GelBond support film (Lonza, Morristown, NJ, USA). After polymerization, the film was immersed in lysis buffer A solution (2.5 M sodium chloride, 100 mM tetrasodium ethylenediaminetetraacetic acid, 10 mM Tris base, and 35 mM <i>n</i>-lauroylsarcosine) and kept in the dark at 4 °C overnight. All subsequent steps were performed in the dark. The next morning, lysis buffer A was removed, and the film was washed with distilled water and subsequently immersed in lysis Buffer B (2.5 M sodium chloride, 100 mM tetrasodium ethylenediaminetetraacetic acid, and 10 mM Tris base) for 1 h at 37 °C. The film thereafter was rinsed with distilled water and incubated in unwinding buffer (300 mM sodium hydroxide, 10 mM tetrasodium ethylenediaminetetraacetic acid, and 7 mM 8-hydroxyquinoline) for 30 min prior to electrophoresis in unwinding buffer under the following conditions: voltage = 20 V, amperage = 400 mA, and time = 20 min. The film was then subjected to rewinding buffer (1 M ammonium acetate) for 30 min and was washed in distilled water twice before being immersed in 100% ethanol for 2 h. The films were then dried overnight and stained using 10,000× concentrate of SYBR Gold (Molecular Probes, Eugene, OR, USA) diluted in distilled water and subsequently dried prior to analysis. Comets were captured using both a Leica DM IL fluorescence microscope (S/N: 521228) and a Leica DFC300 FX camera (S/N: 234762307). DNA damage was quantified as a function of tail moment using Comet Assay IV software (Bury St. Edmunds, Suffolk, UK). The mean tail moments were calculated from two independent experiments.</div></div><div id="sec4_15" class="NLM_sec NLM_sec_level_2"><div id="ac_i29" class="anchor-spacer"></div><h3 class="article-section__title" id="_i29"> Western Blot Analysis</h3><div class="NLM_p last">Cells were seeded in 6-well plates at a concentration of 500,000 cells/well and left to attach overnight. Once confluent, the media was aspirated, and the cells were starved in serum-free media for 24 h. Following starvation, cells were exposed to drugs and diluted in serum-free media at 10 μM, and <b>JS230</b> was used in a dose range of 0.1, 1, 10, and 100 μM for 2 h. Cells were then washed and stimulated with 50 ng/mL EGF (Sigma-Aldrich, MO, USA) and also diluted in serum-free media for 30 min. Cells were scraped over ice in RIPA buffer (Cell Signaling Technology, Danvers, MA, USA) containing 1 mM PMSF (BioShop Canada Inc., Burlington, Ontario, Canada), harvested, and incubated over ice for 30 min. Lysates were centrifuged at 13,000 rpm for 20 min, and the supernatants were collected. The total protein concentration was assessed using the standard Bradford assay protocol. Samples containing 50 μg of protein were loaded on Mini-PROTEAN TGX Stain-Free precast gels (Bio-Rad Laboratories, Hercules, CA, USA) after boiling samples in Laemmli buffer (Bio-Rad Laboratories, Hercules, CA, USA) for 5 min. Gel electrophoresis was conducted at 100 V for 1 h in a Bio-Rad Mini-PROTEAN Tetra cell (S/N: 552BR-051039), and the proteins were subsequently transferred to a polyvinylidene difluoride (PVDF) membrane (Millipore, Bedford, MA, USA) using a Bio-Rad Mini-PROTEAN 3 cell (S/N: 525BR-005750) at 100 V for 1 h and 30 min (Millipore, Bedford, MA, USA). The membranes were blocked using 5% skim milk in PBS prior to overnight incubation at 4 °C with primary antibody. Primary antibodies used were selective for phospho-EGFR, phospho-p44/42 MAPK, phospho-AKT, total p44/42 MAPK, total AKT, β-actin (Cell Signaling Technology, Danvers, MA, USA), and total EGFR (Santa Cruz Biotechnology, Dallas, TX, USA), all of which were used according to manufacturer specifications. After incubation, the membranes were washed with TBST and incubated with the appropriate secondary antibody (Cell Signaling Technology, Danvers, MA, USA) for 1 h and 30 min at room temperature. Signals were developed using a SuperSignal West Pico chemiluminescent substrate (Thermo Fisher Scientific, Waltham, MA, USA) according to manufacturer specifications, and images were recorded using the GE Healthcare ImageQuant LAS4000 system (S/N: 28955810-0632092). For the detection of phosphor-γ-H2AX (Cell Signaling Technology, Danvers, MA, USA) and PAR (Trevigen, Gaithersburg, MD, USA) levels, cells were treated with drugs at 10 μM, and <b>JS230</b> was used in a dose range of 0.1, 1, 10, and 20 μM for 48 h without EGF stimulation. Cells harvested under these conditions were handled in an identical manner, as previously described.</div></div><div id="sec4_16" class="NLM_sec NLM_sec_level_2"><div id="ac_i30" class="anchor-spacer"></div><h3 class="article-section__title" id="_i30"> Fluorescence Imaging by Confocal Microscope</h3><div class="NLM_p last">Cells were seeded at 5000 cells/dish in a volume of 500 μL in glass bottom dishes (MatTek Corporation, Ashland, USA) and left to attach overnight. Cells were then treated with 10 μM <b>JS230</b> and incubated for 2 h post-treatment, and images were recorded using both an Olympus model IX81S1F-3 inverted microscope and an Olympus FV1000 (S/N: 7M23548) confocal laser scanning microscope (S/N: 7M13827). Confocal images were processed using Olympus FLUOVIEW4 software (Richmond Hill, Ontario, Canada).</div></div><div id="sec4_17" class="NLM_sec NLM_sec_level_2"><div id="ac_i31" class="anchor-spacer"></div><h3 class="article-section__title" id="_i31"> <b>JS230</b> Cleavage Kinetics in Cells and Cellular Uptake</h3><div class="NLM_p last">Briefly, cells were seeded in 6-well plates at a concentration of 500,000 cells/well and left to attach overnight. The cells were treated with 25 μM <b>JS230</b> and incubated for either 0, 1, 2, 3, or 6 h. After incubation, treated cells were washed with PBS and subsequently harvested using conventional methods. Cells were collected in separate tubes and centrifuged at 2000 rpm for 5 min. The supernatant was then discarded, the cells were washed with 1 mL of PBS, and the samples were centrifuged once more. Once the supernatant was discarded, the cells were lysed using 500 μL of HPLC grade methanol and kept on ice for 1 h. The cells were subsequently centrifuged at 13,000 rpm for 20 min, and this lysis step was repeated once more. Supernatants were pooled, evaporated to dryness, and stored at −80 °C until further use. The LC–MS/MS analysis was done in the same conditions as for the in vitro alkylation of 2′-deoxyguanosine by <b>JS230</b>.</div></div></div><div class="NLM_back"><div class="article_supporting-info" id="notes1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i32"><a href="/doi/suppl/10.1021/acs.jmedchem.9b02008" class="ext-link">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_21658" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_21658" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge at <a href="/doi/10.1021/acs.jmedchem.9b02008?goto=supporting-info" class="ext-link">https://pubs.acs.org/doi/10.1021/acs.jmedchem.9b02008</a>.<ul class="NLM_list-list_type-label" id="silist"><li><p class="inline">Supplementary figures, molecular modeling, and NMR and HRMS spectra and HPLC chromatograms of the final compound <b>JS230</b> (<a href="/doi/suppl/10.1021/acs.jmedchem.9b02008/suppl_file/jm9b02008_si_001.pdf" class="ext-link">PDF</a>)</p></li><li><p class="inline">Molecular strings of compounds <b>1</b>–<b>6</b> and <b>JS230</b> (<a href="/doi/suppl/10.1021/acs.jmedchem.9b02008/suppl_file/jm9b02008_si_002.csv" class="ext-link">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.9b02008/suppl_file/jm9b02008_si_001.pdf">jm9b02008_si_001.pdf (3.4 MB)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.9b02008/suppl_file/jm9b02008_si_002.csv">jm9b02008_si_002.csv (0.52 kb)</a></li></ul></div></div></div><div class="testing" data-doi="10.1021/acs.jmedchem.9b02008" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_25563" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_25563" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Author</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Bertrand J. Jean-Claude</span> - <span class="hlFld-Affiliation affiliation">Cancer
Drug Research Laboratory, Department of Medicine, The Research Institute of the McGill University Health Center/Glen
Hospital, Montreal, QC H4A 3J1, Canada</span>; 
    <span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#85e7e0f7f1f7e4ebe1efabcfe0e4eba8e6e9e4f0e1e0c5e8e6e2ece9e9abe6e4"><span class="__cf_email__" data-cfemail="610304131513000f050b4f2b04000f4c020d00140504210c0206080d0d4f0200">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Julie Schmitt</span> - <span class="hlFld-Affiliation affiliation">Cancer
Drug Research Laboratory, Department of Medicine, The Research Institute of the McGill University Health Center/Glen
Hospital, Montreal, QC H4A 3J1, Canada</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-1990-1429" title="Orcid link">http://orcid.org/0000-0002-1990-1429</a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Shanlong Huang</span> - <span class="hlFld-Affiliation affiliation">Cancer
Drug Research Laboratory, Department of Medicine, The Research Institute of the McGill University Health Center/Glen
Hospital, Montreal, QC H4A 3J1, Canada</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Elliot Goodfellow</span> - <span class="hlFld-Affiliation affiliation">Cancer
Drug Research Laboratory, Department of Medicine, The Research Institute of the McGill University Health Center/Glen
Hospital, Montreal, QC H4A 3J1, Canada</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Christopher Williams</span> - <span class="hlFld-Affiliation affiliation">Scientific
Support, Chemical Computing Group Inc., Montreal, QC H3A
2R7, Canada</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0001-5428-2742" title="Orcid link">http://orcid.org/0000-0001-5428-2742</a></span></div></li></ul></li><li></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare no competing financial interest.<br /></br></div></li></ul></div><div class="ack" id="ack1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i33">Acknowledgments</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_68685" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_68685" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">This study was supported by the Canadian Institutes of Health (CIHR) (MOP-130363). J.S. acknowledges the RI-MUHC for a post-doctoral fellowship. S.H. acknowledges the China Scholarship Council (CSC) for a studentship. We wish to thank the Center for Translational Biology (CTB) of the RI-MUHC Drug Discovery Platform for NMR access, mass spectrometry data, and LC–MS analysis.</p></div><table summary="" class="NLM_def-list" id="dl1"><tr><td colspan="2" class="NLM_title">Abbreviations</td></tr><tr><td class="NLM_term">PARP</td><td class="NLM_def"><p class="first last">poly(ADP-ribose) polymerase</p></td></tr><tr><td class="NLM_term">BER</td><td class="NLM_def"><p class="first last">base excision repair</p></td></tr><tr><td class="NLM_term">EGFR</td><td class="NLM_def"><p class="first last">epidermal growth factor receptor</p></td></tr><tr><td class="NLM_term">DNA</td><td class="NLM_def"><p class="first last">deoxyribonucleic acid</p></td></tr><tr><td class="NLM_term">dG</td><td class="NLM_def"><p class="first last">2′-deoxyguanosine</p></td></tr><tr><td class="NLM_term">HPLC</td><td class="NLM_def"><p class="first last">high-performance liquid chromatography</p></td></tr><tr><td class="NLM_term">HRMS</td><td class="NLM_def"><p class="first last">high-resolution mass spectrometry</p></td></tr><tr><td class="NLM_term">ES-MS</td><td class="NLM_def"><p class="first last">electrospray mass spectrometry</p></td></tr><tr><td class="NLM_term">HOBt</td><td class="NLM_def"><p class="first last">hydroxybenzotriazole</p></td></tr><tr><td class="NLM_term">EDCI</td><td class="NLM_def"><p class="first last">1-ethyl-3-(3-dimethylaminopropyl)carbodiimide</p></td></tr><tr><td class="NLM_term">Et<sub>3</sub>N</td><td class="NLM_def"><p class="first last">triethylamine</p></td></tr><tr><td class="NLM_term">DCM</td><td class="NLM_def"><p class="first last">dichloromethane</p></td></tr><tr><td class="NLM_term">DMF</td><td class="NLM_def"><p class="first last"><i>N</i>,<i>N</i>-dimethylformamide</p></td></tr><tr><td class="NLM_term">DMSO</td><td class="NLM_def"><p class="first last">dimethyl sulfoxide</p></td></tr><tr><td class="NLM_term">AcOH</td><td class="NLM_def"><p class="first last">acetic acid</p></td></tr><tr><td class="NLM_term">EtOH</td><td class="NLM_def"><p class="first last">ethanol</p></td></tr><tr><td class="NLM_term">MeOH</td><td class="NLM_def"><p class="first last">methanol</p></td></tr><tr><td class="NLM_term">EtOAc</td><td class="NLM_def"><p class="first last">ethyl acetate</p></td></tr><tr><td class="NLM_term">rt</td><td class="NLM_def"><p class="first last">room temperature</p></td></tr><tr><td class="NLM_term">h</td><td class="NLM_def"><p class="first last">hour(s)</p></td></tr><tr><td class="NLM_term">min</td><td class="NLM_def"><p class="first last">minute</p></td></tr><tr><td class="NLM_term">quant</td><td class="NLM_def"><p class="first last">quantitative</p></td></tr><tr><td class="NLM_term">on</td><td class="NLM_def"><p class="first last">overnight</p></td></tr><tr><td class="NLM_term">TLC</td><td class="NLM_def"><p class="first last">thin-layer chromatography</p></td></tr></table><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i35">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_08821" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_08821" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 29 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chabner, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roberts, T. G.,  Jr.</span></span> <span> </span><span class="NLM_article-title">Chemotherapy and the war on cancer</span>. <i>Nat. Rev. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">65</span>– <span class="NLM_lpage">72</span>, <span class="refDoi"> DOI: 10.1038/nrc1529</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02008&amp;key=10.1038%2Fnrc1529" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02008&amp;key=15630416" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02008&amp;key=1%3ACAS%3A528%3ADC%252BD2MXlvVek" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2005&pages=65-72&author=B.+A.+Chabnerauthor=T.+G.+Roberts&title=Chemotherapy+and+the+war+on+cancer&doi=10.1038%2Fnrc1529"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Chemotherapy and the war on cancer</span></div><div class="casAuthors">Chabner, Bruce A.; Roberts, Thomas G.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">65-72</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The era of chemotherapy began in the 1940s with the first uses of nitrogen mustards and antifolate drugs.  Cancer drug development since then has transformed from a low-budget, government-supported research effort to a high-stakes, multi-billion dollar industry.  The targeted-therapy revolution has arrived, but the principles and limitations of chemotherapy discovered by the early researchers still apply.  This article chronicles the history of modern chemotherapy and identifies remaining challenges for the next generation of researchers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrszgbuDuTBobVg90H21EOLACvtfcHk0li4bmSbqRJWDA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXlvVek&md5=d5c8b3dba59b9d6dcca473552525fa14</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1038%2Fnrc1529&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc1529%26sid%3Dliteratum%253Aachs%26aulast%3DChabner%26aufirst%3DB.%2BA.%26aulast%3DRoberts%26aufirst%3DT.%2BG.%26atitle%3DChemotherapy%2520and%2520the%2520war%2520on%2520cancer%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2005%26volume%3D5%26spage%3D65%26epage%3D72%26doi%3D10.1038%2Fnrc1529" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Goldstein, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kastan, M. B.</span></span> <span> </span><span class="NLM_article-title">The DNA damage response: implications for tumor responses to radiation and chemotherapy</span>. <i>Annu. Rev. Med.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>66</i></span>,  <span class="NLM_fpage">129</span>– <span class="NLM_lpage">143</span>, <span class="refDoi"> DOI: 10.1146/annurev-med-081313-121208</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02008&amp;key=10.1146%2Fannurev-med-081313-121208" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02008&amp;key=25423595" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02008&amp;key=1%3ACAS%3A528%3ADC%252BC2MXjvFyhs7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=66&publication_year=2015&pages=129-143&author=M.+Goldsteinauthor=M.+B.+Kastan&title=The+DNA+damage+response%3A+implications+for+tumor+responses+to+radiation+and+chemotherapy&doi=10.1146%2Fannurev-med-081313-121208"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">The DNA damage response: implications for tumor responses to radiation and chemotherapy</span></div><div class="casAuthors">Goldstein, Michael; Kastan, Michael B.</div><div class="citationInfo"><span class="NLM_cas:title">Annual Review of Medicine</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">66</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">129-143</span>CODEN:
                <span class="NLM_cas:coden">ARMCAH</span>;
        ISSN:<span class="NLM_cas:issn">0066-4219</span>.
    
            (<span class="NLM_cas:orgname">Annual Reviews</span>)
        </div><div class="casAbstract">Cellular responses to DNA damage are important determinants of both cancer development and cancer outcome following radiation therapy and chemotherapy.  Identification of mol. pathways governing DNA damage signaling and DNA repair in response to different types of DNA lesions allows for a better understanding of the effects of radiation and chemotherapy on normal and tumor cells.  Although dysregulation of the DNA damage response (DDR) is assocd. with predisposition to cancer development, it can also result in hypersensitivity or resistance of tumors to therapy and can be exploited for improvement of cancer treatment.  We highlight the DDR pathways that are activated after treatment with radiation and different classes of chemotherapeutic drugs and describe mechanisms detg. tumor sensitivity and resistance to these agents.  Further, we discuss approaches to enhance tumor sensitivity to radiation and chemotherapy by modulating the DDR with a goal of enhancing the effectiveness of cancer therapies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqapVTP41nzXLVg90H21EOLACvtfcHk0li4bmSbqRJWDA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXjvFyhs7g%253D&md5=d4c54e8dae50f61cfee4d54b022b551c</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1146%2Fannurev-med-081313-121208&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1146%252Fannurev-med-081313-121208%26sid%3Dliteratum%253Aachs%26aulast%3DGoldstein%26aufirst%3DM.%26aulast%3DKastan%26aufirst%3DM.%2BB.%26atitle%3DThe%2520DNA%2520damage%2520response%253A%2520implications%2520for%2520tumor%2520responses%2520to%2520radiation%2520and%2520chemotherapy%26jtitle%3DAnnu.%2520Rev.%2520Med.%26date%3D2015%26volume%3D66%26spage%3D129%26epage%3D143%26doi%3D10.1146%2Fannurev-med-081313-121208" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pegg, A. E.</span></span> <span> </span><span class="NLM_article-title">Multifaceted roles of alkyltransferase and related proteins in DNA repair, DNA damage, resistance to chemotherapy, and research tools</span>. <i>Chem. Res. Toxicol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">618</span>– <span class="NLM_lpage">639</span>, <span class="refDoi"> DOI: 10.1021/tx200031q</span> </span><div class="citationLinks">[<a href="/doi/10.1021/tx200031q" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02008&amp;key=1%3ACAS%3A528%3ADC%252BC3MXltlGhsLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2011&pages=618-639&author=A.+E.+Pegg&title=Multifaceted+roles+of+alkyltransferase+and+related+proteins+in+DNA+repair%2C+DNA+damage%2C+resistance+to+chemotherapy%2C+and+research+tools&doi=10.1021%2Ftx200031q"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Multifaceted Roles of Alkyltransferase and Related Proteins in DNA Repair, DNA Damage, Resistance to Chemotherapy, and Research Tools</span></div><div class="casAuthors">Pegg, Anthony E.</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Research in Toxicology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">618-639</span>CODEN:
                <span class="NLM_cas:coden">CRTOEC</span>;
        ISSN:<span class="NLM_cas:issn">0893-228X</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  O6-Alkylguanine-DNA alkyltransferase (AGT) is a widely distributed, unique DNA repair protein that acts as a single agent to directly remove alkyl groups located on the O6-position of guanine from DNA restoring the DNA in one step.  The protein acts only once, and its alkylated form is degraded rapidly.  It is a major factor in counteracting the mutagenic, carcinogenic, and cytotoxic effects of agents that form such adducts including N-nitroso-compds. and a no. of cancer chemotherapeutics.  This review describes the structure, function, and mechanism of action of AGTs and of a family of related alkyltransferase-like proteins, which do not act alone to repair O6-alkylguanines in DNA but link repair to other pathways.  The paradoxical ability of AGTs to stimulate the DNA-damaging ability of dihaloalkanes and other bis-electrophiles via the formation of AGT-DNA cross-links is also described.  Other important properties of AGTs include the ability to provide resistance to cancer therapeutic alkylating agents, and the availability of AGT inhibitors such as O6-benzylguanine that might overcome this resistance is discussed.  Finally, the properties of fusion proteins in which AGT sequences are linked to other proteins are outlined.  Such proteins occur naturally, and synthetic variants engineered to react specifically with derivs. of O6-benzylguanine are the basis of a valuable research technique for tagging proteins with specific reagents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpO3LqHTkLd_7Vg90H21EOLACvtfcHk0lgAJjZmmNrzCg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXltlGhsLc%253D&md5=ed36c05b50ec9f37ebf85d9d9773ce0a</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1021%2Ftx200031q&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Ftx200031q%26sid%3Dliteratum%253Aachs%26aulast%3DPegg%26aufirst%3DA.%2BE.%26atitle%3DMultifaceted%2520roles%2520of%2520alkyltransferase%2520and%2520related%2520proteins%2520in%2520DNA%2520repair%252C%2520DNA%2520damage%252C%2520resistance%2520to%2520chemotherapy%252C%2520and%2520research%2520tools%26jtitle%3DChem.%2520Res.%2520Toxicol.%26date%3D2011%26volume%3D24%26spage%3D618%26epage%3D639%26doi%3D10.1021%2Ftx200031q" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ray
Chaudhuri, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nussenzweig, A.</span></span> <span> </span><span class="NLM_article-title">The multifaceted roles of PARP1 in DNA repair and chromatin remodelling</span>. <i>Nat. Rev. Mol. Cell Biol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">610</span>– <span class="NLM_lpage">621</span>, <span class="refDoi"> DOI: 10.1038/nrm.2017.53</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02008&amp;key=10.1038%2Fnrm.2017.53" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02008&amp;key=28676700" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02008&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtFanurfI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2017&pages=610-621&author=A.+Ray%0AChaudhuriauthor=A.+Nussenzweig&title=The+multifaceted+roles+of+PARP1+in+DNA+repair+and+chromatin+remodelling&doi=10.1038%2Fnrm.2017.53"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">The multifaceted roles of PARP1 in DNA repair and chromatin remodelling</span></div><div class="casAuthors">Ray Chaudhuri, Arnab; Nussenzweig, Andre</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Molecular Cell Biology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">610-621</span>CODEN:
                <span class="NLM_cas:coden">NRMCBP</span>;
        ISSN:<span class="NLM_cas:issn">1471-0072</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">A review.  Cells are exposed to various endogenous and exogenous insults that induce DNA damage, which, if unrepaired, impairs genome integrity and leads to the development of various diseases, including cancer.  Recent evidence has implicated poly(ADP-ribose) polymerase 1 (PARP1) in various DNA repair pathways and in the maintenance of genomic stability.  The inhibition of PARP1 is therefore being exploited clin. for the treatment of various cancers, which include DNA repair-deficient ovarian, breast and prostate cancers.  Understanding the role of PARP1 in maintaining genome integrity is not only important for the design of novel chemotherapeutic agents, but is also crucial for gaining insights into the mechanisms of chemoresistance in cancer cells.  In this Review, we discuss the roles of PARP1 in mediating various aspects of DNA metab., such as single-strand break repair, nucleotide excision repair, double-strand break repair and the stabilization of replication forks, and in modulating chromatin structure.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoIUBUS4wtkKrVg90H21EOLACvtfcHk0lgAJjZmmNrzCg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtFanurfI&md5=593d6bb5d0a16940d0ba3f8f1eaccf71</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1038%2Fnrm.2017.53&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrm.2017.53%26sid%3Dliteratum%253Aachs%26aulast%3DRay%2BChaudhuri%26aufirst%3DA.%26aulast%3DNussenzweig%26aufirst%3DA.%26atitle%3DThe%2520multifaceted%2520roles%2520of%2520PARP1%2520in%2520DNA%2520repair%2520and%2520chromatin%2520remodelling%26jtitle%3DNat.%2520Rev.%2520Mol.%2520Cell%2520Biol.%26date%3D2017%26volume%3D18%26spage%3D610%26epage%3D621%26doi%3D10.1038%2Fnrm.2017.53" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kelley, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Logsdon, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fishel, M. L.</span></span> <span> </span><span class="NLM_article-title">Targeting DNA repair pathways for cancer treatment: what’s new?</span>. <i>Future Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">1215</span>– <span class="NLM_lpage">1237</span>, <span class="refDoi"> DOI: 10.2217/fon.14.60</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02008&amp;key=10.2217%2Ffon.14.60" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02008&amp;key=24947262" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02008&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtVWmsLjP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2014&pages=1215-1237&author=M.+R.+Kelleyauthor=D.+Logsdonauthor=M.+L.+Fishel&title=Targeting+DNA+repair+pathways+for+cancer+treatment%3A+what%E2%80%99s+new%3F&doi=10.2217%2Ffon.14.60"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting DNA repair pathways for cancer treatment: what's new?</span></div><div class="casAuthors">Kelley, Mark R.; Logsdon, Derek; Fishel, Melissa L.</div><div class="citationInfo"><span class="NLM_cas:title">Future Oncology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1215-1237</span>CODEN:
                <span class="NLM_cas:coden">FOUNBN</span>;
        ISSN:<span class="NLM_cas:issn">1479-6694</span>.
    
            (<span class="NLM_cas:orgname">Future Medicine Ltd.</span>)
        </div><div class="casAbstract">A review.  Disruptions in DNA repair pathways predispose cells to accumulating DNA damage.  A growing body of evidence indicates that tumors accumulate progressively more mutations in DNA repair proteins as cancers progress.  DNA repair mechanisms greatly affect the response to cytotoxic treatments, so understanding those mechanisms and finding ways to turn dysregulated repair processes against themselves to induce tumor death is the goal of all DNA repair inhibition efforts.  Inhibition may be direct or indirect.  This burgeoning field of research is replete with promise and challenge, as more intricacies of each repair pathway are discovered.  In an era of increasing concern about healthcare costs, use of DNA repair inhibitors can prove to be highly effective stewardship of R&D resources and patient expenses.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpDbAS-i0CKqbVg90H21EOLACvtfcHk0lgAJjZmmNrzCg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtVWmsLjP&md5=20f5c07ae16d46176d515dcc869ffc7e</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.2217%2Ffon.14.60&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2217%252Ffon.14.60%26sid%3Dliteratum%253Aachs%26aulast%3DKelley%26aufirst%3DM.%2BR.%26aulast%3DLogsdon%26aufirst%3DD.%26aulast%3DFishel%26aufirst%3DM.%2BL.%26atitle%3DTargeting%2520DNA%2520repair%2520pathways%2520for%2520cancer%2520treatment%253A%2520what%25E2%2580%2599s%2520new%253F%26jtitle%3DFuture%2520Oncol.%26date%3D2014%26volume%3D10%26spage%3D1215%26epage%3D1237%26doi%3D10.2217%2Ffon.14.60" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Scott, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Swisher, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaufmann, S. H.</span></span> <span> </span><span class="NLM_article-title">Poly (ADP-Ribose) Polymerase inhibitors: recent advances and future development</span>. <i>J. Clin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>33</i></span>,  <span class="NLM_fpage">1397</span>– <span class="NLM_lpage">1406</span>, <span class="refDoi"> DOI: 10.1200/JCO.2014.58.8848</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02008&amp;key=10.1200%2FJCO.2014.58.8848" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02008&amp;key=25779564" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02008&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtVaqtL%252FM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2015&pages=1397-1406&author=C.+L.+Scottauthor=E.+M.+Swisherauthor=S.+H.+Kaufmann&title=Poly+%28ADP-Ribose%29+Polymerase+inhibitors%3A+recent+advances+and+future+development&doi=10.1200%2FJCO.2014.58.8848"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Poly (ADP-Ribose) polymerase inhibitors: recent advances and future development</span></div><div class="casAuthors">Scott, Clare L.; Swisher, Elizabeth M.; Kaufmann, Scott H.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">33</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1397-1406</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">Poly (ADP-ribose) polymerase (PARP) inhibitors have shown promising activity in epithelial ovarian cancers, esp. relapsed platinum-sensitive high-grade serous disease.  Consistent with preclin. studies, ovarian cancers and a no. of other solid tumor types occurring in patients with deleterious germline mutations in BRCA1 or BRCA2 seem to be particularly sensitive.  However, it is also becoming clear that germline BRCA1/2 mutations are neither necessary nor sufficient for patients to derive benefit from PARP inhibitors.  We provide an update on PARP inhibitor clin. development, describe recent advances in our understanding of PARP inhibitor mechanism of action, and discuss current issues in the development of these agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGowf5pO-7WPjrVg90H21EOLACvtfcHk0liCtv3d9FSHaQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtVaqtL%252FM&md5=a9a1668a322c4a2e099a1fd9891a15da</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1200%2FJCO.2014.58.8848&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2014.58.8848%26sid%3Dliteratum%253Aachs%26aulast%3DScott%26aufirst%3DC.%2BL.%26aulast%3DSwisher%26aufirst%3DE.%2BM.%26aulast%3DKaufmann%26aufirst%3DS.%2BH.%26atitle%3DPoly%2520%2528ADP-Ribose%2529%2520Polymerase%2520inhibitors%253A%2520recent%2520advances%2520and%2520future%2520development%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2015%26volume%3D33%26spage%3D1397%26epage%3D1406%26doi%3D10.1200%2FJCO.2014.58.8848" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Senhaji
Mouhri, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goodfellow, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jean-Claude, B.</span></span> <span> </span><span class="NLM_article-title">A type I combi-targeting approach for the design of molecules with enhanced potency against BRCA1/2 mutant- and O6-methylguanine-DNA methyltransferase (mgmt)- expressing tumour cells</span>. <i>BMC Cancer</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">540</span>– <span class="NLM_lpage">540</span>, <span class="refDoi"> DOI: 10.1186/s12885-017-3504-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02008&amp;key=10.1186%2Fs12885-017-3504-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02008&amp;key=28800752" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02008&amp;key=1%3ACAS%3A280%3ADC%252BC1cfmvVCjsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2017&pages=540-540&author=Z.+Senhaji%0AMouhriauthor=E.+Goodfellowauthor=B.+Jean-Claude&title=A+type+I+combi-targeting+approach+for+the+design+of+molecules+with+enhanced+potency+against+BRCA1%2F2+mutant-+and+O6-methylguanine-DNA+methyltransferase+%28mgmt%29-+expressing+tumour+cells&doi=10.1186%2Fs12885-017-3504-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">A type I combi-targeting approach for the design of molecules with enhanced potency against BRCA1/2 mutant- and O6-methylguanine-DNA methyltransferase (mgmt)- expressing tumour cells</span></div><div class="casAuthors">Senhaji Mouhri Zhor; Goodfellow Elliot; Jean-Claude Bertrand</div><div class="citationInfo"><span class="NLM_cas:title">BMC cancer</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">540</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  Mutations of the DNA repair proteins BRCA1/2 are synthetically lethal with the DNA repair enzyme poly(ADP-ribose) polymerase (PARP), which when inhibited, leads to cell death due to the absence of compensatory DNA repair mechanism.  The potency of PARP inhibitors has now been clinically proven.  However, disappointingly, acquired resistance mediated by the reactivation of wild type BRCA1/2 has been reported.  In order to improve their efficacy, trials are ongoing to explore their combinations with temozolomide (TMZ).  Here, in order to enhance potency in BRCA1/2-mutant cells, we report on the design of single molecules termed "combi-molecules" capable of not only inhibiting PARP but also damaging DNA like TMZ, which is known to induce a large number of DNA adducts.  The majority of these lesions are processed through PARP-dependent base-excision repair machinery.  Paradoxically, the least abundant lesion, the O6-methylguanine adduct is the most cytotoxic.  Its repair by the O6-methylguanine DNA methyl transferase (MGMT) confers robust resistance to TMZ.  Thus, we surmise that a combi-molecule designed to generate the same DNA adducts as TMZ, with an additional ability to block PARP, could induce BRCA1/2 mutant selective potency and a growth inhibitory profile independent of MGMT status.  METHODS:  The hydrolysis of EG22 and its stabilized form ZSM02 was analyzed by HPLC and fluorescence spectroscopy.  Growth inhibitory potency was determined by SRB assay.  PARP inhibition was determined by an enzyme assay and DNA damage by the comet assay.  Subcellular distribution was visualized by confocal microscopy.  RESULTS:  Studies on EG22 showed that: (a) it inflicted anomalously higher levels of DNA damage than TMZ (b) it induced PARP inhibitory potency in the same range as ANI, a known PARP inhibitor (IC50 = 0.10 μM) (c) it showed strong potency in both BRCA1/2 wild type and mutated cells with 6-fold selectivity for the mutants and it was 65-303-fold more potent than TMZ and 4-63-fold than ANI alone and 3-47-fold than their corresponding equimolar combinations and (d) its potency was independent of MGMT expression.  CONCLUSION:  The results in toto suggest that a combi-molecular approach directed at blocking PARP and damaging DNA can lead to single molecules with selective and enhanced potency against BRCA1/2 mutant and with activity independent of MGMT, the major predictive biomarker for resistance to TMZ.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRf37bciQUfj0g6wdEZmT2rfW6udTcc2eabR15sOE26aLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1cfmvVCjsg%253D%253D&md5=4a0fe4976628ff7e51f44a41e351f905</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1186%2Fs12885-017-3504-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs12885-017-3504-1%26sid%3Dliteratum%253Aachs%26aulast%3DSenhaji%2BMouhri%26aufirst%3DZ.%26aulast%3DGoodfellow%26aufirst%3DE.%26aulast%3DJean-Claude%26aufirst%3DB.%26atitle%3DA%2520type%2520I%2520combi-targeting%2520approach%2520for%2520the%2520design%2520of%2520molecules%2520with%2520enhanced%2520potency%2520against%2520BRCA1%252F2%2520mutant-%2520and%2520O6-methylguanine-DNA%2520methyltransferase%2520%2528mgmt%2529-%2520expressing%2520tumour%2520cells%26jtitle%3DBMC%2520Cancer%26date%3D2017%26volume%3D17%26spage%3D540%26epage%3D540%26doi%3D10.1186%2Fs12885-017-3504-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gupta, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mladek, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tian, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Decker, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kizilbash, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kitange, G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sarkaria, J. N.</span></span> <span> </span><span class="NLM_article-title">PARP inhibitors for sensitization of alkylation chemotherapy in glioblastoma: impact of blood-brain barrier and molecular heterogeneity</span>. <i>Front. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">670</span>, <span class="refDoi"> DOI: 10.3389/fonc.2018.00670</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02008&amp;key=10.3389%2Ffonc.2018.00670" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02008&amp;key=30723695" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2019&pages=670&author=S.+K.+Guptaauthor=E.+J.+Smithauthor=A.+C.+Mladekauthor=S.+Tianauthor=P.+A.+Deckerauthor=S.+H.+Kizilbashauthor=G.+J.+Kitangeauthor=J.+N.+Sarkaria&title=PARP+inhibitors+for+sensitization+of+alkylation+chemotherapy+in+glioblastoma%3A+impact+of+blood-brain+barrier+and+molecular+heterogeneity&doi=10.3389%2Ffonc.2018.00670"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.3389%2Ffonc.2018.00670&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffonc.2018.00670%26sid%3Dliteratum%253Aachs%26aulast%3DGupta%26aufirst%3DS.%2BK.%26aulast%3DSmith%26aufirst%3DE.%2BJ.%26aulast%3DMladek%26aufirst%3DA.%2BC.%26aulast%3DTian%26aufirst%3DS.%26aulast%3DDecker%26aufirst%3DP.%2BA.%26aulast%3DKizilbash%26aufirst%3DS.%2BH.%26aulast%3DKitange%26aufirst%3DG.%2BJ.%26aulast%3DSarkaria%26aufirst%3DJ.%2BN.%26atitle%3DPARP%2520inhibitors%2520for%2520sensitization%2520of%2520alkylation%2520chemotherapy%2520in%2520glioblastoma%253A%2520impact%2520of%2520blood-brain%2520barrier%2520and%2520molecular%2520heterogeneity%26jtitle%3DFront.%2520Oncol.%26date%3D2019%26volume%3D8%26spage%3D670%26doi%3D10.3389%2Ffonc.2018.00670" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Salvati, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Botta, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Amato, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Di Leva, F. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zizza, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gioiello, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pagano, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Graziani, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tarsounas, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Randazzo, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Novellino, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Biroccio, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cosconati, S.</span></span> <span> </span><span class="NLM_article-title">Lead discovery of dual G-Quadruplex stabilizers and Poly(ADP-ribose) Polymerases (PARPs) inhibitors: a new avenue in anticancer treatment</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">3626</span>– <span class="NLM_lpage">3635</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b01563</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b01563" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02008&amp;key=1%3ACAS%3A528%3ADC%252BC2sXms1Wntbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=3626-3635&author=E.+Salvatiauthor=L.+Bottaauthor=J.+Amatoauthor=F.+S.+Di+Levaauthor=P.+Zizzaauthor=A.+Gioielloauthor=B.+Paganoauthor=G.+Grazianiauthor=M.+Tarsounasauthor=A.+Randazzoauthor=E.+Novellinoauthor=A.+Biroccioauthor=S.+Cosconati&title=Lead+discovery+of+dual+G-Quadruplex+stabilizers+and+Poly%28ADP-ribose%29+Polymerases+%28PARPs%29+inhibitors%3A+a+new+avenue+in+anticancer+treatment&doi=10.1021%2Facs.jmedchem.6b01563"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Lead Discovery of Dual G-Quadruplex Stabilizers and Poly(ADP-ribose) Polymerases (PARPs) Inhibitors: A New Avenue in Anticancer Treatment</span></div><div class="casAuthors">Salvati, Erica; Botta, Lorenzo; Amato, Jussara; Di Leva, Francesco Saverio; Zizza, Pasquale; Gioiello, Antimo; Pagano, Bruno; Graziani, Grazia; Tarsounas, Madalena; Randazzo, Antonio; Novellino, Ettore; Biroccio, Annamaria; Cosconati, Sandro</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">3626-3635</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">G-quadruplex stabilizers are an established opportunity in anticancer chemotherapy.  To circumvent the antiproliferative effects of G4 ligands, cancer cells recruit PARP enzymes at telomeres.  Herein, starting from the structural similarity of a potent G4 ligand previously discovered by our group and a congeneric PARP inhibitor, a library of derivs. was synthesized to discover the first dual G4/PARP ligand.  We demonstrate that a properly decorated thieno[3,2-c]quinolin-4(5H)-one stabilizes the G4 fold in vitro and in cells, induces a DNA damage response localized to telomeres, inhibits PARylation in cells, and has an antiproliferative effect in BRCA2 deficient tumor cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoNobRG8jUGVLVg90H21EOLACvtfcHk0liCtv3d9FSHaQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXms1Wntbw%253D&md5=2355803dca16e068d7c6b19be66dd2e2</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b01563&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b01563%26sid%3Dliteratum%253Aachs%26aulast%3DSalvati%26aufirst%3DE.%26aulast%3DBotta%26aufirst%3DL.%26aulast%3DAmato%26aufirst%3DJ.%26aulast%3DDi%2BLeva%26aufirst%3DF.%2BS.%26aulast%3DZizza%26aufirst%3DP.%26aulast%3DGioiello%26aufirst%3DA.%26aulast%3DPagano%26aufirst%3DB.%26aulast%3DGraziani%26aufirst%3DG.%26aulast%3DTarsounas%26aufirst%3DM.%26aulast%3DRandazzo%26aufirst%3DA.%26aulast%3DNovellino%26aufirst%3DE.%26aulast%3DBiroccio%26aufirst%3DA.%26aulast%3DCosconati%26aufirst%3DS.%26atitle%3DLead%2520discovery%2520of%2520dual%2520G-Quadruplex%2520stabilizers%2520and%2520Poly%2528ADP-ribose%2529%2520Polymerases%2520%2528PARPs%2529%2520inhibitors%253A%2520a%2520new%2520avenue%2520in%2520anticancer%2520treatment%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26volume%3D60%26spage%3D3626%26epage%3D3635%26doi%3D10.1021%2Facs.jmedchem.6b01563" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yacoub, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McKinstry, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hinman, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chung, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dent, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hagan, M. P.</span></span> <span> </span><span class="NLM_article-title">Epidermal growth factor and ionizing radiation up-regulate the DNA repair genes XRCC1 and ERCC1 in DU145 and LNCaP prostate carcinoma through MAPK signaling</span>. <i>Radiat. Res.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>159</i></span>,  <span class="NLM_fpage">439</span>– <span class="NLM_lpage">452</span>, <span class="refDoi"> DOI: 10.1667/0033-7587(2003)159[0439:EGFAIR]2.0.CO;2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02008&amp;key=10.1667%2F0033-7587%282003%29159%5B0439%3AEGFAIR%5D2.0.CO%3B2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02008&amp;key=12643788" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02008&amp;key=1%3ACAS%3A528%3ADC%252BD3sXivVersL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=159&publication_year=2003&pages=439-452&author=A.+Yacoubauthor=R.+McKinstryauthor=D.+Hinmanauthor=T.+Chungauthor=P.+Dentauthor=M.+P.+Hagan&title=Epidermal+growth+factor+and+ionizing+radiation+up-regulate+the+DNA+repair+genes+XRCC1+and+ERCC1+in+DU145+and+LNCaP+prostate+carcinoma+through+MAPK+signaling&doi=10.1667%2F0033-7587%282003%29159%5B0439%3AEGFAIR%5D2.0.CO%3B2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Epidermal growth factor and ionizing radiation up-regulate the DNA repair genes XRCC1 and ERCC1 in DU145 and LNCaP prostate carcinoma through MAPK signaling</span></div><div class="casAuthors">Yacoub, Adly; McKinstry, Robert; Hinman, Darin; Chung, Theodore; Dent, Paul; Hagan, Michael P.</div><div class="citationInfo"><span class="NLM_cas:title">Radiation Research</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">159</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">439-452</span>CODEN:
                <span class="NLM_cas:coden">RAREAE</span>;
        ISSN:<span class="NLM_cas:issn">0033-7587</span>.
    
            (<span class="NLM_cas:orgname">Radiation Research Society</span>)
        </div><div class="casAbstract">This work examd. the importance of radiation-induced and ligand-induced EGFR-ERK signaling for the regulation of DNA repair proteins XRCC1 and ERCC1 in prostate carcinoma cells, DU145 (TP53mut), displaying EGFR-TGFA-dependent autocrine growth and high MAPK (ERK1/2) activity, and LNCaP (TP53wt) cells expressing low constitutive levels of ERK1/2 activity.  Using quant. RT-PCR and Western analyses, we detd. that ionizing radiation activated the DNA repair genes XRCC1 and ERCC1 in an ERK1/2-dependent fashion for each cell line.  After irradn., a rapid increase followed by a decrease in ERK1/2 activity preceded the increase in XRCC1/ERCC1 expression in DU145 cells, while only the rapid decrease in ERK1/2 preceded the increase in XRCC1/ERCC1 expression in LNCaP cells.  Administration of EGF, however, markedly increased the up-regulation of phospho-ERK, ERCC1 and XRCC1 in both cell lines.  Although the EGFR inhibitor tyrphostin (AG-1478) and the MEK inhibitor PD90859 both attenuated EGF-induced levels of the ERCC1 and XRCC1 protein, PD98059 blocked the induction of ERCC1 and XRCC1 by radiation more effectively in both cell lines.  Inhibition of ERK at a level that reduced the up-regulation of DNA repair led to the persistence of apurinic/apyrimidinic (AP) sites of DNA damage and increased cell killing.  Taken together, these data imply a complex control of DNA repair activation that may be more generally dependent on MAPK (ERK1/2) signaling than was previously noted.  These data provide novel insights into the capacity of the EGFR-ERK signaling to modulate DNA repair in cancer cells and into the functional significance of this signaling.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqH8DufM3lxR7Vg90H21EOLACvtfcHk0li1wnpCrDTfNQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXivVersL4%253D&md5=0042f1fce51c1c8ea88109cd7bd815de</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1667%2F0033-7587%282003%29159%5B0439%3AEGFAIR%5D2.0.CO%3B2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1667%252F0033-7587%25282003%2529159%255B0439%253AEGFAIR%255D2.0.CO%253B2%26sid%3Dliteratum%253Aachs%26aulast%3DYacoub%26aufirst%3DA.%26aulast%3DMcKinstry%26aufirst%3DR.%26aulast%3DHinman%26aufirst%3DD.%26aulast%3DChung%26aufirst%3DT.%26aulast%3DDent%26aufirst%3DP.%26aulast%3DHagan%26aufirst%3DM.%2BP.%26atitle%3DEpidermal%2520growth%2520factor%2520and%2520ionizing%2520radiation%2520up-regulate%2520the%2520DNA%2520repair%2520genes%2520XRCC1%2520and%2520ERCC1%2520in%2520DU145%2520and%2520LNCaP%2520prostate%2520carcinoma%2520through%2520MAPK%2520signaling%26jtitle%3DRadiat.%2520Res.%26date%3D2003%26volume%3D159%26spage%3D439%26epage%3D452%26doi%3D10.1667%2F0033-7587%282003%29159%5B0439%3AEGFAIR%5D2.0.CO%3B2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Day, K. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hiles, G. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kozminsky, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dawsey, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paul, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Broses, L. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shah, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kunja, L. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hall, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palanisamy, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Daignault-Newton, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">El-Sawy, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilson, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chou, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ignatoski, K. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keller, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagrath, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morgan, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Day, M. L.</span></span> <span> </span><span class="NLM_article-title">HER2 and EGFR overexpression support metastatic progression of prostate cancer to bone</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>77</i></span>,  <span class="NLM_fpage">74</span>– <span class="NLM_lpage">85</span>, <span class="refDoi"> DOI: 10.1158/0008-5472.CAN-16-1656</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02008&amp;key=10.1158%2F0008-5472.CAN-16-1656" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02008&amp;key=27793843" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02008&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhsFSl" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=77&publication_year=2017&pages=74-85&author=K.+C.+Dayauthor=G.+L.+Hilesauthor=M.+Kozminskyauthor=S.+J.+Dawseyauthor=A.+Paulauthor=L.+J.+Brosesauthor=R.+Shahauthor=L.+P.+Kunjaauthor=C.+Hallauthor=N.+Palanisamyauthor=S.+Daignault-Newtonauthor=L.+El-Sawyauthor=S.+J.+Wilsonauthor=A.+Chouauthor=K.+W.+Ignatoskiauthor=E.+Kellerauthor=D.+Thomasauthor=S.+Nagrathauthor=T.+Morganauthor=M.+L.+Day&title=HER2+and+EGFR+overexpression+support+metastatic+progression+of+prostate+cancer+to+bone&doi=10.1158%2F0008-5472.CAN-16-1656"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">HER2 and EGFR Overexpression Support Metastatic Progression of Prostate Cancer to Bone</span></div><div class="casAuthors">Day, Kathleen C.; Hiles, Guadalupe Lorenzatti; Kozminsky, Molly; Dawsey, Scott J.; Paul, Alyssa; Broses, Luke J.; Shah, Rajal; Kunja, Lakshmi P.; Hall, Christopher; Palanisamy, Nallasivam; Daignault-Newton, Stephanie; El-Sawy, Layla; Wilson, Steven James; Chou, Andrew; Ignatoski, Kathleen Woods; Keller, Evan; Thomas, Dafydd; Nagrath, Sunitha; Morgan, Todd; Day, Mark L.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">77</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">74-85</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Activation of the EGF receptors EGFR (ErbB1) and HER2 (ErbB2) drives the progression of multiple cancer types through complex mechanisms that are still not fully understood.  In this study, we report that HER2 expression is elevated in bone metastases of prostate cancer independently of gene amplification.  An examn. of HER2 and NF-κB receptor (RANK) coexpression revealed increased levels of both proteins in aggressive prostate tumors and metastatic deposits.  Inhibiting HER2 expression in bone tumor xenografts reduced proliferation and RANK expression while maintaining EGFR expression.  In examg. the role of EGFR in tumor-initiating cells (TIC), we found that EGFR expression was required for primary and secondary sphere formation of prostate cancer cells.  EGFR expression was also obsd. in circulating tumor cells (CTC) during prostate cancer metastasis.  Dual inhibition of HER2 and EGFR resulted in significant inhibition of tumor xenograft growth, further supporting the significance of these receptors in prostate cancer progression.  Overall, our results indicate that EGFR promotes survival of prostate TIC and CTC that metastasize to bone, whereas HER2 supports the growth of prostate cancer cells once they are established at metastatic sites.  Cancer Res; 77(1); 74-85. 2016 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoMSjSQ1vG3pbVg90H21EOLACvtfcHk0li1wnpCrDTfNQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhsFSl&md5=8aed330d8b40475e0450e6ca380ebef7</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-16-1656&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-16-1656%26sid%3Dliteratum%253Aachs%26aulast%3DDay%26aufirst%3DK.%2BC.%26aulast%3DHiles%26aufirst%3DG.%2BL.%26aulast%3DKozminsky%26aufirst%3DM.%26aulast%3DDawsey%26aufirst%3DS.%2BJ.%26aulast%3DPaul%26aufirst%3DA.%26aulast%3DBroses%26aufirst%3DL.%2BJ.%26aulast%3DShah%26aufirst%3DR.%26aulast%3DKunja%26aufirst%3DL.%2BP.%26aulast%3DHall%26aufirst%3DC.%26aulast%3DPalanisamy%26aufirst%3DN.%26aulast%3DDaignault-Newton%26aufirst%3DS.%26aulast%3DEl-Sawy%26aufirst%3DL.%26aulast%3DWilson%26aufirst%3DS.%2BJ.%26aulast%3DChou%26aufirst%3DA.%26aulast%3DIgnatoski%26aufirst%3DK.%2BW.%26aulast%3DKeller%26aufirst%3DE.%26aulast%3DThomas%26aufirst%3DD.%26aulast%3DNagrath%26aufirst%3DS.%26aulast%3DMorgan%26aufirst%3DT.%26aulast%3DDay%26aufirst%3DM.%2BL.%26atitle%3DHER2%2520and%2520EGFR%2520overexpression%2520support%2520metastatic%2520progression%2520of%2520prostate%2520cancer%2520to%2520bone%26jtitle%3DCancer%2520Res.%26date%3D2017%26volume%3D77%26spage%3D74%26epage%3D85%26doi%3D10.1158%2F0008-5472.CAN-16-1656" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Baek, K. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hong, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jung, Y. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, C. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, E. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, M. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoo, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, S. W.</span></span> <span> </span><span class="NLM_article-title">Correlation of AR, EGFR, and HER2 expression levels in prostate cancer: immunohistochemical analysis and chromogenic in situ hybridization</span>. <i>Cancer Res Treat</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>44</i></span>,  <span class="NLM_fpage">50</span>– <span class="NLM_lpage">56</span>, <span class="refDoi"> DOI: 10.4143/crt.2012.44.1.50</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02008&amp;key=10.4143%2Fcrt.2012.44.1.50" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02008&amp;key=22500161" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02008&amp;key=1%3ACAS%3A280%3ADC%252BC38rkslChtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=44&publication_year=2012&pages=50-56&author=K.+H.+Baekauthor=M.+E.+Hongauthor=Y.+Y.+Jungauthor=C.+H.+Leeauthor=T.+J.+Leeauthor=E.+S.+Parkauthor=M.+K.+Kimauthor=J.+H.+Yooauthor=S.+W.+Lee&title=Correlation+of+AR%2C+EGFR%2C+and+HER2+expression+levels+in+prostate+cancer%3A+immunohistochemical+analysis+and+chromogenic+in+situ+hybridization&doi=10.4143%2Fcrt.2012.44.1.50"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Correlation of AR, EGFR, and HER2 Expression Levels in Prostate Cancer: Immunohistochemical Analysis and Chromogenic In Situ Hybridization</span></div><div class="casAuthors">Baek Kwang Hyun; Hong Min Eui; Jung Yoon Yang; Lee Chung Hun; Lee Tae Jin; Park Eon Sub; Kim Mi Kyung; Yoo Jae Hyung; Lee Soo Whan</div><div class="citationInfo"><span class="NLM_cas:title">Cancer research and treatment : official journal of Korean Cancer Association</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">44</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">50-6</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">PURPOSE:  The androgen receptor (AR) plays a central role in prostate cancer.  Evidence from several groups indicates that epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2) may enhance AR activity in prostate cancer cell lines.  This study was designed to investigate the protein expression of AR, EGFR, and HER2 and to determine whether the EGFR and HER2 genes are amplified in prostate cancer tissues.  MATERIALS AND METHODS:  The protein expression levels of AR, EGFR, and HER2 in a tissue microarray block of 66 prostate cancer samples were investigated by immunohistochemical analysis and chromogenic in situ hybridization was used to determine whether the EGFR and HER2 genes were amplified in these tissues.  RESULTS:  The AR and EGFR proteins were expressed in 59.1% and 40.9% of prostate cancers, respectively, but their expression levels were not significantly associated with clinicopathologic factors.  Of the cases in which tissues were negative for EGFR protein expression, 69.2% were positive for AR protein expression; however, AR protein expression was significantly reduced (44.4%) in tissues in which EGFR protein was expressed.  HER2 expression was detected in only 1 case (1.5%).  No amplification of the EGFR or HER2 genes was found in prostate cancer specimens.  CONCLUSION:  This study was limited by small number of subjects, but it can still be inferred that the expression levels of the AR and EGFR proteins are inversely correlated in prostate cancer patients.  The potential utility of EGFR and HER2 as prognostic factors or therapeutic targets warrants further study.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQCEHsxuDVeOiA3UY9EwTNrfW6udTcc2eaRC1HUiPpkzLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC38rkslChtA%253D%253D&md5=31b79397371105702abd98e80daf36ce</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.4143%2Fcrt.2012.44.1.50&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4143%252Fcrt.2012.44.1.50%26sid%3Dliteratum%253Aachs%26aulast%3DBaek%26aufirst%3DK.%2BH.%26aulast%3DHong%26aufirst%3DM.%2BE.%26aulast%3DJung%26aufirst%3DY.%2BY.%26aulast%3DLee%26aufirst%3DC.%2BH.%26aulast%3DLee%26aufirst%3DT.%2BJ.%26aulast%3DPark%26aufirst%3DE.%2BS.%26aulast%3DKim%26aufirst%3DM.%2BK.%26aulast%3DYoo%26aufirst%3DJ.%2BH.%26aulast%3DLee%26aufirst%3DS.%2BW.%26atitle%3DCorrelation%2520of%2520AR%252C%2520EGFR%252C%2520and%2520HER2%2520expression%2520levels%2520in%2520prostate%2520cancer%253A%2520immunohistochemical%2520analysis%2520and%2520chromogenic%2520in%2520situ%2520hybridization%26jtitle%3DCancer%2520Res%2520Treat%26date%3D2012%26volume%3D44%26spage%3D50%26epage%3D56%26doi%3D10.4143%2Fcrt.2012.44.1.50" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Todorova, M. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Larroque, A.-L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dauphin-Pierre, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fang, Y.-Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jean-Claude, B. J.</span></span> <span> </span><span class="NLM_article-title">Subcellular distribution of a fluorescence-labeled combi-molecule designed to block epidermal growth factor receptor tyrosine kinase and damage DNA with a green fluorescent species</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">869</span>– <span class="NLM_lpage">882</span>, <span class="refDoi"> DOI: 10.1158/1535-7163.MCT-09-0673</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02008&amp;key=10.1158%2F1535-7163.MCT-09-0673" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02008&amp;key=20354119" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02008&amp;key=1%3ACAS%3A528%3ADC%252BC3cXktlCqt7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2010&pages=869-882&author=M.+I.+Todorovaauthor=A.-L.+Larroqueauthor=S.+Dauphin-Pierreauthor=Y.-Q.+Fangauthor=B.+J.+Jean-Claude&title=Subcellular+distribution+of+a+fluorescence-labeled+combi-molecule+designed+to+block+epidermal+growth+factor+receptor+tyrosine+kinase+and+damage+DNA+with+a+green+fluorescent+species&doi=10.1158%2F1535-7163.MCT-09-0673"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Subcellular Distribution of a Fluorescence-Labeled Combi-Molecule Designed to Block Epidermal Growth Factor Receptor Tyrosine Kinase and Damage DNA with a Green Fluorescent Species</span></div><div class="casAuthors">Todorova, Margarita I.; Larroque, Anne-Laure; Dauphin-Pierre, Sabine; Fang, You-Qiang; Jean-Claude, Bertrand J.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">869-882</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">To monitor the subcellular distribution of mixed epidermal growth factor (EGF) receptor (EGFR)-DNA targeting drugs termed combi-mols., we designed AL237, a fluorescent prototype, to degrade into a green fluorescent DNA damaging species and FD105, a blue fluorescent EGFR inhibitor.  Here we showed that AL237 damaged DNA in the 12.5 to 50 μmol/L range.  Despite its size, it blocked EGFR phosphorylation in an enzyme assay (IC50 = 0.27 μmol/L) and in MDA-MB468 breast cancer cells in the same concn. range as for DNA damage.  This translated into inhibition of extracellular signal-regulated kinase 1/2 or BAD phosphorylation and downregulation of DNA repair proteins (XRCC1, ERCC1).  Having shown that AL237 was a balanced EGFR-DNA targeting mol., it was used as an imaging probe to show that (a) green and blue colors were primarily colocalized in the perinuclear and partially in the nucleus in EGFR- or ErbB2-expressing cells, (b) the blue fluorescence assocd. with FD105, but not the green, was colocalized with anti-EGFR red-labeled antibody, (c) the green fluorescence of nuclei was significantly more intense in NIH 3T3 cells expressing EGFR or ErbB2 than in their wild-type counterparts (P < 0.05).  Similarly, the growth inhibitory potency of AL237 was selectively stronger in the transfectants.  In summary, the results suggest that AL237 diffuses into the cells and localizes abundantly in the perinuclear region and partially in the nucleus where it degrades into EGFR and DNA targeting species.  This bystander-like effect translates into high levels of DNA damage in the nucleus.  Sufficient quinazoline levels are released in the cells to block EGF-induced activation of downstream signaling.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoOwehXKbZBD7Vg90H21EOLACvtfcHk0lhaancvhgKEWQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXktlCqt7w%253D&md5=cd0998f04045a30bdfa1e29e6ee799a9</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-09-0673&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-09-0673%26sid%3Dliteratum%253Aachs%26aulast%3DTodorova%26aufirst%3DM.%2BI.%26aulast%3DLarroque%26aufirst%3DA.-L.%26aulast%3DDauphin-Pierre%26aufirst%3DS.%26aulast%3DFang%26aufirst%3DY.-Q.%26aulast%3DJean-Claude%26aufirst%3DB.%2BJ.%26atitle%3DSubcellular%2520distribution%2520of%2520a%2520fluorescence-labeled%2520combi-molecule%2520designed%2520to%2520block%2520epidermal%2520growth%2520factor%2520receptor%2520tyrosine%2520kinase%2520and%2520damage%2520DNA%2520with%2520a%2520green%2520fluorescent%2520species%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2010%26volume%3D9%26spage%3D869%26epage%3D882%26doi%3D10.1158%2F1535-7163.MCT-09-0673" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Goodfellow, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Senhaji Mouhri, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jean-Claude, B. J.</span></span> <span> </span><span class="NLM_article-title">Design, synthesis and biological activity of novel molecules designed to target PARP and DNA</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>27</i></span>,  <span class="NLM_fpage">688</span>– <span class="NLM_lpage">694</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2016.09.054</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02008&amp;key=10.1016%2Fj.bmcl.2016.09.054" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02008&amp;key=28003142" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02008&amp;key=1%3ACAS%3A528%3ADC%252BC28XitFamtLzN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2017&pages=688-694&author=E.+Goodfellowauthor=Z.+Senhaji+Mouhriauthor=C.+Williamsauthor=B.+J.+Jean-Claude&title=Design%2C+synthesis+and+biological+activity+of+novel+molecules+designed+to+target+PARP+and+DNA&doi=10.1016%2Fj.bmcl.2016.09.054"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Design, synthesis and biological activity of novel molecules designed to target PARP and DNA</span></div><div class="casAuthors">Goodfellow, Elliot; Senhaji Mouhri, Zhor; Williams, Christopher; Jean-Claude, Bertrand J.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">688-694</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">In order to enhance the cytotoxic potential of poly(ADP-ribose) polymerase (PARP) inhibitors in BRCA1 or 2 deficient tumors, the authors designed a series of mols. contg. a 1,2,3-triazene moiety tethered to a PARP targeting scaffold.  A cell-based selectivity assay involving a BRCA2-deficient Chinese hamster cell line and its corresponding BRCA2 wild type transfectant, was used to predict the PARP targeting potential of the latter agents.  The results showed that adding a DNA damaging function to the PARP inhibitors decreased but did not abrogate the selective targeting of the BRCA2-deficient cells.  The DNA damaging moiety augmented the potency in BRCA2 deficient cells by 2-20-fold.  The most selective dual PARP-DNA targeting agent I was found to possess dual DNA and PARP targeting properties.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqz1x3BscUmJrVg90H21EOLACvtfcHk0lhaancvhgKEWQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XitFamtLzN&md5=fdce34354322d2389749a63ff0ebb9fe</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2016.09.054&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2016.09.054%26sid%3Dliteratum%253Aachs%26aulast%3DGoodfellow%26aufirst%3DE.%26aulast%3DSenhaji%2BMouhri%26aufirst%3DZ.%26aulast%3DWilliams%26aufirst%3DC.%26aulast%3DJean-Claude%26aufirst%3DB.%2BJ.%26atitle%3DDesign%252C%2520synthesis%2520and%2520biological%2520activity%2520of%2520novel%2520molecules%2520designed%2520to%2520target%2520PARP%2520and%2520DNA%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2017%26volume%3D27%26spage%3D688%26epage%3D694%26doi%3D10.1016%2Fj.bmcl.2016.09.054" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rao, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Larroque-Lombard, A.-L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peyrard, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thauvin, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rachid, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jean-Claude, B. J.</span></span> <span> </span><span class="NLM_article-title">Target modulation by a kinase inhibitor engineered to induce a tandem blockade of the Epidermal Growth Factor Receptor (EGFR) and c-Src: the concept of type III Combi-Targeting</span>. <i>PLoS One</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>10</i></span>, <span class="NLM_elocation-id">e0117215</span> <span class="refDoi"> DOI: 10.1371/journal.pone.0117215</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02008&amp;key=10.1371%2Fjournal.pone.0117215" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02008&amp;key=25658745" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02008&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhsVGrsr7F" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2015&author=S.+Raoauthor=A.-L.+Larroque-Lombardauthor=L.+Peyrardauthor=C.+Thauvinauthor=Z.+Rachidauthor=C.+Williamsauthor=B.+J.+Jean-Claude&title=Target+modulation+by+a+kinase+inhibitor+engineered+to+induce+a+tandem+blockade+of+the+Epidermal+Growth+Factor+Receptor+%28EGFR%29+and+c-Src%3A+the+concept+of+type+III+Combi-Targeting&doi=10.1371%2Fjournal.pone.0117215"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Target modulation by a kinase inhibitor engineered to induce a tandem blockade of the epidermal growth factor receptor (EGFR) and c-Src: the concept of type III combi-targeting</span></div><div class="casAuthors">Rao, Suman; Larroque-Lombard, Anne-Laure; Peyrard, Lisa; Thauvin, Cedric; Rachid, Zakaria; Williams, Christopher; Jean-Claude, Bertrand J.</div><div class="citationInfo"><span class="NLM_cas:title">PLoS One</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">e0117215/1-e0117215/24</span>CODEN:
                <span class="NLM_cas:coden">POLNCL</span>;
        ISSN:<span class="NLM_cas:issn">1932-6203</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">Cancer cells are characterized by a complex network of interrelated and compensatory signaling driven by multiple kinases that reduce their sensitivity to targeted therapy.  Therefore, strategies directed at inhibiting two or more kinases are required to robustly block the growth of refractory tumor cells.  Here we report on a novel strategy to promote sustained inhibition of two oncogenic kinases (Kin-1 and Kin-2) by designing a mol. K1-K2, termed "combi-mol.", to induce a tandem blockade of Kin-1 and Kin-2, as an intact structure and to be further hydrolyzed to two inhibitors K1 and K2 directed at Kin-1 and Kin-2, resp.  We chose to target EGFR (Kin-1) and c-Src (Kin-2), two tyrosine kinases known to synergize to promote tumor growth and progression.  Variation of K1-K2 linkers led to AL776, our first optimized EGFR-c-Src targeting prototype.  Here we showed that: (a) AL776 blocked EGFR and c-Src as an intact structure using an in vitro kinase assay (IC50 EGFR = 0.12 μM and IC50 c-Src = 3 nM), (b) it could release K1 (AL621, a nanomolar EGFR inhibitor) and K2 (dasatinib, a clin. approved Abl/c-Src inhibitor) by hydrolytic cleavage both in vitro and in vivo, (c) it could robustly inhibit phosphorylation of EGFR and c-Src (0.25-1 μM) in cells, (d) it induced 2-4 fold stronger growth inhibition than gefitinib or dasatinib and apoptosis at concns. as low as 1 μM, and, (e) blocked motility and invasion at sub-micromolar doses in the highly invasive 4T1 and MDA-MB-231 cells.  Despite its size (MW = 1032), AL776 blocked phosphorylation of EGFR and c-Src in 4T1 tumors in vivo.  We now term this new targeting model consisting of designing a kinase inhibitor K1-K2 to target Kin-1 and Kin-2, and to further release two inhibitors K1 and K2 of the latter kinases, "type III combi-targeting".</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrUidvfzZGlVLVg90H21EOLACvtfcHk0lhaancvhgKEWQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhsVGrsr7F&md5=3549409ebadc579533ccb96d1d7ad8cf</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0117215&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0117215%26sid%3Dliteratum%253Aachs%26aulast%3DRao%26aufirst%3DS.%26aulast%3DLarroque-Lombard%26aufirst%3DA.-L.%26aulast%3DPeyrard%26aufirst%3DL.%26aulast%3DThauvin%26aufirst%3DC.%26aulast%3DRachid%26aufirst%3DZ.%26aulast%3DWilliams%26aufirst%3DC.%26aulast%3DJean-Claude%26aufirst%3DB.%2BJ.%26atitle%3DTarget%2520modulation%2520by%2520a%2520kinase%2520inhibitor%2520engineered%2520to%2520induce%2520a%2520tandem%2520blockade%2520of%2520the%2520Epidermal%2520Growth%2520Factor%2520Receptor%2520%2528EGFR%2529%2520and%2520c-Src%253A%2520the%2520concept%2520of%2520type%2520III%2520Combi-Targeting%26jtitle%3DPLoS%2520One%26date%3D2015%26volume%3D10%26doi%3D10.1371%2Fjournal.pone.0117215" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rupp, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mouhri, Z. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jean-Claude, B. J.</span></span> <span> </span><span class="NLM_article-title">Molecular analysis of the dual targeting of the epidermal growth factor receptor and the O<sup>6</sup>-methylguanine-DNA methyltransferase with a double arm hybrid molecule</span>. <i>Oncotarget</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">35041</span>– <span class="NLM_lpage">35055</span>, <span class="refDoi"> DOI: 10.18632/oncotarget.25120</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02008&amp;key=10.18632%2Foncotarget.25120" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02008&amp;key=30416678" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02008&amp;key=1%3ACAS%3A280%3ADC%252BB3cvovVGmug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2018&pages=35041-35055&author=M.+Ruppauthor=Z.+S.+Mouhriauthor=C.+Williamsauthor=B.+J.+Jean-Claude&title=Molecular+analysis+of+the+dual+targeting+of+the+epidermal+growth+factor+receptor+and+the+O6-methylguanine-DNA+methyltransferase+with+a+double+arm+hybrid+molecule&doi=10.18632%2Foncotarget.25120"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular analysis of the dual targeting of the epidermal growth factor receptor and the O(6)-methylguanine-DNA methyltransferase with a double arm hybrid molecule</span></div><div class="casAuthors">Rupp Martin; Mouhri Zhor Senhaji; Jean-Claude Bertrand J; Williams Christopher</div><div class="citationInfo"><span class="NLM_cas:title">Oncotarget</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">80</span>),
    <span class="NLM_cas:pages">35041-35055</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Disordered expression of the epidermal growth factor receptor (EGFR) has been associated with induction of DNA repair genes (e.g.  XRCC1, ERCC1) and resistance to radiation and genotoxic drugs.  However, our previous work showed that EGFR inhibition did not affect O(6)-methylguanine-DNA methyltransferase (MGMT)-mediated resistance.  In order to block uncoupled events associated with EGFR and MGMT, we designed MR30, a single molecule termed "combi-molecule" that contains a quinazoline arm targeted to EGFR and an O(6)-benzylguanine (O(6)-BG) moiety to block MGMT.  Molecular analysis of the mechanism of action of its two arms showed that: (a) it could block EGFR phosphorylation, (b) down-regulate the RAF-MAPK and the PI3K-AKT pathways, and (c) covalently modify MGMT through S-benzylation, as confirmed by MALDI analysis of a direct binding assay with isolated MGMT, (d) it induced a dose-dependent down-regulation of MGMT in lung and melanoma cells.  The pleiotropic mechanism of action of MR30 culminated into strong growth inhibition (IC50: 0.018-6.02 μM), with superior activity when compared with an equimolar combination of gefitinib (a clinical EGFR inhibitor) and O(6)-BG (a known MGMT inhibitor).  Pulse exposure experiments were required to attenuate the contribution of EGFR inhibition to the strong potency of MR30, thereby allowing to achieve the dose level required to sensitize cells to temozolomide (TMZ).  Indeed, MR30 significantly sensitized EGFR-MGMT co-expressing cells to TMZ (p<0.05-0.0001).  The results in toto suggest that MR30 is the first prototype of agents that may be used against tumours addicted to EGFR and to sensitize resistant tumours co-expressing EGFR and MGMT to TMZ.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQbRfzZK_yPGoqdXsLcGTEUfW6udTcc2eabv1UyorM20bntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3cvovVGmug%253D%253D&md5=0b0233e4c881f422a29eeebc4f2b547d</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.18632%2Foncotarget.25120&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.18632%252Foncotarget.25120%26sid%3Dliteratum%253Aachs%26aulast%3DRupp%26aufirst%3DM.%26aulast%3DMouhri%26aufirst%3DZ.%2BS.%26aulast%3DWilliams%26aufirst%3DC.%26aulast%3DJean-Claude%26aufirst%3DB.%2BJ.%26atitle%3DMolecular%2520analysis%2520of%2520the%2520dual%2520targeting%2520of%2520the%2520epidermal%2520growth%2520factor%2520receptor%2520and%2520the%2520O6-methylguanine-DNA%2520methyltransferase%2520with%2520a%2520double%2520arm%2520hybrid%2520molecule%26jtitle%3DOncotarget%26date%3D2018%26volume%3D9%26spage%3D35041%26epage%3D35055%26doi%3D10.18632%2Foncotarget.25120" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Remon, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steuer, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramalingam, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Felip, E.</span></span> <span> </span><span class="NLM_article-title">Osimertinib and other third-generation EGFR TKI in EGFR-mutant NSCLC patients</span>. <i>Ann. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>29</i></span>,  <span class="NLM_fpage">i20</span>– <span class="NLM_lpage">i27</span>, <span class="refDoi"> DOI: 10.1093/annonc/mdx704</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02008&amp;key=10.1093%2Fannonc%2Fmdx704" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02008&amp;key=29462255" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2018&pages=i20-i27&author=J.+Remonauthor=C.+E.+Steuerauthor=S.+S.+Ramalingamauthor=E.+Felip&title=Osimertinib+and+other+third-generation+EGFR+TKI+in+EGFR-mutant+NSCLC+patients&doi=10.1093%2Fannonc%2Fmdx704"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1093%2Fannonc%2Fmdx704&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fannonc%252Fmdx704%26sid%3Dliteratum%253Aachs%26aulast%3DRemon%26aufirst%3DJ.%26aulast%3DSteuer%26aufirst%3DC.%2BE.%26aulast%3DRamalingam%26aufirst%3DS.%2BS.%26aulast%3DFelip%26aufirst%3DE.%26atitle%3DOsimertinib%2520and%2520other%2520third-generation%2520EGFR%2520TKI%2520in%2520EGFR-mutant%2520NSCLC%2520patients%26jtitle%3DAnn.%2520Oncol.%26date%3D2018%26volume%3D29%26spage%3Di20%26epage%3Di27%26doi%3D10.1093%2Fannonc%2Fmdx704" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Buggia, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Locatelli, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Regazzi, M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zecca, M.</span></span> <span> </span><span class="NLM_article-title">Busulfan</span>. <i>Ann. Pharmacother.</i> <span class="NLM_year" style="font-weight: bold;">1994</span>,  <span class="NLM_volume"><i>28</i></span>,  <span class="NLM_fpage">1055</span>– <span class="NLM_lpage">1062</span>, <span class="refDoi"> DOI: 10.1177/106002809402800911</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02008&amp;key=10.1177%2F106002809402800911" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02008&amp;key=7803883" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02008&amp;key=1%3ACAS%3A280%3ADyaK2M7gt1Wrsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=1994&pages=1055-1062&author=I.+Buggiaauthor=F.+Locatelliauthor=M.+B.+Regazziauthor=M.+Zecca&title=Busulfan&doi=10.1177%2F106002809402800911"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Busulfan</span></div><div class="casAuthors">Buggia I; Locatelli F; Regazzi M B; Zecca M</div><div class="citationInfo"><span class="NLM_cas:title">The Annals of pharmacotherapy</span>
        (<span class="NLM_cas:date">1994</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1055-62</span>
        ISSN:<span class="NLM_cas:issn">1060-0280</span>.
    </div><div class="casAbstract">OBJECTIVE:  To review the current published studies evaluating the pharmacokinetics, clinical efficacy, safety, and toxicity of busulfan in pediatric and adult patients.  DATA SOURCES:  English-language literature published between 1953 and 1993 was analyzed; pertinent literature was reviewed.  STUDY SELECTION:  Emphasis was placed on pharmacologic studies and clinical trials involving busulfan therapy both in myeloproliferative disorders and in conditioning regimens for autologous or allogeneic bone marrow transplantation.  DATA EXTRACTION:  Data from both pediatric and adult studies were evaluated; emphasis was placed on the relationship between plasma concentrations of busulfan and its efficacy and toxicity.  DATA SYNTHESIS:  Busulfan has been used widely at conventional dosages (1-12 mg/d) for the treatment of patients with chronic myelogenous leukemia (CML).  Busulfan at high doses (usually 16 mg/kg) given with other cytotoxic drugs (especially cyclophosphamide) is a common preparative regimen in patients undergoing allogeneic or autologous bone marrow transplantation (BMT) for acute or chronic leukemia and other nonmalignant disorders (e.g., hemoglobinopathies, inborn error of immune system, congenital metabolic disorders).  Pharmacokinetics of high-dose busulfan are age-dependent.  Busulfan systemic exposure and, thus, tissue and tumor exposure are lower in children than with adults.  Relationships between toxicity (principally neutropenia, hepatic veno-occlusive disease, incidence of seizures) and drug exposure were found for busulfan.  CONCLUSIONS:  Busulfan is a useful, sufficiently safe drug in the treatment of patients with CML.  At higher dosages, busulfan is a fundamental part of myeloablative therapies for patients undergoing BMT.  As the pharmacokinetics and metabolism of busulfan is further understood, there is great potential for improving treatment outcome.  An assessment of maximal tolerated exposure determined by therapeutic drug monitoring may decrease the incidence and lethality of regimen-related toxicities.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRCKXIcmdY-TrGbPKh4T9eAfW6udTcc2eabv1UyorM20bntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaK2M7gt1Wrsg%253D%253D&md5=e1a5b38f4f075cdd625936805c555c53</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1177%2F106002809402800911&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F106002809402800911%26sid%3Dliteratum%253Aachs%26aulast%3DBuggia%26aufirst%3DI.%26aulast%3DLocatelli%26aufirst%3DF.%26aulast%3DRegazzi%26aufirst%3DM.%2BB.%26aulast%3DZecca%26aufirst%3DM.%26atitle%3DBusulfan%26jtitle%3DAnn.%2520Pharmacother.%26date%3D1994%26volume%3D28%26spage%3D1055%26epage%3D1062%26doi%3D10.1177%2F106002809402800911" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Haapala, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hakala, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jokipelto, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vilpo, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hovinen, J.</span></span> <span> </span><span class="NLM_article-title">Reactions of N,N-Bis(2-chloroethyl)-p-aminophenylbutyric acid (Chlorambucil) with 2′-Deoxyguanosine</span>. <i>Chem. Res. Toxicol.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">988</span>– <span class="NLM_lpage">995</span>, <span class="refDoi"> DOI: 10.1021/tx000249u</span> </span><div class="citationLinks">[<a href="/doi/10.1021/tx000249u" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02008&amp;key=1%3ACAS%3A528%3ADC%252BD3MXkvFSjtbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2001&pages=988-995&author=E.+Haapalaauthor=K.+Hakalaauthor=E.+Jokipeltoauthor=J.+Vilpoauthor=J.+Hovinen&title=Reactions+of+N%2CN-Bis%282-chloroethyl%29-p-aminophenylbutyric+acid+%28Chlorambucil%29+with+2%E2%80%B2-Deoxyguanosine&doi=10.1021%2Ftx000249u"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Reactions of N,N-bis(2-chloroethyl)-p-aminophenylbutyric acid (chlorambucil) with 2'-deoxyguanosine</span></div><div class="casAuthors">Haapala, Elina; Hakala, Kristo; Jokipelto, Eeva; Vilpo, Juhani; Hovinen, Jari</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Research in Toxicology</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">988-995</span>CODEN:
                <span class="NLM_cas:coden">CRTOEC</span>;
        ISSN:<span class="NLM_cas:issn">0893-228X</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">N,N-Bis(2-chloroethyl)-p-aminophenylbutyric acid (chlorambucil, 1) was allowed to react in the presence of 2'-deoxyguanosine (16 mM) at physiol. pH (cacodylic acid, 50% base), and the reactions were followed by HPLC/MS/MS techniques.  Although the predominant reaction obsd. was chlorambucil hydrolysis, ca. 24% of 1 reacted with different heteroatoms of the nucleoside.  As expected, the principal site of 2'-deoxyguanosine alkylation was N7.  Alkylation of N7 caused spontaneous depurination, and N-(7-guaninylethyl)-N-hydroxyethyl-p-aminophenylbutyric acid (5) and the corresponding N7,N7-bis-adduct (6) were the major stable dGuo derivs.  Also several other adducts were detected and tentatively identified by means of MS/MS and UV.  From them, the O6-, N1-, N2-, and O5'-derivs. can be biol. significant.  Our results shed new light on DNA modifications caused by chlorambucil, which is an important chemotherapeutic drug and a known carcinogen.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqQow-dkNtGVbVg90H21EOLACvtfcHk0liqA33_eliJ5A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXkvFSjtbg%253D&md5=c9ecd19ed88c6710e40fe80eb6e9e5a7</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1021%2Ftx000249u&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Ftx000249u%26sid%3Dliteratum%253Aachs%26aulast%3DHaapala%26aufirst%3DE.%26aulast%3DHakala%26aufirst%3DK.%26aulast%3DJokipelto%26aufirst%3DE.%26aulast%3DVilpo%26aufirst%3DJ.%26aulast%3DHovinen%26aufirst%3DJ.%26atitle%3DReactions%2520of%2520N%252CN-Bis%25282-chloroethyl%2529-p-aminophenylbutyric%2520acid%2520%2528Chlorambucil%2529%2520with%25202%25E2%2580%25B2-Deoxyguanosine%26jtitle%3DChem.%2520Res.%2520Toxicol.%26date%3D2001%26volume%3D14%26spage%3D988%26epage%3D995%26doi%3D10.1021%2Ftx000249u" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Puyo, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Montaudon, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pourquier, P.</span></span> <span> </span><span class="NLM_article-title">From old alkylating agents to new minor groove binders</span>. <i>Crit. Rev. Oncol. Hematol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>89</i></span>,  <span class="NLM_fpage">43</span>– <span class="NLM_lpage">61</span>, <span class="refDoi"> DOI: 10.1016/j.critrevonc.2013.07.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02008&amp;key=10.1016%2Fj.critrevonc.2013.07.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02008&amp;key=23972663" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02008&amp;key=1%3ACAS%3A280%3ADC%252BC3sbjvVegsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=89&publication_year=2014&pages=43-61&author=S.+Puyoauthor=D.+Montaudonauthor=P.+Pourquier&title=From+old+alkylating+agents+to+new+minor+groove+binders&doi=10.1016%2Fj.critrevonc.2013.07.006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">From old alkylating agents to new minor groove binders</span></div><div class="casAuthors">Puyo Stephane; Montaudon Daniele; Pourquier Philippe</div><div class="citationInfo"><span class="NLM_cas:title">Critical reviews in oncology/hematology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">89</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">43-61</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Alkylating agents represent the oldest class of anticancer agents with the approval of mechloretamine by the FDA in 1949.  Even though their clinical use is far beyond the use of new targeted therapies, they still occupy a major place in the treatment of specific malignancies, sometimes representing the unique option for the treatment of refractory tumors.  Here, we are reviewing the major classes of alkylating agents, with a particular focus on the latest generations of compounds that specifically target the minor groove of the DNA.  These naturally occurring derivatives have a unique mechanism of action that explains the recent regain of interest in developing new classes of alkylating agents that could be used in combination with other anticancer drugs to enhance tumor response in the clinic.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRG8YhZZYBEXukdrW1FkXG-fW6udTcc2eaT2OueQ5o_s7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3sbjvVegsA%253D%253D&md5=dd2ca22a19a6618b83baeaa677efac54</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1016%2Fj.critrevonc.2013.07.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.critrevonc.2013.07.006%26sid%3Dliteratum%253Aachs%26aulast%3DPuyo%26aufirst%3DS.%26aulast%3DMontaudon%26aufirst%3DD.%26aulast%3DPourquier%26aufirst%3DP.%26atitle%3DFrom%2520old%2520alkylating%2520agents%2520to%2520new%2520minor%2520groove%2520binders%26jtitle%3DCrit.%2520Rev.%2520Oncol.%2520Hematol.%26date%3D2014%26volume%3D89%26spage%3D43%26epage%3D61%26doi%3D10.1016%2Fj.critrevonc.2013.07.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Iwamoto, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hiraku, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oikawa, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mizutani, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kojima, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kawanishi, S.</span></span> <span> </span><span class="NLM_article-title">DNA intrastrand cross-link at the 5′-GA-3′ sequence formed by busulfan and its role in the cytotoxic effect</span>. <i>Cancer Sci.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>95</i></span>,  <span class="NLM_fpage">454</span>– <span class="NLM_lpage">458</span>, <span class="refDoi"> DOI: 10.1111/j.1349-7006.2004.tb03231.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02008&amp;key=10.1111%2Fj.1349-7006.2004.tb03231.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02008&amp;key=15132775" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02008&amp;key=1%3ACAS%3A528%3ADC%252BD2cXltlaitbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=95&publication_year=2004&pages=454-458&author=T.+Iwamotoauthor=Y.+Hirakuauthor=S.+Oikawaauthor=H.+Mizutaniauthor=M.+Kojimaauthor=S.+Kawanishi&title=DNA+intrastrand+cross-link+at+the+5%E2%80%B2-GA-3%E2%80%B2+sequence+formed+by+busulfan+and+its+role+in+the+cytotoxic+effect&doi=10.1111%2Fj.1349-7006.2004.tb03231.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">DNA intrastrand cross-link at the 5'-GA-3' sequence formed by busulfan and its role in the cytotoxic effect</span></div><div class="casAuthors">Iwamoto, Takuya; Hiraku, Yusuke; Oikawa, Shinji; Mizutani, Hideki; Kojima, Michio; Kawanishi, Shosuke</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Science</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">95</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">454-458</span>CODEN:
                <span class="NLM_cas:coden">CSACCM</span>;
        ISSN:<span class="NLM_cas:issn">1347-9032</span>.
    
            (<span class="NLM_cas:orgname">Japanese Cancer Association</span>)
        </div><div class="casAbstract">Busulfan (1,4-butanediol dimethanesulfonate) has been used widely for the treatment of patients with chronic myelogenous leukemia.  Busulfan is bifunctional and thus may effectively induce DNA damage, which may play an important role in the cytotoxicity.  In this study, we compared the cytotoxicity of bifunctional busulfan with that of monofunctional Et methanesulfonate (EMS) in human promyelocytic leukemia HL-60 cells.  Busulfan showed a significant inhibitory effect on cell growth, whereas the cells grew in the presence of EMS.  To clarify the mechanism of cytotoxicity of busulfan, we investigated DNA damage induced by busulfan using 32P-5'-end-labeled DNA fragments obtained from the human p16 tumor suppressor gene.  Busulfan induced DNA damage dose-dependently, whereas EMS caused little DNA damage.  DNA-sequencing expts. using piperidine and 3-methyladenine DNA glycosylase indicated that busulfan caused double-base lesions mainly at 5'-GA-3' and, to a lesser extent, at 5'-GG-3' sequences.  Time of flight mass spectrometry confirmed that busulfan forms an intrastrand cross-link at the 5'-GA-3' sequence, in addn. to mono-alkylation.  The mechanism and the role of crosslinking at the 5'-GA-3' sequence are discussed in relation to the cytotoxicity induced by busulfan.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp3npiNdSFXBrVg90H21EOLACvtfcHk0liqA33_eliJ5A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXltlaitbk%253D&md5=037bf5d6f984e4a8b68a4674bfbbadd8</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1111%2Fj.1349-7006.2004.tb03231.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1349-7006.2004.tb03231.x%26sid%3Dliteratum%253Aachs%26aulast%3DIwamoto%26aufirst%3DT.%26aulast%3DHiraku%26aufirst%3DY.%26aulast%3DOikawa%26aufirst%3DS.%26aulast%3DMizutani%26aufirst%3DH.%26aulast%3DKojima%26aufirst%3DM.%26aulast%3DKawanishi%26aufirst%3DS.%26atitle%3DDNA%2520intrastrand%2520cross-link%2520at%2520the%25205%25E2%2580%25B2-GA-3%25E2%2580%25B2%2520sequence%2520formed%2520by%2520busulfan%2520and%2520its%2520role%2520in%2520the%2520cytotoxic%2520effect%26jtitle%3DCancer%2520Sci.%26date%3D2004%26volume%3D95%26spage%3D454%26epage%3D458%26doi%3D10.1111%2Fj.1349-7006.2004.tb03231.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schmitt, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goodfellow, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gomes, I. N. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosa, M. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reis, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Titi, H. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jean-Claude, B. J.</span></span> <span> </span><span class="NLM_article-title">Comparative analysis of the dual EGFR-DNA targeting and growth inhibitory properties of 6-mono-alkylamino- and 6,6-dialkylaminoquinazoline-based type II combi-molecules</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>192</i></span>,  <span class="NLM_fpage">112185</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2020.112185</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02008&amp;key=10.1016%2Fj.ejmech.2020.112185" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02008&amp;key=32145644" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02008&amp;key=1%3ACAS%3A528%3ADC%252BB3cXksFelsrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=192&publication_year=2020&pages=112185&author=J.+Schmittauthor=E.+Goodfellowauthor=S.+Huangauthor=C.+Williamsauthor=I.+N.+F.+Gomesauthor=M.+N.+Rosaauthor=R.+M.+Reisauthor=R.+Yangauthor=H.+M.+Titiauthor=B.+J.+Jean-Claude&title=Comparative+analysis+of+the+dual+EGFR-DNA+targeting+and+growth+inhibitory+properties+of+6-mono-alkylamino-+and+6%2C6-dialkylaminoquinazoline-based+type+II+combi-molecules&doi=10.1016%2Fj.ejmech.2020.112185"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Comparative analysis of the dual EGFR-DNA targeting and growth inhibitory properties of 6-mono-alkylamino- and 6,6-dialkylaminoquinazoline-based type II combi-molecules</span></div><div class="casAuthors">Schmitt, Julie; Goodfellow, Elliot; Huang, Shanlong; Williams, Christopher; Gomes, Izabela N. F.; Rosa, Marcela N.; Reis, Rui M.; Yang, Richard; Titi, Hatem M.; Jean-Claude, Bertrand J.</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">192</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">112185</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">Over the past decade, we described a novel tumor targeted approach that sought to design "combi-mols." to hit two distinct targets in tumor cells.  Here, to generate small combi-mols. with strong DNA damaging potential while retaining EGFR inhibitory potency, we developed the first synthetic strategy to access the 6-N, N-disubstituted quinazoline scaffold and designed JS61 to possess a nitrogen mustard function directly attached to the 6-position of the quinazoline ring.  We compared its biol. activity with that of structures contg. either a hemi mustard or a non-alkylating substituent.  Surprisingly, the results showed that JS61, while capable of inducing strong DNA damage, exhibited moderate EGFR inhibitory potency.  In contrast, "combi-mols." with no bulky substituent at the N-6 position (e.g. ZR2002 and JS84) showed stronger EGFR and growth inhibitory potency than JS61 in a panel of lung cancer cells.  To rationalize these results, X-ray crystallog. and mol. modeling studies were undertaken, and the data obtained indicated that bulkiness of the 6-N,N-disubstituted moieties hinder its binding to the ATP site and affects binding reversibility.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpUx5ebf6KJdLVg90H21EOLACvtfcHk0liqA33_eliJ5A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXksFelsrg%253D&md5=f6b6fc11a474179932ec6b16db1db7fe</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2020.112185&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2020.112185%26sid%3Dliteratum%253Aachs%26aulast%3DSchmitt%26aufirst%3DJ.%26aulast%3DGoodfellow%26aufirst%3DE.%26aulast%3DHuang%26aufirst%3DS.%26aulast%3DWilliams%26aufirst%3DC.%26aulast%3DGomes%26aufirst%3DI.%2BN.%2BF.%26aulast%3DRosa%26aufirst%3DM.%2BN.%26aulast%3DReis%26aufirst%3DR.%2BM.%26aulast%3DYang%26aufirst%3DR.%26aulast%3DTiti%26aufirst%3DH.%2BM.%26aulast%3DJean-Claude%26aufirst%3DB.%2BJ.%26atitle%3DComparative%2520analysis%2520of%2520the%2520dual%2520EGFR-DNA%2520targeting%2520and%2520growth%2520inhibitory%2520properties%2520of%25206-mono-alkylamino-%2520and%25206%252C6-dialkylaminoquinazoline-based%2520type%2520II%2520combi-molecules%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2020%26volume%3D192%26spage%3D112185%26doi%3D10.1016%2Fj.ejmech.2020.112185" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Avendaño, C.</span>; <span class="NLM_string-name">Menéndez, J. C.</span></span> <span> </span><span class="NLM_article-title">Chapter 5 - DNA alkylating agents</span>. In  <i>Medicinal Chemistry of Anticancer Drugs</i>; <span class="NLM_contrib-group"><span class="NLM_string-name">Avendaño, C.</span>; <span class="NLM_string-name">Menéndez, J. C.</span></span>, Eds. <span class="NLM_publisher-name">Elsevier</span>: <span class="NLM_publisher-loc">Amsterdam</span>, <span class="NLM_year">2008</span>; pp  <span class="NLM_fpage">139</span>– <span class="NLM_lpage">176</span>.</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02008&amp;key=10.1016%2FB978-0-444-52824-7.00005-6" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2008&pages=139-176&author=C.+Avenda%C3%B1o&author=J.+C.+Men%C3%A9ndezauthor=C.+Avenda%C3%B1o&author=J.+C.+Men%C3%A9ndez&title=Medicinal+Chemistry+of+Anticancer+Drugs"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1016%2FB978-0-444-52824-7.00005-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26id%3Ddoi%3A10.1016%252FB978-0-444-52824-7.00005-6%26sid%3Dliteratum%253Aachs%26aulast%3DAvenda%25C3%25B1o%26aufirst%3DC.%26atitle%3DChapter%25205%2520-%2520DNA%2520alkylating%2520agents%26btitle%3DMedicinal%2520Chemistry%2520of%2520Anticancer%2520Drugs%26aulast%3DAvenda%25C3%25B1o%26aufirst%3DC.%26pub%3DElsevier%26date%3D2008%26spage%3D139%26epage%3D176" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Müller, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eisenbrand, G.</span></span> <span> </span><span class="NLM_article-title">The influence of N7 substituents on the stability of N7-alkylated guanosines</span>. <i>Chem.-Biol. Interact.</i> <span class="NLM_year" style="font-weight: bold;">1985</span>,  <span class="NLM_volume"><i>53</i></span>,  <span class="NLM_fpage">173</span>– <span class="NLM_lpage">181</span>, <span class="refDoi"> DOI: 10.1016/S0009-2797(85)80094-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02008&amp;key=10.1016%2FS0009-2797%2885%2980094-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02008&amp;key=3995651" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02008&amp;key=1%3ACAS%3A528%3ADyaL28XovV2huw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=1985&pages=173-181&author=N.+M%C3%BCllerauthor=G.+Eisenbrand&title=The+influence+of+N7+substituents+on+the+stability+of+N7-alkylated+guanosines&doi=10.1016%2FS0009-2797%2885%2980094-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">The influence of N7 substituents on the stability of N7-alkylated guanosines</span></div><div class="casAuthors">Mueller, Norbert; Eisenbrand, Gerhard</div><div class="citationInfo"><span class="NLM_cas:title">Chemico-Biological Interactions</span>
        (<span class="NLM_cas:date">1985</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">1-2</span>),
    <span class="NLM_cas:pages">173-81</span>CODEN:
                <span class="NLM_cas:coden">CBINA8</span>;
        ISSN:<span class="NLM_cas:issn">0009-2797</span>.
    </div><div class="casAbstract">Guanosine alkylated at the 7-position readily decompd. by imidazole ring opening and depurination.  There is a direct correlation between the electron-withdrawing effects, expressed as the Taft substituent const. σ*, of alkyl substituents in 7-position and the resp. acid dissocn. consts. and chem. stabilities of 7-alkylated guanosines.  The resp. values for the slopes of the regression lines were ρ* = +1.89 for imidazole ring opening and ρ* = +0.175 for the depurination reaction.  Unknown Taft consts. can be detd. from the σ*/pKa regression line.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoUzxIbXqrqNbVg90H21EOLACvtfcHk0lgBRbkJcXoDkw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL28XovV2huw%253D%253D&md5=0f759a4808a45082779f20aeb9adea16</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1016%2FS0009-2797%2885%2980094-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0009-2797%252885%252980094-6%26sid%3Dliteratum%253Aachs%26aulast%3DM%25C3%25BCller%26aufirst%3DN.%26aulast%3DEisenbrand%26aufirst%3DG.%26atitle%3DThe%2520influence%2520of%2520N7%2520substituents%2520on%2520the%2520stability%2520of%2520N7-alkylated%2520guanosines%26jtitle%3DChem.-Biol.%2520Interact.%26date%3D1985%26volume%3D53%26spage%3D173%26epage%3D181%26doi%3D10.1016%2FS0009-2797%2885%2980094-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wee, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Z.</span></span> <span> </span><span class="NLM_article-title">Epidermal growth factor receptor cell proliferation signaling pathways</span>. <i>Cancers (Basel)</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">52</span>, <span class="refDoi"> DOI: 10.3390/cancers9050052</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02008&amp;key=10.3390%2Fcancers9050052" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02008&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhvVemtL%252FK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2017&pages=52&author=P.+Weeauthor=Z.+Wang&title=Epidermal+growth+factor+receptor+cell+proliferation+signaling+pathways&doi=10.3390%2Fcancers9050052"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Epidermal growth factor receptor cell proliferation signaling pathways</span></div><div class="casAuthors">Wee, Ping; Wang, Zhixiang</div><div class="citationInfo"><span class="NLM_cas:title">Cancers</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">52/1-52/45</span>CODEN:
                <span class="NLM_cas:coden">CANCCT</span>;
        ISSN:<span class="NLM_cas:issn">2072-6694</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">The epidermal growth factor receptor (EGFR) is a receptor tyrosine kinase that is commonly upregulated in cancers such as in non-small-cell lung cancer, metastatic colorectal cancer, glioblastoma, head and neck cancer, pancreatic cancer, and breast cancer.  Various mechanisms mediate the upregulation of EGFR activity, including common mutations and truncations to its extracellular domain, such as in the EGFRvIII truncations, as well as to its kinase domain, such as the L858R and T790M mutations, or the exon 19 truncation.  These EGFR aberrations over-activate downstream pro-oncogenic signaling pathways, including the RAS-RAF-MEK-ERK MAPK and AKT-PI3K-mTOR pathways.  These pathways then activate many biol. outputs that are beneficial to cancer cell proliferation, including their chronic initiation and progression through the cell cycle.  Here, we review the mol. mechanisms that regulate EGFR signal transduction, including the EGFR structure and its mutations, ligand binding and EGFR dimerization, as well as the signaling pathways that lead to G1 cell cycle progression.  We focus on the induction of CYCLIN D expression, CDK4/6 activation, and the repression of cyclin-dependent kinase inhibitor proteins (CDKi) by EGFR signaling pathways.  We also discuss the successes and challenges of EGFR-targeted therapies, and the potential for their use in combination with CDK4/6 inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpti1TbuQ7GPrVg90H21EOLACvtfcHk0lgBRbkJcXoDkw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhvVemtL%252FK&md5=5d5a81e10b147d1a74957dfa293e75c3</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.3390%2Fcancers9050052&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fcancers9050052%26sid%3Dliteratum%253Aachs%26aulast%3DWee%26aufirst%3DP.%26aulast%3DWang%26aufirst%3DZ.%26atitle%3DEpidermal%2520growth%2520factor%2520receptor%2520cell%2520proliferation%2520signaling%2520pathways%26jtitle%3DCancers%2520%2528Basel%2529%26date%3D2017%26volume%3D9%26spage%3D52%26doi%3D10.3390%2Fcancers9050052" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Isakoff, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Puhalla, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Domchek, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Friedlander, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaufman, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robson, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Telli, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diéras, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, H. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garber, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, E. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maag, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qin, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giranda, V. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shepherd, S. P.</span></span> <span> </span><span class="NLM_article-title">A randomized Phase II study of veliparib with temozolomide or carboplatin/paclitaxel versus placebo with carboplatin/paclitaxel in BRCA1/2 metastatic breast cancer: design and rationale</span>. <i>Future Oncol</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">307</span>– <span class="NLM_lpage">320</span>, <span class="refDoi"> DOI: 10.2217/fon-2016-0412</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02008&amp;key=10.2217%2Ffon-2016-0412" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02008&amp;key=27739325" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02008&amp;key=1%3ACAS%3A528%3ADC%252BC2sXosF2lsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2017&pages=307-320&author=S.+J.+Isakoffauthor=S.+Puhallaauthor=S.+M.+Domchekauthor=M.+Friedlanderauthor=B.+Kaufmanauthor=M.+Robsonauthor=M.+L.+Telliauthor=V.+Di%C3%A9rasauthor=H.+S.+Hanauthor=J.+E.+Garberauthor=E.+F.+Johnsonauthor=D.+Maagauthor=Q.+Qinauthor=V.+L.+Girandaauthor=S.+P.+Shepherd&title=A+randomized+Phase+II+study+of+veliparib+with+temozolomide+or+carboplatin%2Fpaclitaxel+versus+placebo+with+carboplatin%2Fpaclitaxel+in+BRCA1%2F2+metastatic+breast+cancer%3A+design+and+rationale&doi=10.2217%2Ffon-2016-0412"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">A randomized Phase II study of veliparib with temozolomide or carboplatin/paclitaxel versus placebo with carboplatin/paclitaxel in BRCA1/2 metastatic breast cancer: design and rationale</span></div><div class="casAuthors">Isakoff, Steven J.; Puhalla, Shannon; Domchek, Susan M.; Friedlander, Michael; Kaufman, Bella; Robson, Mark; Telli, Melinda L.; Dieras, Veronique; Han, Hyo Sook; Garber, Judy E.; Johnson, Eric F.; Maag, David; Qin, Qin; Giranda, Vincent L.; Shepherd, Stacie P.</div><div class="citationInfo"><span class="NLM_cas:title">Future Oncology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">307-320</span>CODEN:
                <span class="NLM_cas:coden">FOUNBN</span>;
        ISSN:<span class="NLM_cas:issn">1479-6694</span>.
    
            (<span class="NLM_cas:orgname">Future Medicine Ltd.</span>)
        </div><div class="casAbstract">Veliparib is an orally administered poly(ADP-ribose) polymerase inhibitor that is being studied in Phase I-III clin. trials, including Phase III studies in non-small-cell lung cancer, ovarian cancer and breast cancer.  Tumor cells with deleterious BRCA1 or BRCA2 mutations are deficient in homologous recombination DNA repair and are intrinsically sensitive to platinum therapy and poly(ADP-ribose) polymerase inhibitors.  We describe herein the design and rationale of a Phase II trial investigating whether the addn. of veliparib to temozolomide or carboplatin/paclitaxel provides clin. benefit over carboplatin/paclitaxel with placebo in patients with locally recurrent or metastatic breast cancer harboring a deleterious BRCA1 or BRCA2 germline mutation (Trial registration: EudraCT 2011-002913-12, NCT01506609).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpMicV7820PzLVg90H21EOLACvtfcHk0lhcqhNF-CufpQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXosF2lsQ%253D%253D&md5=8a6fb6b2b50603229645617d68f54154</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.2217%2Ffon-2016-0412&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2217%252Ffon-2016-0412%26sid%3Dliteratum%253Aachs%26aulast%3DIsakoff%26aufirst%3DS.%2BJ.%26aulast%3DPuhalla%26aufirst%3DS.%26aulast%3DDomchek%26aufirst%3DS.%2BM.%26aulast%3DFriedlander%26aufirst%3DM.%26aulast%3DKaufman%26aufirst%3DB.%26aulast%3DRobson%26aufirst%3DM.%26aulast%3DTelli%26aufirst%3DM.%2BL.%26aulast%3DDi%25C3%25A9ras%26aufirst%3DV.%26aulast%3DHan%26aufirst%3DH.%2BS.%26aulast%3DGarber%26aufirst%3DJ.%2BE.%26aulast%3DJohnson%26aufirst%3DE.%2BF.%26aulast%3DMaag%26aufirst%3DD.%26aulast%3DQin%26aufirst%3DQ.%26aulast%3DGiranda%26aufirst%3DV.%2BL.%26aulast%3DShepherd%26aufirst%3DS.%2BP.%26atitle%3DA%2520randomized%2520Phase%2520II%2520study%2520of%2520veliparib%2520with%2520temozolomide%2520or%2520carboplatin%252Fpaclitaxel%2520versus%2520placebo%2520with%2520carboplatin%252Fpaclitaxel%2520in%2520BRCA1%252F2%2520metastatic%2520breast%2520cancer%253A%2520design%2520and%2520rationale%26jtitle%3DFuture%2520Oncol%26date%3D2017%26volume%3D13%26spage%3D307%26epage%3D320%26doi%3D10.2217%2Ffon-2016-0412" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Burke, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ali, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Connell, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sullivan, F. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Glynn, S. A.</span></span> <span> </span><span class="NLM_article-title">Sensitivity profiles of human prostate cancer cell lines to an 80 Kinase inhibitor panel</span>. <i>Anticancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>36</i></span>,  <span class="NLM_fpage">633</span>– <span class="NLM_lpage">641</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02008&amp;key=26851018" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02008&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtFalsLbE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=2016&pages=633-641&author=A.+J.+Burkeauthor=H.+Aliauthor=E.+O%E2%80%99Connellauthor=F.+J.+Sullivanauthor=S.+A.+Glynn&title=Sensitivity+profiles+of+human+prostate+cancer+cell+lines+to+an+80+Kinase+inhibitor+panel"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Sensitivity profiles of human prostate cancer cell lines to an 80 kinase inhibitor panel</span></div><div class="casAuthors">Burke, Amy J.; Ali, Husnain; O'Connell, Enda; Sullivan, Francis J.; Glynn, Sharon A.</div><div class="citationInfo"><span class="NLM_cas:title">Anticancer Research</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">36</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">633-642</span>CODEN:
                <span class="NLM_cas:coden">ANTRD4</span>;
        ISSN:<span class="NLM_cas:issn">0250-7005</span>.
    
            (<span class="NLM_cas:orgname">International Institute of Anticancer Research</span>)
        </div><div class="casAbstract">Background: Taxanes and anti-androgen therapies are routinely used for the treatment of metastatic prostate cancer, however the majority of patients eventually develop resistance.  Materials and Methods: Eighty kinase inhibitors were screened regarding their ability to inhibit cell viability in CWR22, 22Rv1, PC-3 and DU145 prostate cancer cells using automated toxicity assays.  Four kinase inhibitors were selected for further investigation.  Results: No significant difference in sensitivity patterns was found between the androgen receptor wild-type CWR22 and its androgen receptor mutant variant 22Rv1, indicating that androgen receptor mutation did not impact on kinase inhibitor sensitivity in this model.  Metastatic PC-3 and DU145 prostate cancer cell lines were less sensitive to kinase inhibitors than the non-metastatic CWR22 and 22Rv1.  All four cell lines responded to GSK-3 inhibitor BIO, and MEK inhibitor PD198306.  DU145 cells were resistant to p75NTR/TrkA and CHK4 inhibitors, RO-082750 and Ryuvidine.  Conclusion: Kinase inhibition may be an appropriate strategy for the treatment of prostate cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrdh-H_JcuOj7Vg90H21EOLACvtfcHk0lhcqhNF-CufpQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtFalsLbE&md5=6688d5c15abed4a9cb078efbcd35ac3a</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBurke%26aufirst%3DA.%2BJ.%26aulast%3DAli%26aufirst%3DH.%26aulast%3DO%25E2%2580%2599Connell%26aufirst%3DE.%26aulast%3DSullivan%26aufirst%3DF.%2BJ.%26aulast%3DGlynn%26aufirst%3DS.%2BA.%26atitle%3DSensitivity%2520profiles%2520of%2520human%2520prostate%2520cancer%2520cell%2520lines%2520to%2520an%252080%2520Kinase%2520inhibitor%2520panel%26jtitle%3DAnticancer%2520Res.%26date%3D2016%26volume%3D36%26spage%3D633%26epage%3D641" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Skehan, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Storeng, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scudiero, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Monks, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McMahon, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vistica, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Warren, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bokesch, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kenney, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boyd, M. R.</span></span> <span> </span><span class="NLM_article-title">New colorimetric cytotoxicity assay for anticancer-drug screening</span>. <i>J. Natl. Cancer Inst.</i> <span class="NLM_year" style="font-weight: bold;">1990</span>,  <span class="NLM_volume"><i>82</i></span>,  <span class="NLM_fpage">1107</span>– <span class="NLM_lpage">1112</span>, <span class="refDoi"> DOI: 10.1093/jnci/82.13.1107</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02008&amp;key=10.1093%2Fjnci%2F82.13.1107" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02008&amp;key=2359136" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02008&amp;key=1%3ACAS%3A528%3ADyaK3cXltVylsL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=82&publication_year=1990&pages=1107-1112&author=P.+Skehanauthor=R.+Storengauthor=D.+Scudieroauthor=A.+Monksauthor=J.+McMahonauthor=D.+Visticaauthor=J.+T.+Warrenauthor=H.+Bokeschauthor=S.+Kenneyauthor=M.+R.+Boyd&title=New+colorimetric+cytotoxicity+assay+for+anticancer-drug+screening&doi=10.1093%2Fjnci%2F82.13.1107"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">New colorimetric cytotoxicity assay for anticancer-drug screening</span></div><div class="casAuthors">Skehan, Philip; Storeng, Ritsa; Scudiero, Dominic; Monks, Anne; McMahon, James; Vistica, David; Warren, Jonathan T.; Bokesch, Heidi; Kenney, Susan; Boyd, Michael R.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the National Cancer Institute</span>
        (<span class="NLM_cas:date">1990</span>),
    <span class="NLM_cas:volume">82</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">1107-12</span>CODEN:
                <span class="NLM_cas:coden">JNCIEQ</span>;
        ISSN:<span class="NLM_cas:issn">0027-8874</span>.
    </div><div class="casAbstract">A rapid, sensitive, and inexpensive method was developed for measuring the cellular protein content of adherent and suspension cultures in 96-well microtiter plates.  The method is suitable for ordinary lab. purposes and for very large-scale applications, such as the National Cancer Institute's disease-oriented in vitro anticancer-drug discovery screen, which requires the use of several million culture wells per yr.  Cultures fixed with trichloroacetic acid were stained for 30 min with 0.4% (wt/vol) sulforhodamine B (SRB) dissolved in 1% acetic acid.  Unbound dye was removed by four washes with 1% acetic acid, and protein-bound dye was extd. with 10 mM unbuffered Tris base [tris(hydroxymethyl)aminomethane] for detn. of optical d. in a computer-interfaced, 96-well microtiter plate reader.  The SRB assay results were linear with the no. of cells and with values for cellular protein measured by both the Lowry and Bradford assays at densities ranging from sparse subconfluence to multilayered supraconfluence.  The signal-to-noise ratio at 564 nm was approx. 1.5 with 1,000 cells per well.  The sensitivity of the SRB assay compared favorably with sensitivities of several fluorescence assays and was superior to those of both the Lowry and Bradford assays and to those of 20 other visible dyes.  The SRB assay provides a colorimetric end point that is nondestructive, indefinitely stable, and visible to the naked eye.  It provides a sensitive measure of drug-induced cytotoxicity, is useful in quantitating clonogenicity, and is well suited to high-vol., automated drug screening.  SRB fluoresces strongly with laser excitation at 488 nm and can be measured quant. at the single-cell level by static fluorescence cytometry.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrA1MIZ3rkcqLVg90H21EOLACvtfcHk0lhcqhNF-CufpQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3cXltVylsL8%253D&md5=d7bc1784a1f181842d2999efa7fa870c</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1093%2Fjnci%2F82.13.1107&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fjnci%252F82.13.1107%26sid%3Dliteratum%253Aachs%26aulast%3DSkehan%26aufirst%3DP.%26aulast%3DStoreng%26aufirst%3DR.%26aulast%3DScudiero%26aufirst%3DD.%26aulast%3DMonks%26aufirst%3DA.%26aulast%3DMcMahon%26aufirst%3DJ.%26aulast%3DVistica%26aufirst%3DD.%26aulast%3DWarren%26aufirst%3DJ.%2BT.%26aulast%3DBokesch%26aufirst%3DH.%26aulast%3DKenney%26aufirst%3DS.%26aulast%3DBoyd%26aufirst%3DM.%2BR.%26atitle%3DNew%2520colorimetric%2520cytotoxicity%2520assay%2520for%2520anticancer-drug%2520screening%26jtitle%3DJ.%2520Natl.%2520Cancer%2520Inst.%26date%3D1990%26volume%3D82%26spage%3D1107%26epage%3D1112%26doi%3D10.1093%2Fjnci%2F82.13.1107" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Matheson, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McNamee, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alaoui-Jamali, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tari, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jean-Claude, B. J.</span></span> <span> </span><span class="NLM_article-title">The combi-targeting concept: dissection of the binary mechanism of action of the combi-triazene SMA41 in vitro and antitumor activity in vivo</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>311</i></span>,  <span class="NLM_fpage">1163</span>– <span class="NLM_lpage">1170</span>, <span class="refDoi"> DOI: 10.1124/jpet.104.071977</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02008&amp;key=10.1124%2Fjpet.104.071977" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02008&amp;key=15358812" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02008&amp;key=1%3ACAS%3A528%3ADC%252BD2cXhtVKmtLjF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=311&publication_year=2004&pages=1163-1170&author=S.+L.+Mathesonauthor=J.+P.+McNameeauthor=T.+Wangauthor=M.+A.+Alaoui-Jamaliauthor=A.+M.+Tariauthor=B.+J.+Jean-Claude&title=The+combi-targeting+concept%3A+dissection+of+the+binary+mechanism+of+action+of+the+combi-triazene+SMA41+in+vitro+and+antitumor+activity+in+vivo&doi=10.1124%2Fjpet.104.071977"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">The combi-targeting concept: Dissection of the binary mechanism of action of the combi-triazene SMA41 in vitro and antitumor activity in vivo</span></div><div class="casAuthors">Matheson, Stephanie L.; McNamee, James P.; Wang, Taiqui; Alaoui-Jamali, Moulay A.; Tari, Ana M.; Jean-Claude, Bertrand J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">311</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1163-1170</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">We have previously reported the synthesis of SMA41, a unimol. combination of an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) of the quinazoline class and a DNA-damaging monomethyltriazene termed "combimol.".  Hydrolysis of 1-[4-(m-tolylamino)-6-quinazolinyl]-3-methyltriazene (SMA41) gives rise to an intact TKI [6-amino-4-(3-methylanilino)quinazoline; SMA52] capable of inhibiting epidermal growth factor (EGF)-induced EGFR autophosphorylation and a DNA-targeting methyldiazonium species.  Herein, we showed that SMA41 blocked EGF-induced EGFR autophosphorylation by an irreversible mechanism, suggesting that it may covalently damage the receptor in these cells.  More importantly, this was assocd. with significant inhibition of mitogen-activated protein kinase activation in A431 cells.  In cells treated with [14C]SMA41, radio-high-performance liq. chromatog. detection of both N7- and O6-methylguanine revealed an almost complete repair of the O6-methylguanine lesions and a greater tolerance of the N7-methylguanine adducts 24 h post-treatment.  In contrast to temozolomide (a cyclic triazene used in the clinic) and the reversible inhibitor SMA52, SMA41 induced significant cell cycle arrest in S, G2, and M phases 24 h after a 2-h drug exposure.  Furthermore, in vivo studies demonstrated that SMA41 was well tolerated.  At 200 mg/kg, it showed approx. 2-fold greater antiproliferative activity than SMA52 in A431 cells implanted in immunocompromised SCID mice.  These results suggest that the binary targeting properties of SMA41 are assocd. with a binary cascade of events in the cells that seem to culminate into significant growth inhibition in vitro and in vivo.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqkhi3W-ADWZLVg90H21EOLACvtfcHk0lhcqhNF-CufpQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXhtVKmtLjF&md5=e4d1a0bfe3202e961e7e2a1f2ecb8d21</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1124%2Fjpet.104.071977&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.104.071977%26sid%3Dliteratum%253Aachs%26aulast%3DMatheson%26aufirst%3DS.%2BL.%26aulast%3DMcNamee%26aufirst%3DJ.%2BP.%26aulast%3DWang%26aufirst%3DT.%26aulast%3DAlaoui-Jamali%26aufirst%3DM.%2BA.%26aulast%3DTari%26aufirst%3DA.%2BM.%26aulast%3DJean-Claude%26aufirst%3DB.%2BJ.%26atitle%3DThe%2520combi-targeting%2520concept%253A%2520dissection%2520of%2520the%2520binary%2520mechanism%2520of%2520action%2520of%2520the%2520combi-triazene%2520SMA41%2520in%2520vitro%2520and%2520antitumor%2520activity%2520in%2520vivo%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2004%26volume%3D311%26spage%3D1163%26epage%3D1170%26doi%3D10.1124%2Fjpet.104.071977" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 1 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors">Mengzhu Zheng, Junfeng Huo, Xiaoxia Gu, Yali Wang, Canrong Wu, Qingzhe Zhang, Wang Wang, Yang Liu, Yu Liu, Xuechen Zhou, Lixia Chen, Yirong Zhou, <span class="NLM_string-name hlFld-ContribAuthor">Hua Li</span>. </span><span class="cited-content_cbyCitation_article-title">Rational Design and Synthesis of Novel Dual PROTACs for Simultaneous Degradation of EGFR and PARP. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>64 </em>
                                    (11)
                                     , 7839-7852. <a href="https://doi.org/10.1021/acs.jmedchem.1c00649" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.1c00649</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.1c00649&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.1c00649%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DRational%252BDesign%252Band%252BSynthesis%252Bof%252BNovel%252BDual%252BPROTACs%252Bfor%252BSimultaneous%252BDegradation%252Bof%252BEGFR%252Band%252BPARP%26aulast%3DZheng%26aufirst%3DMengzhu%26date%3D2021%26date%3D2021%26date%3D2021%26date%3D09042021%26date%3D26052021%26volume%3D64%26issue%3D11%26spage%3D7839%26epage%3D7852" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="_i1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b02008/20200604/images/medium/jm9b02008_0012.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b02008/20200604/images/large/jm9b02008_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b02008&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b02008/20200604/images/medium/jm9b02008_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b02008/20200604/images/large/jm9b02008_0001.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Prototypes of type I, type II, and type III targeting molecules.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b02008/20200604/images/large/jm9b02008_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b02008&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b02008/20200604/images/medium/jm9b02008_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b02008/20200604/images/large/jm9b02008_0003.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. <b>JS230</b>, a “trifunctional combi-molecule” designed as a new “chimeric structure” to mimic the combined effect of blocking EGFR signaling pathways (gefitinib-like), damaging DNA (busulfan-like), and preventing DNA repair by inhibiting PARP (olaparib-like).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b02008/20200604/images/large/jm9b02008_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b02008&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch1" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b02008/20200604/images/medium/jm9b02008_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b02008/20200604/images/large/jm9b02008_0011.jpeg" id="rightTab-gr11" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthetic Scheme of <b>JS230</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b02008/20200604/images/large/jm9b02008_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b02008&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) Cs<sub>2</sub>CO<sub>3</sub>, DMSO, 100 °C, on, 91%; (b) Fe, AcOH, EtOH/H<sub>2</sub>O, 100 °C, 2 h, 98%; (c) DMF dimethylacetal, 110 °C, 1.5 h, 64%; (d) 3-bromoaniline, AcOH, 110 °C, 1 h, 36%; (e) sulfonyl chloride, pyridine, 20 min, 84%; (f) piperazine, 4-azidobutyric acid, HOBt, EDCI, Et<sub>3</sub>N, DMF, 0 °C, on, 72%; and (g) CuSO<sub>4</sub>·5H<sub>2</sub>O, Na ascorbate, DMF, on, rt, 45%.</p></p></figure><figure data-id="fig3" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b02008/20200604/images/medium/jm9b02008_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b02008/20200604/images/large/jm9b02008_0004.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Hypothetical mechanism of action of <b>JS230</b> based on the products identified by LC–MS analysis. I<sub>1</sub>–I<sub>2</sub>–I<sub>3</sub> as an intact molecule can block target T<sub>1</sub> (EGFR) and T<sub>3</sub> (PARP) while being allowed to form a transient aziridinium ion that can further block target T<sub>1</sub> (EGFR) and damage T<sub>2</sub> (DNA), while I<sub>3</sub> remains capable of inhibiting T<sub>3</sub> (PARP). Compounds <b>4</b>, <b>7</b>, and <b>8</b> have been identified by LC–MS analysis.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b02008/20200604/images/large/jm9b02008_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b02008&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b02008/20200604/images/medium/jm9b02008_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b02008/20200604/images/large/jm9b02008_0005.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Inhibition of EGFR signaling by <b>JS230</b> and clinical drugs in PC3 and 22Rv1 cell lines. The cells were treated with differing concentrations (μM) of all compounds for 2 h and subsequently followed by EGF (50 ng/mL) stimulation for 30 min.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b02008/20200604/images/large/jm9b02008_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b02008&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b02008/20200604/images/medium/jm9b02008_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b02008/20200604/images/large/jm9b02008_0006.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. IC<sub>50</sub> of <b>JS230</b> compared against clinical EGFR inhibitor gefitinib on cell lines NIH-3T3 (EGFR wild-type) and NIH-3T3-EGFR (EGFR transfectant). Selectivity of 7-fold is observed for the combi-molecule <b>JS230</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b02008/20200604/images/large/jm9b02008_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b02008&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig6" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b02008/20200604/images/medium/jm9b02008_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b02008/20200604/images/large/jm9b02008_0007.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Assessment of DNA damage using the alkaline comet assay. The results indicate that DNA damage is not only sustained but enhanced 24 h post-treatment with respect to a drug incubation of 2 h. <b>JS230</b> has been compared to single drugs (G, gefitinib; O, olaparib; and B, busulfan) and their equimolar double or triple combinations.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b02008/20200604/images/large/jm9b02008_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b02008&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig7" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b02008/20200604/images/medium/jm9b02008_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b02008/20200604/images/large/jm9b02008_0008.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Detection of γ-H2AX phosphorylation and PAR levels induced in PC3 and 22Rv1 cells (48 h post-treatment).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b02008/20200604/images/large/jm9b02008_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b02008&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig8" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b02008/20200604/images/medium/jm9b02008_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b02008/20200604/images/large/jm9b02008_0009.jpeg" id="rightTab-gr8" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. IC<sub>50</sub> of <b>JS230</b> compared against clinical PARP inhibitor olaparib on cell lines VC8 (BRCA mutant) and VC8-BRCA (BRCA transfectant). Selectivity of 3-fold is observed for the combi-molecule <b>JS230</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b02008/20200604/images/large/jm9b02008_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b02008&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig9" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b02008/20200604/images/medium/jm9b02008_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b02008/20200604/images/large/jm9b02008_0010.jpeg" id="rightTab-gr9" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 9. Response of <b>JS230</b> in a cell-based growth inhibition assay using a panel of prostate cancer cell lines. <b>JS230</b> shows a similar growth inhibition profile as the triple combination of clinical drugs in DU145, whereas in PC3 and 22Rv1, <b>JS230</b> is significantly more potent.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b02008/20200604/images/large/jm9b02008_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b02008&amp;id=fig9"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig10" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Figure 10</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b02008/20200604/images/medium/jm9b02008_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b02008/20200604/images/large/jm9b02008_0002.jpeg" id="rightTab-gr10" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 10. (A) Time-course analysis of the level of intact <b>JS230</b> in the prostate cancer cell line 22Rv1. (B) Confocal microscopy of <b>JS230</b> at 10 μM in prostate cancer cell line 22Rv1 (2 h post-treatment).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b02008/20200604/images/large/jm9b02008_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b02008&amp;id=fig10"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i35">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_53060" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_53060" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 29 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chabner, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roberts, T. G.,  Jr.</span></span> <span> </span><span class="NLM_article-title">Chemotherapy and the war on cancer</span>. <i>Nat. Rev. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">65</span>– <span class="NLM_lpage">72</span>, <span class="refDoi"> DOI: 10.1038/nrc1529</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02008&amp;key=10.1038%2Fnrc1529" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02008&amp;key=15630416" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02008&amp;key=1%3ACAS%3A528%3ADC%252BD2MXlvVek" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2005&pages=65-72&author=B.+A.+Chabnerauthor=T.+G.+Roberts&title=Chemotherapy+and+the+war+on+cancer&doi=10.1038%2Fnrc1529"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Chemotherapy and the war on cancer</span></div><div class="casAuthors">Chabner, Bruce A.; Roberts, Thomas G.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">65-72</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The era of chemotherapy began in the 1940s with the first uses of nitrogen mustards and antifolate drugs.  Cancer drug development since then has transformed from a low-budget, government-supported research effort to a high-stakes, multi-billion dollar industry.  The targeted-therapy revolution has arrived, but the principles and limitations of chemotherapy discovered by the early researchers still apply.  This article chronicles the history of modern chemotherapy and identifies remaining challenges for the next generation of researchers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrszgbuDuTBobVg90H21EOLACvtfcHk0li0sGontIykbw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXlvVek&md5=d5c8b3dba59b9d6dcca473552525fa14</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1038%2Fnrc1529&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc1529%26sid%3Dliteratum%253Aachs%26aulast%3DChabner%26aufirst%3DB.%2BA.%26aulast%3DRoberts%26aufirst%3DT.%2BG.%26atitle%3DChemotherapy%2520and%2520the%2520war%2520on%2520cancer%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2005%26volume%3D5%26spage%3D65%26epage%3D72%26doi%3D10.1038%2Fnrc1529" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Goldstein, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kastan, M. B.</span></span> <span> </span><span class="NLM_article-title">The DNA damage response: implications for tumor responses to radiation and chemotherapy</span>. <i>Annu. Rev. Med.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>66</i></span>,  <span class="NLM_fpage">129</span>– <span class="NLM_lpage">143</span>, <span class="refDoi"> DOI: 10.1146/annurev-med-081313-121208</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02008&amp;key=10.1146%2Fannurev-med-081313-121208" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02008&amp;key=25423595" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02008&amp;key=1%3ACAS%3A528%3ADC%252BC2MXjvFyhs7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=66&publication_year=2015&pages=129-143&author=M.+Goldsteinauthor=M.+B.+Kastan&title=The+DNA+damage+response%3A+implications+for+tumor+responses+to+radiation+and+chemotherapy&doi=10.1146%2Fannurev-med-081313-121208"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">The DNA damage response: implications for tumor responses to radiation and chemotherapy</span></div><div class="casAuthors">Goldstein, Michael; Kastan, Michael B.</div><div class="citationInfo"><span class="NLM_cas:title">Annual Review of Medicine</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">66</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">129-143</span>CODEN:
                <span class="NLM_cas:coden">ARMCAH</span>;
        ISSN:<span class="NLM_cas:issn">0066-4219</span>.
    
            (<span class="NLM_cas:orgname">Annual Reviews</span>)
        </div><div class="casAbstract">Cellular responses to DNA damage are important determinants of both cancer development and cancer outcome following radiation therapy and chemotherapy.  Identification of mol. pathways governing DNA damage signaling and DNA repair in response to different types of DNA lesions allows for a better understanding of the effects of radiation and chemotherapy on normal and tumor cells.  Although dysregulation of the DNA damage response (DDR) is assocd. with predisposition to cancer development, it can also result in hypersensitivity or resistance of tumors to therapy and can be exploited for improvement of cancer treatment.  We highlight the DDR pathways that are activated after treatment with radiation and different classes of chemotherapeutic drugs and describe mechanisms detg. tumor sensitivity and resistance to these agents.  Further, we discuss approaches to enhance tumor sensitivity to radiation and chemotherapy by modulating the DDR with a goal of enhancing the effectiveness of cancer therapies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqapVTP41nzXLVg90H21EOLACvtfcHk0liNdj5FAqfqNA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXjvFyhs7g%253D&md5=d4c54e8dae50f61cfee4d54b022b551c</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1146%2Fannurev-med-081313-121208&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1146%252Fannurev-med-081313-121208%26sid%3Dliteratum%253Aachs%26aulast%3DGoldstein%26aufirst%3DM.%26aulast%3DKastan%26aufirst%3DM.%2BB.%26atitle%3DThe%2520DNA%2520damage%2520response%253A%2520implications%2520for%2520tumor%2520responses%2520to%2520radiation%2520and%2520chemotherapy%26jtitle%3DAnnu.%2520Rev.%2520Med.%26date%3D2015%26volume%3D66%26spage%3D129%26epage%3D143%26doi%3D10.1146%2Fannurev-med-081313-121208" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pegg, A. E.</span></span> <span> </span><span class="NLM_article-title">Multifaceted roles of alkyltransferase and related proteins in DNA repair, DNA damage, resistance to chemotherapy, and research tools</span>. <i>Chem. Res. Toxicol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">618</span>– <span class="NLM_lpage">639</span>, <span class="refDoi"> DOI: 10.1021/tx200031q</span> </span><div class="citationLinks">[<a href="/doi/10.1021/tx200031q" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02008&amp;key=1%3ACAS%3A528%3ADC%252BC3MXltlGhsLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2011&pages=618-639&author=A.+E.+Pegg&title=Multifaceted+roles+of+alkyltransferase+and+related+proteins+in+DNA+repair%2C+DNA+damage%2C+resistance+to+chemotherapy%2C+and+research+tools&doi=10.1021%2Ftx200031q"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Multifaceted Roles of Alkyltransferase and Related Proteins in DNA Repair, DNA Damage, Resistance to Chemotherapy, and Research Tools</span></div><div class="casAuthors">Pegg, Anthony E.</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Research in Toxicology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">618-639</span>CODEN:
                <span class="NLM_cas:coden">CRTOEC</span>;
        ISSN:<span class="NLM_cas:issn">0893-228X</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  O6-Alkylguanine-DNA alkyltransferase (AGT) is a widely distributed, unique DNA repair protein that acts as a single agent to directly remove alkyl groups located on the O6-position of guanine from DNA restoring the DNA in one step.  The protein acts only once, and its alkylated form is degraded rapidly.  It is a major factor in counteracting the mutagenic, carcinogenic, and cytotoxic effects of agents that form such adducts including N-nitroso-compds. and a no. of cancer chemotherapeutics.  This review describes the structure, function, and mechanism of action of AGTs and of a family of related alkyltransferase-like proteins, which do not act alone to repair O6-alkylguanines in DNA but link repair to other pathways.  The paradoxical ability of AGTs to stimulate the DNA-damaging ability of dihaloalkanes and other bis-electrophiles via the formation of AGT-DNA cross-links is also described.  Other important properties of AGTs include the ability to provide resistance to cancer therapeutic alkylating agents, and the availability of AGT inhibitors such as O6-benzylguanine that might overcome this resistance is discussed.  Finally, the properties of fusion proteins in which AGT sequences are linked to other proteins are outlined.  Such proteins occur naturally, and synthetic variants engineered to react specifically with derivs. of O6-benzylguanine are the basis of a valuable research technique for tagging proteins with specific reagents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpO3LqHTkLd_7Vg90H21EOLACvtfcHk0liNdj5FAqfqNA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXltlGhsLc%253D&md5=ed36c05b50ec9f37ebf85d9d9773ce0a</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1021%2Ftx200031q&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Ftx200031q%26sid%3Dliteratum%253Aachs%26aulast%3DPegg%26aufirst%3DA.%2BE.%26atitle%3DMultifaceted%2520roles%2520of%2520alkyltransferase%2520and%2520related%2520proteins%2520in%2520DNA%2520repair%252C%2520DNA%2520damage%252C%2520resistance%2520to%2520chemotherapy%252C%2520and%2520research%2520tools%26jtitle%3DChem.%2520Res.%2520Toxicol.%26date%3D2011%26volume%3D24%26spage%3D618%26epage%3D639%26doi%3D10.1021%2Ftx200031q" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ray
Chaudhuri, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nussenzweig, A.</span></span> <span> </span><span class="NLM_article-title">The multifaceted roles of PARP1 in DNA repair and chromatin remodelling</span>. <i>Nat. Rev. Mol. Cell Biol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">610</span>– <span class="NLM_lpage">621</span>, <span class="refDoi"> DOI: 10.1038/nrm.2017.53</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02008&amp;key=10.1038%2Fnrm.2017.53" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02008&amp;key=28676700" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02008&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtFanurfI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2017&pages=610-621&author=A.+Ray%0AChaudhuriauthor=A.+Nussenzweig&title=The+multifaceted+roles+of+PARP1+in+DNA+repair+and+chromatin+remodelling&doi=10.1038%2Fnrm.2017.53"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">The multifaceted roles of PARP1 in DNA repair and chromatin remodelling</span></div><div class="casAuthors">Ray Chaudhuri, Arnab; Nussenzweig, Andre</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Molecular Cell Biology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">610-621</span>CODEN:
                <span class="NLM_cas:coden">NRMCBP</span>;
        ISSN:<span class="NLM_cas:issn">1471-0072</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">A review.  Cells are exposed to various endogenous and exogenous insults that induce DNA damage, which, if unrepaired, impairs genome integrity and leads to the development of various diseases, including cancer.  Recent evidence has implicated poly(ADP-ribose) polymerase 1 (PARP1) in various DNA repair pathways and in the maintenance of genomic stability.  The inhibition of PARP1 is therefore being exploited clin. for the treatment of various cancers, which include DNA repair-deficient ovarian, breast and prostate cancers.  Understanding the role of PARP1 in maintaining genome integrity is not only important for the design of novel chemotherapeutic agents, but is also crucial for gaining insights into the mechanisms of chemoresistance in cancer cells.  In this Review, we discuss the roles of PARP1 in mediating various aspects of DNA metab., such as single-strand break repair, nucleotide excision repair, double-strand break repair and the stabilization of replication forks, and in modulating chromatin structure.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoIUBUS4wtkKrVg90H21EOLACvtfcHk0liNdj5FAqfqNA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtFanurfI&md5=593d6bb5d0a16940d0ba3f8f1eaccf71</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1038%2Fnrm.2017.53&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrm.2017.53%26sid%3Dliteratum%253Aachs%26aulast%3DRay%2BChaudhuri%26aufirst%3DA.%26aulast%3DNussenzweig%26aufirst%3DA.%26atitle%3DThe%2520multifaceted%2520roles%2520of%2520PARP1%2520in%2520DNA%2520repair%2520and%2520chromatin%2520remodelling%26jtitle%3DNat.%2520Rev.%2520Mol.%2520Cell%2520Biol.%26date%3D2017%26volume%3D18%26spage%3D610%26epage%3D621%26doi%3D10.1038%2Fnrm.2017.53" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kelley, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Logsdon, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fishel, M. L.</span></span> <span> </span><span class="NLM_article-title">Targeting DNA repair pathways for cancer treatment: what’s new?</span>. <i>Future Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">1215</span>– <span class="NLM_lpage">1237</span>, <span class="refDoi"> DOI: 10.2217/fon.14.60</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02008&amp;key=10.2217%2Ffon.14.60" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02008&amp;key=24947262" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02008&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtVWmsLjP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2014&pages=1215-1237&author=M.+R.+Kelleyauthor=D.+Logsdonauthor=M.+L.+Fishel&title=Targeting+DNA+repair+pathways+for+cancer+treatment%3A+what%E2%80%99s+new%3F&doi=10.2217%2Ffon.14.60"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting DNA repair pathways for cancer treatment: what's new?</span></div><div class="casAuthors">Kelley, Mark R.; Logsdon, Derek; Fishel, Melissa L.</div><div class="citationInfo"><span class="NLM_cas:title">Future Oncology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1215-1237</span>CODEN:
                <span class="NLM_cas:coden">FOUNBN</span>;
        ISSN:<span class="NLM_cas:issn">1479-6694</span>.
    
            (<span class="NLM_cas:orgname">Future Medicine Ltd.</span>)
        </div><div class="casAbstract">A review.  Disruptions in DNA repair pathways predispose cells to accumulating DNA damage.  A growing body of evidence indicates that tumors accumulate progressively more mutations in DNA repair proteins as cancers progress.  DNA repair mechanisms greatly affect the response to cytotoxic treatments, so understanding those mechanisms and finding ways to turn dysregulated repair processes against themselves to induce tumor death is the goal of all DNA repair inhibition efforts.  Inhibition may be direct or indirect.  This burgeoning field of research is replete with promise and challenge, as more intricacies of each repair pathway are discovered.  In an era of increasing concern about healthcare costs, use of DNA repair inhibitors can prove to be highly effective stewardship of R&D resources and patient expenses.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpDbAS-i0CKqbVg90H21EOLACvtfcHk0lhRM9h9wZAUWA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtVWmsLjP&md5=20f5c07ae16d46176d515dcc869ffc7e</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.2217%2Ffon.14.60&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2217%252Ffon.14.60%26sid%3Dliteratum%253Aachs%26aulast%3DKelley%26aufirst%3DM.%2BR.%26aulast%3DLogsdon%26aufirst%3DD.%26aulast%3DFishel%26aufirst%3DM.%2BL.%26atitle%3DTargeting%2520DNA%2520repair%2520pathways%2520for%2520cancer%2520treatment%253A%2520what%25E2%2580%2599s%2520new%253F%26jtitle%3DFuture%2520Oncol.%26date%3D2014%26volume%3D10%26spage%3D1215%26epage%3D1237%26doi%3D10.2217%2Ffon.14.60" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Scott, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Swisher, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaufmann, S. H.</span></span> <span> </span><span class="NLM_article-title">Poly (ADP-Ribose) Polymerase inhibitors: recent advances and future development</span>. <i>J. Clin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>33</i></span>,  <span class="NLM_fpage">1397</span>– <span class="NLM_lpage">1406</span>, <span class="refDoi"> DOI: 10.1200/JCO.2014.58.8848</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02008&amp;key=10.1200%2FJCO.2014.58.8848" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02008&amp;key=25779564" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02008&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtVaqtL%252FM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2015&pages=1397-1406&author=C.+L.+Scottauthor=E.+M.+Swisherauthor=S.+H.+Kaufmann&title=Poly+%28ADP-Ribose%29+Polymerase+inhibitors%3A+recent+advances+and+future+development&doi=10.1200%2FJCO.2014.58.8848"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Poly (ADP-Ribose) polymerase inhibitors: recent advances and future development</span></div><div class="casAuthors">Scott, Clare L.; Swisher, Elizabeth M.; Kaufmann, Scott H.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">33</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1397-1406</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">Poly (ADP-ribose) polymerase (PARP) inhibitors have shown promising activity in epithelial ovarian cancers, esp. relapsed platinum-sensitive high-grade serous disease.  Consistent with preclin. studies, ovarian cancers and a no. of other solid tumor types occurring in patients with deleterious germline mutations in BRCA1 or BRCA2 seem to be particularly sensitive.  However, it is also becoming clear that germline BRCA1/2 mutations are neither necessary nor sufficient for patients to derive benefit from PARP inhibitors.  We provide an update on PARP inhibitor clin. development, describe recent advances in our understanding of PARP inhibitor mechanism of action, and discuss current issues in the development of these agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGowf5pO-7WPjrVg90H21EOLACvtfcHk0lhRM9h9wZAUWA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtVaqtL%252FM&md5=a9a1668a322c4a2e099a1fd9891a15da</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1200%2FJCO.2014.58.8848&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2014.58.8848%26sid%3Dliteratum%253Aachs%26aulast%3DScott%26aufirst%3DC.%2BL.%26aulast%3DSwisher%26aufirst%3DE.%2BM.%26aulast%3DKaufmann%26aufirst%3DS.%2BH.%26atitle%3DPoly%2520%2528ADP-Ribose%2529%2520Polymerase%2520inhibitors%253A%2520recent%2520advances%2520and%2520future%2520development%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2015%26volume%3D33%26spage%3D1397%26epage%3D1406%26doi%3D10.1200%2FJCO.2014.58.8848" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Senhaji
Mouhri, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goodfellow, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jean-Claude, B.</span></span> <span> </span><span class="NLM_article-title">A type I combi-targeting approach for the design of molecules with enhanced potency against BRCA1/2 mutant- and O6-methylguanine-DNA methyltransferase (mgmt)- expressing tumour cells</span>. <i>BMC Cancer</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">540</span>– <span class="NLM_lpage">540</span>, <span class="refDoi"> DOI: 10.1186/s12885-017-3504-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02008&amp;key=10.1186%2Fs12885-017-3504-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02008&amp;key=28800752" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02008&amp;key=1%3ACAS%3A280%3ADC%252BC1cfmvVCjsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2017&pages=540-540&author=Z.+Senhaji%0AMouhriauthor=E.+Goodfellowauthor=B.+Jean-Claude&title=A+type+I+combi-targeting+approach+for+the+design+of+molecules+with+enhanced+potency+against+BRCA1%2F2+mutant-+and+O6-methylguanine-DNA+methyltransferase+%28mgmt%29-+expressing+tumour+cells&doi=10.1186%2Fs12885-017-3504-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">A type I combi-targeting approach for the design of molecules with enhanced potency against BRCA1/2 mutant- and O6-methylguanine-DNA methyltransferase (mgmt)- expressing tumour cells</span></div><div class="casAuthors">Senhaji Mouhri Zhor; Goodfellow Elliot; Jean-Claude Bertrand</div><div class="citationInfo"><span class="NLM_cas:title">BMC cancer</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">540</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  Mutations of the DNA repair proteins BRCA1/2 are synthetically lethal with the DNA repair enzyme poly(ADP-ribose) polymerase (PARP), which when inhibited, leads to cell death due to the absence of compensatory DNA repair mechanism.  The potency of PARP inhibitors has now been clinically proven.  However, disappointingly, acquired resistance mediated by the reactivation of wild type BRCA1/2 has been reported.  In order to improve their efficacy, trials are ongoing to explore their combinations with temozolomide (TMZ).  Here, in order to enhance potency in BRCA1/2-mutant cells, we report on the design of single molecules termed "combi-molecules" capable of not only inhibiting PARP but also damaging DNA like TMZ, which is known to induce a large number of DNA adducts.  The majority of these lesions are processed through PARP-dependent base-excision repair machinery.  Paradoxically, the least abundant lesion, the O6-methylguanine adduct is the most cytotoxic.  Its repair by the O6-methylguanine DNA methyl transferase (MGMT) confers robust resistance to TMZ.  Thus, we surmise that a combi-molecule designed to generate the same DNA adducts as TMZ, with an additional ability to block PARP, could induce BRCA1/2 mutant selective potency and a growth inhibitory profile independent of MGMT status.  METHODS:  The hydrolysis of EG22 and its stabilized form ZSM02 was analyzed by HPLC and fluorescence spectroscopy.  Growth inhibitory potency was determined by SRB assay.  PARP inhibition was determined by an enzyme assay and DNA damage by the comet assay.  Subcellular distribution was visualized by confocal microscopy.  RESULTS:  Studies on EG22 showed that: (a) it inflicted anomalously higher levels of DNA damage than TMZ (b) it induced PARP inhibitory potency in the same range as ANI, a known PARP inhibitor (IC50 = 0.10 μM) (c) it showed strong potency in both BRCA1/2 wild type and mutated cells with 6-fold selectivity for the mutants and it was 65-303-fold more potent than TMZ and 4-63-fold than ANI alone and 3-47-fold than their corresponding equimolar combinations and (d) its potency was independent of MGMT expression.  CONCLUSION:  The results in toto suggest that a combi-molecular approach directed at blocking PARP and damaging DNA can lead to single molecules with selective and enhanced potency against BRCA1/2 mutant and with activity independent of MGMT, the major predictive biomarker for resistance to TMZ.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRf37bciQUfj0g6wdEZmT2rfW6udTcc2eaE3HwtTZJbL7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1cfmvVCjsg%253D%253D&md5=4a0fe4976628ff7e51f44a41e351f905</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1186%2Fs12885-017-3504-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs12885-017-3504-1%26sid%3Dliteratum%253Aachs%26aulast%3DSenhaji%2BMouhri%26aufirst%3DZ.%26aulast%3DGoodfellow%26aufirst%3DE.%26aulast%3DJean-Claude%26aufirst%3DB.%26atitle%3DA%2520type%2520I%2520combi-targeting%2520approach%2520for%2520the%2520design%2520of%2520molecules%2520with%2520enhanced%2520potency%2520against%2520BRCA1%252F2%2520mutant-%2520and%2520O6-methylguanine-DNA%2520methyltransferase%2520%2528mgmt%2529-%2520expressing%2520tumour%2520cells%26jtitle%3DBMC%2520Cancer%26date%3D2017%26volume%3D17%26spage%3D540%26epage%3D540%26doi%3D10.1186%2Fs12885-017-3504-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gupta, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mladek, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tian, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Decker, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kizilbash, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kitange, G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sarkaria, J. N.</span></span> <span> </span><span class="NLM_article-title">PARP inhibitors for sensitization of alkylation chemotherapy in glioblastoma: impact of blood-brain barrier and molecular heterogeneity</span>. <i>Front. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">670</span>, <span class="refDoi"> DOI: 10.3389/fonc.2018.00670</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02008&amp;key=10.3389%2Ffonc.2018.00670" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02008&amp;key=30723695" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2019&pages=670&author=S.+K.+Guptaauthor=E.+J.+Smithauthor=A.+C.+Mladekauthor=S.+Tianauthor=P.+A.+Deckerauthor=S.+H.+Kizilbashauthor=G.+J.+Kitangeauthor=J.+N.+Sarkaria&title=PARP+inhibitors+for+sensitization+of+alkylation+chemotherapy+in+glioblastoma%3A+impact+of+blood-brain+barrier+and+molecular+heterogeneity&doi=10.3389%2Ffonc.2018.00670"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.3389%2Ffonc.2018.00670&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffonc.2018.00670%26sid%3Dliteratum%253Aachs%26aulast%3DGupta%26aufirst%3DS.%2BK.%26aulast%3DSmith%26aufirst%3DE.%2BJ.%26aulast%3DMladek%26aufirst%3DA.%2BC.%26aulast%3DTian%26aufirst%3DS.%26aulast%3DDecker%26aufirst%3DP.%2BA.%26aulast%3DKizilbash%26aufirst%3DS.%2BH.%26aulast%3DKitange%26aufirst%3DG.%2BJ.%26aulast%3DSarkaria%26aufirst%3DJ.%2BN.%26atitle%3DPARP%2520inhibitors%2520for%2520sensitization%2520of%2520alkylation%2520chemotherapy%2520in%2520glioblastoma%253A%2520impact%2520of%2520blood-brain%2520barrier%2520and%2520molecular%2520heterogeneity%26jtitle%3DFront.%2520Oncol.%26date%3D2019%26volume%3D8%26spage%3D670%26doi%3D10.3389%2Ffonc.2018.00670" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Salvati, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Botta, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Amato, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Di Leva, F. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zizza, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gioiello, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pagano, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Graziani, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tarsounas, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Randazzo, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Novellino, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Biroccio, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cosconati, S.</span></span> <span> </span><span class="NLM_article-title">Lead discovery of dual G-Quadruplex stabilizers and Poly(ADP-ribose) Polymerases (PARPs) inhibitors: a new avenue in anticancer treatment</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">3626</span>– <span class="NLM_lpage">3635</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b01563</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b01563" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02008&amp;key=1%3ACAS%3A528%3ADC%252BC2sXms1Wntbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=3626-3635&author=E.+Salvatiauthor=L.+Bottaauthor=J.+Amatoauthor=F.+S.+Di+Levaauthor=P.+Zizzaauthor=A.+Gioielloauthor=B.+Paganoauthor=G.+Grazianiauthor=M.+Tarsounasauthor=A.+Randazzoauthor=E.+Novellinoauthor=A.+Biroccioauthor=S.+Cosconati&title=Lead+discovery+of+dual+G-Quadruplex+stabilizers+and+Poly%28ADP-ribose%29+Polymerases+%28PARPs%29+inhibitors%3A+a+new+avenue+in+anticancer+treatment&doi=10.1021%2Facs.jmedchem.6b01563"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Lead Discovery of Dual G-Quadruplex Stabilizers and Poly(ADP-ribose) Polymerases (PARPs) Inhibitors: A New Avenue in Anticancer Treatment</span></div><div class="casAuthors">Salvati, Erica; Botta, Lorenzo; Amato, Jussara; Di Leva, Francesco Saverio; Zizza, Pasquale; Gioiello, Antimo; Pagano, Bruno; Graziani, Grazia; Tarsounas, Madalena; Randazzo, Antonio; Novellino, Ettore; Biroccio, Annamaria; Cosconati, Sandro</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">3626-3635</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">G-quadruplex stabilizers are an established opportunity in anticancer chemotherapy.  To circumvent the antiproliferative effects of G4 ligands, cancer cells recruit PARP enzymes at telomeres.  Herein, starting from the structural similarity of a potent G4 ligand previously discovered by our group and a congeneric PARP inhibitor, a library of derivs. was synthesized to discover the first dual G4/PARP ligand.  We demonstrate that a properly decorated thieno[3,2-c]quinolin-4(5H)-one stabilizes the G4 fold in vitro and in cells, induces a DNA damage response localized to telomeres, inhibits PARylation in cells, and has an antiproliferative effect in BRCA2 deficient tumor cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoNobRG8jUGVLVg90H21EOLACvtfcHk0lg0CvK7riQL_Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXms1Wntbw%253D&md5=2355803dca16e068d7c6b19be66dd2e2</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b01563&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b01563%26sid%3Dliteratum%253Aachs%26aulast%3DSalvati%26aufirst%3DE.%26aulast%3DBotta%26aufirst%3DL.%26aulast%3DAmato%26aufirst%3DJ.%26aulast%3DDi%2BLeva%26aufirst%3DF.%2BS.%26aulast%3DZizza%26aufirst%3DP.%26aulast%3DGioiello%26aufirst%3DA.%26aulast%3DPagano%26aufirst%3DB.%26aulast%3DGraziani%26aufirst%3DG.%26aulast%3DTarsounas%26aufirst%3DM.%26aulast%3DRandazzo%26aufirst%3DA.%26aulast%3DNovellino%26aufirst%3DE.%26aulast%3DBiroccio%26aufirst%3DA.%26aulast%3DCosconati%26aufirst%3DS.%26atitle%3DLead%2520discovery%2520of%2520dual%2520G-Quadruplex%2520stabilizers%2520and%2520Poly%2528ADP-ribose%2529%2520Polymerases%2520%2528PARPs%2529%2520inhibitors%253A%2520a%2520new%2520avenue%2520in%2520anticancer%2520treatment%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26volume%3D60%26spage%3D3626%26epage%3D3635%26doi%3D10.1021%2Facs.jmedchem.6b01563" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yacoub, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McKinstry, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hinman, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chung, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dent, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hagan, M. P.</span></span> <span> </span><span class="NLM_article-title">Epidermal growth factor and ionizing radiation up-regulate the DNA repair genes XRCC1 and ERCC1 in DU145 and LNCaP prostate carcinoma through MAPK signaling</span>. <i>Radiat. Res.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>159</i></span>,  <span class="NLM_fpage">439</span>– <span class="NLM_lpage">452</span>, <span class="refDoi"> DOI: 10.1667/0033-7587(2003)159[0439:EGFAIR]2.0.CO;2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02008&amp;key=10.1667%2F0033-7587%282003%29159%5B0439%3AEGFAIR%5D2.0.CO%3B2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02008&amp;key=12643788" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02008&amp;key=1%3ACAS%3A528%3ADC%252BD3sXivVersL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=159&publication_year=2003&pages=439-452&author=A.+Yacoubauthor=R.+McKinstryauthor=D.+Hinmanauthor=T.+Chungauthor=P.+Dentauthor=M.+P.+Hagan&title=Epidermal+growth+factor+and+ionizing+radiation+up-regulate+the+DNA+repair+genes+XRCC1+and+ERCC1+in+DU145+and+LNCaP+prostate+carcinoma+through+MAPK+signaling&doi=10.1667%2F0033-7587%282003%29159%5B0439%3AEGFAIR%5D2.0.CO%3B2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Epidermal growth factor and ionizing radiation up-regulate the DNA repair genes XRCC1 and ERCC1 in DU145 and LNCaP prostate carcinoma through MAPK signaling</span></div><div class="casAuthors">Yacoub, Adly; McKinstry, Robert; Hinman, Darin; Chung, Theodore; Dent, Paul; Hagan, Michael P.</div><div class="citationInfo"><span class="NLM_cas:title">Radiation Research</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">159</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">439-452</span>CODEN:
                <span class="NLM_cas:coden">RAREAE</span>;
        ISSN:<span class="NLM_cas:issn">0033-7587</span>.
    
            (<span class="NLM_cas:orgname">Radiation Research Society</span>)
        </div><div class="casAbstract">This work examd. the importance of radiation-induced and ligand-induced EGFR-ERK signaling for the regulation of DNA repair proteins XRCC1 and ERCC1 in prostate carcinoma cells, DU145 (TP53mut), displaying EGFR-TGFA-dependent autocrine growth and high MAPK (ERK1/2) activity, and LNCaP (TP53wt) cells expressing low constitutive levels of ERK1/2 activity.  Using quant. RT-PCR and Western analyses, we detd. that ionizing radiation activated the DNA repair genes XRCC1 and ERCC1 in an ERK1/2-dependent fashion for each cell line.  After irradn., a rapid increase followed by a decrease in ERK1/2 activity preceded the increase in XRCC1/ERCC1 expression in DU145 cells, while only the rapid decrease in ERK1/2 preceded the increase in XRCC1/ERCC1 expression in LNCaP cells.  Administration of EGF, however, markedly increased the up-regulation of phospho-ERK, ERCC1 and XRCC1 in both cell lines.  Although the EGFR inhibitor tyrphostin (AG-1478) and the MEK inhibitor PD90859 both attenuated EGF-induced levels of the ERCC1 and XRCC1 protein, PD98059 blocked the induction of ERCC1 and XRCC1 by radiation more effectively in both cell lines.  Inhibition of ERK at a level that reduced the up-regulation of DNA repair led to the persistence of apurinic/apyrimidinic (AP) sites of DNA damage and increased cell killing.  Taken together, these data imply a complex control of DNA repair activation that may be more generally dependent on MAPK (ERK1/2) signaling than was previously noted.  These data provide novel insights into the capacity of the EGFR-ERK signaling to modulate DNA repair in cancer cells and into the functional significance of this signaling.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqH8DufM3lxR7Vg90H21EOLACvtfcHk0lg0CvK7riQL_Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXivVersL4%253D&md5=0042f1fce51c1c8ea88109cd7bd815de</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1667%2F0033-7587%282003%29159%5B0439%3AEGFAIR%5D2.0.CO%3B2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1667%252F0033-7587%25282003%2529159%255B0439%253AEGFAIR%255D2.0.CO%253B2%26sid%3Dliteratum%253Aachs%26aulast%3DYacoub%26aufirst%3DA.%26aulast%3DMcKinstry%26aufirst%3DR.%26aulast%3DHinman%26aufirst%3DD.%26aulast%3DChung%26aufirst%3DT.%26aulast%3DDent%26aufirst%3DP.%26aulast%3DHagan%26aufirst%3DM.%2BP.%26atitle%3DEpidermal%2520growth%2520factor%2520and%2520ionizing%2520radiation%2520up-regulate%2520the%2520DNA%2520repair%2520genes%2520XRCC1%2520and%2520ERCC1%2520in%2520DU145%2520and%2520LNCaP%2520prostate%2520carcinoma%2520through%2520MAPK%2520signaling%26jtitle%3DRadiat.%2520Res.%26date%3D2003%26volume%3D159%26spage%3D439%26epage%3D452%26doi%3D10.1667%2F0033-7587%282003%29159%5B0439%3AEGFAIR%5D2.0.CO%3B2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Day, K. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hiles, G. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kozminsky, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dawsey, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paul, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Broses, L. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shah, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kunja, L. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hall, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palanisamy, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Daignault-Newton, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">El-Sawy, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilson, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chou, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ignatoski, K. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keller, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagrath, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morgan, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Day, M. L.</span></span> <span> </span><span class="NLM_article-title">HER2 and EGFR overexpression support metastatic progression of prostate cancer to bone</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>77</i></span>,  <span class="NLM_fpage">74</span>– <span class="NLM_lpage">85</span>, <span class="refDoi"> DOI: 10.1158/0008-5472.CAN-16-1656</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02008&amp;key=10.1158%2F0008-5472.CAN-16-1656" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02008&amp;key=27793843" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02008&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhsFSl" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=77&publication_year=2017&pages=74-85&author=K.+C.+Dayauthor=G.+L.+Hilesauthor=M.+Kozminskyauthor=S.+J.+Dawseyauthor=A.+Paulauthor=L.+J.+Brosesauthor=R.+Shahauthor=L.+P.+Kunjaauthor=C.+Hallauthor=N.+Palanisamyauthor=S.+Daignault-Newtonauthor=L.+El-Sawyauthor=S.+J.+Wilsonauthor=A.+Chouauthor=K.+W.+Ignatoskiauthor=E.+Kellerauthor=D.+Thomasauthor=S.+Nagrathauthor=T.+Morganauthor=M.+L.+Day&title=HER2+and+EGFR+overexpression+support+metastatic+progression+of+prostate+cancer+to+bone&doi=10.1158%2F0008-5472.CAN-16-1656"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">HER2 and EGFR Overexpression Support Metastatic Progression of Prostate Cancer to Bone</span></div><div class="casAuthors">Day, Kathleen C.; Hiles, Guadalupe Lorenzatti; Kozminsky, Molly; Dawsey, Scott J.; Paul, Alyssa; Broses, Luke J.; Shah, Rajal; Kunja, Lakshmi P.; Hall, Christopher; Palanisamy, Nallasivam; Daignault-Newton, Stephanie; El-Sawy, Layla; Wilson, Steven James; Chou, Andrew; Ignatoski, Kathleen Woods; Keller, Evan; Thomas, Dafydd; Nagrath, Sunitha; Morgan, Todd; Day, Mark L.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">77</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">74-85</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Activation of the EGF receptors EGFR (ErbB1) and HER2 (ErbB2) drives the progression of multiple cancer types through complex mechanisms that are still not fully understood.  In this study, we report that HER2 expression is elevated in bone metastases of prostate cancer independently of gene amplification.  An examn. of HER2 and NF-κB receptor (RANK) coexpression revealed increased levels of both proteins in aggressive prostate tumors and metastatic deposits.  Inhibiting HER2 expression in bone tumor xenografts reduced proliferation and RANK expression while maintaining EGFR expression.  In examg. the role of EGFR in tumor-initiating cells (TIC), we found that EGFR expression was required for primary and secondary sphere formation of prostate cancer cells.  EGFR expression was also obsd. in circulating tumor cells (CTC) during prostate cancer metastasis.  Dual inhibition of HER2 and EGFR resulted in significant inhibition of tumor xenograft growth, further supporting the significance of these receptors in prostate cancer progression.  Overall, our results indicate that EGFR promotes survival of prostate TIC and CTC that metastasize to bone, whereas HER2 supports the growth of prostate cancer cells once they are established at metastatic sites.  Cancer Res; 77(1); 74-85. 2016 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoMSjSQ1vG3pbVg90H21EOLACvtfcHk0lg2aql6d0cyPQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhsFSl&md5=8aed330d8b40475e0450e6ca380ebef7</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-16-1656&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-16-1656%26sid%3Dliteratum%253Aachs%26aulast%3DDay%26aufirst%3DK.%2BC.%26aulast%3DHiles%26aufirst%3DG.%2BL.%26aulast%3DKozminsky%26aufirst%3DM.%26aulast%3DDawsey%26aufirst%3DS.%2BJ.%26aulast%3DPaul%26aufirst%3DA.%26aulast%3DBroses%26aufirst%3DL.%2BJ.%26aulast%3DShah%26aufirst%3DR.%26aulast%3DKunja%26aufirst%3DL.%2BP.%26aulast%3DHall%26aufirst%3DC.%26aulast%3DPalanisamy%26aufirst%3DN.%26aulast%3DDaignault-Newton%26aufirst%3DS.%26aulast%3DEl-Sawy%26aufirst%3DL.%26aulast%3DWilson%26aufirst%3DS.%2BJ.%26aulast%3DChou%26aufirst%3DA.%26aulast%3DIgnatoski%26aufirst%3DK.%2BW.%26aulast%3DKeller%26aufirst%3DE.%26aulast%3DThomas%26aufirst%3DD.%26aulast%3DNagrath%26aufirst%3DS.%26aulast%3DMorgan%26aufirst%3DT.%26aulast%3DDay%26aufirst%3DM.%2BL.%26atitle%3DHER2%2520and%2520EGFR%2520overexpression%2520support%2520metastatic%2520progression%2520of%2520prostate%2520cancer%2520to%2520bone%26jtitle%3DCancer%2520Res.%26date%3D2017%26volume%3D77%26spage%3D74%26epage%3D85%26doi%3D10.1158%2F0008-5472.CAN-16-1656" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Baek, K. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hong, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jung, Y. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, C. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, E. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, M. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoo, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, S. W.</span></span> <span> </span><span class="NLM_article-title">Correlation of AR, EGFR, and HER2 expression levels in prostate cancer: immunohistochemical analysis and chromogenic in situ hybridization</span>. <i>Cancer Res Treat</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>44</i></span>,  <span class="NLM_fpage">50</span>– <span class="NLM_lpage">56</span>, <span class="refDoi"> DOI: 10.4143/crt.2012.44.1.50</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02008&amp;key=10.4143%2Fcrt.2012.44.1.50" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02008&amp;key=22500161" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02008&amp;key=1%3ACAS%3A280%3ADC%252BC38rkslChtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=44&publication_year=2012&pages=50-56&author=K.+H.+Baekauthor=M.+E.+Hongauthor=Y.+Y.+Jungauthor=C.+H.+Leeauthor=T.+J.+Leeauthor=E.+S.+Parkauthor=M.+K.+Kimauthor=J.+H.+Yooauthor=S.+W.+Lee&title=Correlation+of+AR%2C+EGFR%2C+and+HER2+expression+levels+in+prostate+cancer%3A+immunohistochemical+analysis+and+chromogenic+in+situ+hybridization&doi=10.4143%2Fcrt.2012.44.1.50"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Correlation of AR, EGFR, and HER2 Expression Levels in Prostate Cancer: Immunohistochemical Analysis and Chromogenic In Situ Hybridization</span></div><div class="casAuthors">Baek Kwang Hyun; Hong Min Eui; Jung Yoon Yang; Lee Chung Hun; Lee Tae Jin; Park Eon Sub; Kim Mi Kyung; Yoo Jae Hyung; Lee Soo Whan</div><div class="citationInfo"><span class="NLM_cas:title">Cancer research and treatment : official journal of Korean Cancer Association</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">44</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">50-6</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">PURPOSE:  The androgen receptor (AR) plays a central role in prostate cancer.  Evidence from several groups indicates that epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2) may enhance AR activity in prostate cancer cell lines.  This study was designed to investigate the protein expression of AR, EGFR, and HER2 and to determine whether the EGFR and HER2 genes are amplified in prostate cancer tissues.  MATERIALS AND METHODS:  The protein expression levels of AR, EGFR, and HER2 in a tissue microarray block of 66 prostate cancer samples were investigated by immunohistochemical analysis and chromogenic in situ hybridization was used to determine whether the EGFR and HER2 genes were amplified in these tissues.  RESULTS:  The AR and EGFR proteins were expressed in 59.1% and 40.9% of prostate cancers, respectively, but their expression levels were not significantly associated with clinicopathologic factors.  Of the cases in which tissues were negative for EGFR protein expression, 69.2% were positive for AR protein expression; however, AR protein expression was significantly reduced (44.4%) in tissues in which EGFR protein was expressed.  HER2 expression was detected in only 1 case (1.5%).  No amplification of the EGFR or HER2 genes was found in prostate cancer specimens.  CONCLUSION:  This study was limited by small number of subjects, but it can still be inferred that the expression levels of the AR and EGFR proteins are inversely correlated in prostate cancer patients.  The potential utility of EGFR and HER2 as prognostic factors or therapeutic targets warrants further study.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQCEHsxuDVeOiA3UY9EwTNrfW6udTcc2eZHrCjbAFgiabntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC38rkslChtA%253D%253D&md5=31b79397371105702abd98e80daf36ce</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.4143%2Fcrt.2012.44.1.50&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4143%252Fcrt.2012.44.1.50%26sid%3Dliteratum%253Aachs%26aulast%3DBaek%26aufirst%3DK.%2BH.%26aulast%3DHong%26aufirst%3DM.%2BE.%26aulast%3DJung%26aufirst%3DY.%2BY.%26aulast%3DLee%26aufirst%3DC.%2BH.%26aulast%3DLee%26aufirst%3DT.%2BJ.%26aulast%3DPark%26aufirst%3DE.%2BS.%26aulast%3DKim%26aufirst%3DM.%2BK.%26aulast%3DYoo%26aufirst%3DJ.%2BH.%26aulast%3DLee%26aufirst%3DS.%2BW.%26atitle%3DCorrelation%2520of%2520AR%252C%2520EGFR%252C%2520and%2520HER2%2520expression%2520levels%2520in%2520prostate%2520cancer%253A%2520immunohistochemical%2520analysis%2520and%2520chromogenic%2520in%2520situ%2520hybridization%26jtitle%3DCancer%2520Res%2520Treat%26date%3D2012%26volume%3D44%26spage%3D50%26epage%3D56%26doi%3D10.4143%2Fcrt.2012.44.1.50" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Todorova, M. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Larroque, A.-L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dauphin-Pierre, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fang, Y.-Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jean-Claude, B. J.</span></span> <span> </span><span class="NLM_article-title">Subcellular distribution of a fluorescence-labeled combi-molecule designed to block epidermal growth factor receptor tyrosine kinase and damage DNA with a green fluorescent species</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">869</span>– <span class="NLM_lpage">882</span>, <span class="refDoi"> DOI: 10.1158/1535-7163.MCT-09-0673</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02008&amp;key=10.1158%2F1535-7163.MCT-09-0673" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02008&amp;key=20354119" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02008&amp;key=1%3ACAS%3A528%3ADC%252BC3cXktlCqt7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2010&pages=869-882&author=M.+I.+Todorovaauthor=A.-L.+Larroqueauthor=S.+Dauphin-Pierreauthor=Y.-Q.+Fangauthor=B.+J.+Jean-Claude&title=Subcellular+distribution+of+a+fluorescence-labeled+combi-molecule+designed+to+block+epidermal+growth+factor+receptor+tyrosine+kinase+and+damage+DNA+with+a+green+fluorescent+species&doi=10.1158%2F1535-7163.MCT-09-0673"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Subcellular Distribution of a Fluorescence-Labeled Combi-Molecule Designed to Block Epidermal Growth Factor Receptor Tyrosine Kinase and Damage DNA with a Green Fluorescent Species</span></div><div class="casAuthors">Todorova, Margarita I.; Larroque, Anne-Laure; Dauphin-Pierre, Sabine; Fang, You-Qiang; Jean-Claude, Bertrand J.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">869-882</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">To monitor the subcellular distribution of mixed epidermal growth factor (EGF) receptor (EGFR)-DNA targeting drugs termed combi-mols., we designed AL237, a fluorescent prototype, to degrade into a green fluorescent DNA damaging species and FD105, a blue fluorescent EGFR inhibitor.  Here we showed that AL237 damaged DNA in the 12.5 to 50 μmol/L range.  Despite its size, it blocked EGFR phosphorylation in an enzyme assay (IC50 = 0.27 μmol/L) and in MDA-MB468 breast cancer cells in the same concn. range as for DNA damage.  This translated into inhibition of extracellular signal-regulated kinase 1/2 or BAD phosphorylation and downregulation of DNA repair proteins (XRCC1, ERCC1).  Having shown that AL237 was a balanced EGFR-DNA targeting mol., it was used as an imaging probe to show that (a) green and blue colors were primarily colocalized in the perinuclear and partially in the nucleus in EGFR- or ErbB2-expressing cells, (b) the blue fluorescence assocd. with FD105, but not the green, was colocalized with anti-EGFR red-labeled antibody, (c) the green fluorescence of nuclei was significantly more intense in NIH 3T3 cells expressing EGFR or ErbB2 than in their wild-type counterparts (P < 0.05).  Similarly, the growth inhibitory potency of AL237 was selectively stronger in the transfectants.  In summary, the results suggest that AL237 diffuses into the cells and localizes abundantly in the perinuclear region and partially in the nucleus where it degrades into EGFR and DNA targeting species.  This bystander-like effect translates into high levels of DNA damage in the nucleus.  Sufficient quinazoline levels are released in the cells to block EGF-induced activation of downstream signaling.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoOwehXKbZBD7Vg90H21EOLACvtfcHk0lg2aql6d0cyPQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXktlCqt7w%253D&md5=cd0998f04045a30bdfa1e29e6ee799a9</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-09-0673&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-09-0673%26sid%3Dliteratum%253Aachs%26aulast%3DTodorova%26aufirst%3DM.%2BI.%26aulast%3DLarroque%26aufirst%3DA.-L.%26aulast%3DDauphin-Pierre%26aufirst%3DS.%26aulast%3DFang%26aufirst%3DY.-Q.%26aulast%3DJean-Claude%26aufirst%3DB.%2BJ.%26atitle%3DSubcellular%2520distribution%2520of%2520a%2520fluorescence-labeled%2520combi-molecule%2520designed%2520to%2520block%2520epidermal%2520growth%2520factor%2520receptor%2520tyrosine%2520kinase%2520and%2520damage%2520DNA%2520with%2520a%2520green%2520fluorescent%2520species%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2010%26volume%3D9%26spage%3D869%26epage%3D882%26doi%3D10.1158%2F1535-7163.MCT-09-0673" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Goodfellow, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Senhaji Mouhri, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jean-Claude, B. J.</span></span> <span> </span><span class="NLM_article-title">Design, synthesis and biological activity of novel molecules designed to target PARP and DNA</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>27</i></span>,  <span class="NLM_fpage">688</span>– <span class="NLM_lpage">694</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2016.09.054</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02008&amp;key=10.1016%2Fj.bmcl.2016.09.054" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02008&amp;key=28003142" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02008&amp;key=1%3ACAS%3A528%3ADC%252BC28XitFamtLzN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2017&pages=688-694&author=E.+Goodfellowauthor=Z.+Senhaji+Mouhriauthor=C.+Williamsauthor=B.+J.+Jean-Claude&title=Design%2C+synthesis+and+biological+activity+of+novel+molecules+designed+to+target+PARP+and+DNA&doi=10.1016%2Fj.bmcl.2016.09.054"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Design, synthesis and biological activity of novel molecules designed to target PARP and DNA</span></div><div class="casAuthors">Goodfellow, Elliot; Senhaji Mouhri, Zhor; Williams, Christopher; Jean-Claude, Bertrand J.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">688-694</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">In order to enhance the cytotoxic potential of poly(ADP-ribose) polymerase (PARP) inhibitors in BRCA1 or 2 deficient tumors, the authors designed a series of mols. contg. a 1,2,3-triazene moiety tethered to a PARP targeting scaffold.  A cell-based selectivity assay involving a BRCA2-deficient Chinese hamster cell line and its corresponding BRCA2 wild type transfectant, was used to predict the PARP targeting potential of the latter agents.  The results showed that adding a DNA damaging function to the PARP inhibitors decreased but did not abrogate the selective targeting of the BRCA2-deficient cells.  The DNA damaging moiety augmented the potency in BRCA2 deficient cells by 2-20-fold.  The most selective dual PARP-DNA targeting agent I was found to possess dual DNA and PARP targeting properties.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqz1x3BscUmJrVg90H21EOLACvtfcHk0lgtFyaOaBUe4A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XitFamtLzN&md5=fdce34354322d2389749a63ff0ebb9fe</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2016.09.054&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2016.09.054%26sid%3Dliteratum%253Aachs%26aulast%3DGoodfellow%26aufirst%3DE.%26aulast%3DSenhaji%2BMouhri%26aufirst%3DZ.%26aulast%3DWilliams%26aufirst%3DC.%26aulast%3DJean-Claude%26aufirst%3DB.%2BJ.%26atitle%3DDesign%252C%2520synthesis%2520and%2520biological%2520activity%2520of%2520novel%2520molecules%2520designed%2520to%2520target%2520PARP%2520and%2520DNA%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2017%26volume%3D27%26spage%3D688%26epage%3D694%26doi%3D10.1016%2Fj.bmcl.2016.09.054" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rao, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Larroque-Lombard, A.-L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peyrard, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thauvin, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rachid, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jean-Claude, B. J.</span></span> <span> </span><span class="NLM_article-title">Target modulation by a kinase inhibitor engineered to induce a tandem blockade of the Epidermal Growth Factor Receptor (EGFR) and c-Src: the concept of type III Combi-Targeting</span>. <i>PLoS One</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>10</i></span>, <span class="NLM_elocation-id">e0117215</span> <span class="refDoi"> DOI: 10.1371/journal.pone.0117215</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02008&amp;key=10.1371%2Fjournal.pone.0117215" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02008&amp;key=25658745" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02008&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhsVGrsr7F" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2015&author=S.+Raoauthor=A.-L.+Larroque-Lombardauthor=L.+Peyrardauthor=C.+Thauvinauthor=Z.+Rachidauthor=C.+Williamsauthor=B.+J.+Jean-Claude&title=Target+modulation+by+a+kinase+inhibitor+engineered+to+induce+a+tandem+blockade+of+the+Epidermal+Growth+Factor+Receptor+%28EGFR%29+and+c-Src%3A+the+concept+of+type+III+Combi-Targeting&doi=10.1371%2Fjournal.pone.0117215"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Target modulation by a kinase inhibitor engineered to induce a tandem blockade of the epidermal growth factor receptor (EGFR) and c-Src: the concept of type III combi-targeting</span></div><div class="casAuthors">Rao, Suman; Larroque-Lombard, Anne-Laure; Peyrard, Lisa; Thauvin, Cedric; Rachid, Zakaria; Williams, Christopher; Jean-Claude, Bertrand J.</div><div class="citationInfo"><span class="NLM_cas:title">PLoS One</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">e0117215/1-e0117215/24</span>CODEN:
                <span class="NLM_cas:coden">POLNCL</span>;
        ISSN:<span class="NLM_cas:issn">1932-6203</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">Cancer cells are characterized by a complex network of interrelated and compensatory signaling driven by multiple kinases that reduce their sensitivity to targeted therapy.  Therefore, strategies directed at inhibiting two or more kinases are required to robustly block the growth of refractory tumor cells.  Here we report on a novel strategy to promote sustained inhibition of two oncogenic kinases (Kin-1 and Kin-2) by designing a mol. K1-K2, termed "combi-mol.", to induce a tandem blockade of Kin-1 and Kin-2, as an intact structure and to be further hydrolyzed to two inhibitors K1 and K2 directed at Kin-1 and Kin-2, resp.  We chose to target EGFR (Kin-1) and c-Src (Kin-2), two tyrosine kinases known to synergize to promote tumor growth and progression.  Variation of K1-K2 linkers led to AL776, our first optimized EGFR-c-Src targeting prototype.  Here we showed that: (a) AL776 blocked EGFR and c-Src as an intact structure using an in vitro kinase assay (IC50 EGFR = 0.12 μM and IC50 c-Src = 3 nM), (b) it could release K1 (AL621, a nanomolar EGFR inhibitor) and K2 (dasatinib, a clin. approved Abl/c-Src inhibitor) by hydrolytic cleavage both in vitro and in vivo, (c) it could robustly inhibit phosphorylation of EGFR and c-Src (0.25-1 μM) in cells, (d) it induced 2-4 fold stronger growth inhibition than gefitinib or dasatinib and apoptosis at concns. as low as 1 μM, and, (e) blocked motility and invasion at sub-micromolar doses in the highly invasive 4T1 and MDA-MB-231 cells.  Despite its size (MW = 1032), AL776 blocked phosphorylation of EGFR and c-Src in 4T1 tumors in vivo.  We now term this new targeting model consisting of designing a kinase inhibitor K1-K2 to target Kin-1 and Kin-2, and to further release two inhibitors K1 and K2 of the latter kinases, "type III combi-targeting".</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrUidvfzZGlVLVg90H21EOLACvtfcHk0lgtFyaOaBUe4A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhsVGrsr7F&md5=3549409ebadc579533ccb96d1d7ad8cf</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0117215&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0117215%26sid%3Dliteratum%253Aachs%26aulast%3DRao%26aufirst%3DS.%26aulast%3DLarroque-Lombard%26aufirst%3DA.-L.%26aulast%3DPeyrard%26aufirst%3DL.%26aulast%3DThauvin%26aufirst%3DC.%26aulast%3DRachid%26aufirst%3DZ.%26aulast%3DWilliams%26aufirst%3DC.%26aulast%3DJean-Claude%26aufirst%3DB.%2BJ.%26atitle%3DTarget%2520modulation%2520by%2520a%2520kinase%2520inhibitor%2520engineered%2520to%2520induce%2520a%2520tandem%2520blockade%2520of%2520the%2520Epidermal%2520Growth%2520Factor%2520Receptor%2520%2528EGFR%2529%2520and%2520c-Src%253A%2520the%2520concept%2520of%2520type%2520III%2520Combi-Targeting%26jtitle%3DPLoS%2520One%26date%3D2015%26volume%3D10%26doi%3D10.1371%2Fjournal.pone.0117215" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rupp, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mouhri, Z. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jean-Claude, B. J.</span></span> <span> </span><span class="NLM_article-title">Molecular analysis of the dual targeting of the epidermal growth factor receptor and the O<sup>6</sup>-methylguanine-DNA methyltransferase with a double arm hybrid molecule</span>. <i>Oncotarget</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">35041</span>– <span class="NLM_lpage">35055</span>, <span class="refDoi"> DOI: 10.18632/oncotarget.25120</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02008&amp;key=10.18632%2Foncotarget.25120" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02008&amp;key=30416678" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02008&amp;key=1%3ACAS%3A280%3ADC%252BB3cvovVGmug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2018&pages=35041-35055&author=M.+Ruppauthor=Z.+S.+Mouhriauthor=C.+Williamsauthor=B.+J.+Jean-Claude&title=Molecular+analysis+of+the+dual+targeting+of+the+epidermal+growth+factor+receptor+and+the+O6-methylguanine-DNA+methyltransferase+with+a+double+arm+hybrid+molecule&doi=10.18632%2Foncotarget.25120"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular analysis of the dual targeting of the epidermal growth factor receptor and the O(6)-methylguanine-DNA methyltransferase with a double arm hybrid molecule</span></div><div class="casAuthors">Rupp Martin; Mouhri Zhor Senhaji; Jean-Claude Bertrand J; Williams Christopher</div><div class="citationInfo"><span class="NLM_cas:title">Oncotarget</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">80</span>),
    <span class="NLM_cas:pages">35041-35055</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Disordered expression of the epidermal growth factor receptor (EGFR) has been associated with induction of DNA repair genes (e.g.  XRCC1, ERCC1) and resistance to radiation and genotoxic drugs.  However, our previous work showed that EGFR inhibition did not affect O(6)-methylguanine-DNA methyltransferase (MGMT)-mediated resistance.  In order to block uncoupled events associated with EGFR and MGMT, we designed MR30, a single molecule termed "combi-molecule" that contains a quinazoline arm targeted to EGFR and an O(6)-benzylguanine (O(6)-BG) moiety to block MGMT.  Molecular analysis of the mechanism of action of its two arms showed that: (a) it could block EGFR phosphorylation, (b) down-regulate the RAF-MAPK and the PI3K-AKT pathways, and (c) covalently modify MGMT through S-benzylation, as confirmed by MALDI analysis of a direct binding assay with isolated MGMT, (d) it induced a dose-dependent down-regulation of MGMT in lung and melanoma cells.  The pleiotropic mechanism of action of MR30 culminated into strong growth inhibition (IC50: 0.018-6.02 μM), with superior activity when compared with an equimolar combination of gefitinib (a clinical EGFR inhibitor) and O(6)-BG (a known MGMT inhibitor).  Pulse exposure experiments were required to attenuate the contribution of EGFR inhibition to the strong potency of MR30, thereby allowing to achieve the dose level required to sensitize cells to temozolomide (TMZ).  Indeed, MR30 significantly sensitized EGFR-MGMT co-expressing cells to TMZ (p<0.05-0.0001).  The results in toto suggest that MR30 is the first prototype of agents that may be used against tumours addicted to EGFR and to sensitize resistant tumours co-expressing EGFR and MGMT to TMZ.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQbRfzZK_yPGoqdXsLcGTEUfW6udTcc2eZjW631gxtoHbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3cvovVGmug%253D%253D&md5=0b0233e4c881f422a29eeebc4f2b547d</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.18632%2Foncotarget.25120&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.18632%252Foncotarget.25120%26sid%3Dliteratum%253Aachs%26aulast%3DRupp%26aufirst%3DM.%26aulast%3DMouhri%26aufirst%3DZ.%2BS.%26aulast%3DWilliams%26aufirst%3DC.%26aulast%3DJean-Claude%26aufirst%3DB.%2BJ.%26atitle%3DMolecular%2520analysis%2520of%2520the%2520dual%2520targeting%2520of%2520the%2520epidermal%2520growth%2520factor%2520receptor%2520and%2520the%2520O6-methylguanine-DNA%2520methyltransferase%2520with%2520a%2520double%2520arm%2520hybrid%2520molecule%26jtitle%3DOncotarget%26date%3D2018%26volume%3D9%26spage%3D35041%26epage%3D35055%26doi%3D10.18632%2Foncotarget.25120" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Remon, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steuer, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramalingam, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Felip, E.</span></span> <span> </span><span class="NLM_article-title">Osimertinib and other third-generation EGFR TKI in EGFR-mutant NSCLC patients</span>. <i>Ann. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>29</i></span>,  <span class="NLM_fpage">i20</span>– <span class="NLM_lpage">i27</span>, <span class="refDoi"> DOI: 10.1093/annonc/mdx704</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02008&amp;key=10.1093%2Fannonc%2Fmdx704" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02008&amp;key=29462255" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2018&pages=i20-i27&author=J.+Remonauthor=C.+E.+Steuerauthor=S.+S.+Ramalingamauthor=E.+Felip&title=Osimertinib+and+other+third-generation+EGFR+TKI+in+EGFR-mutant+NSCLC+patients&doi=10.1093%2Fannonc%2Fmdx704"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1093%2Fannonc%2Fmdx704&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fannonc%252Fmdx704%26sid%3Dliteratum%253Aachs%26aulast%3DRemon%26aufirst%3DJ.%26aulast%3DSteuer%26aufirst%3DC.%2BE.%26aulast%3DRamalingam%26aufirst%3DS.%2BS.%26aulast%3DFelip%26aufirst%3DE.%26atitle%3DOsimertinib%2520and%2520other%2520third-generation%2520EGFR%2520TKI%2520in%2520EGFR-mutant%2520NSCLC%2520patients%26jtitle%3DAnn.%2520Oncol.%26date%3D2018%26volume%3D29%26spage%3Di20%26epage%3Di27%26doi%3D10.1093%2Fannonc%2Fmdx704" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Buggia, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Locatelli, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Regazzi, M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zecca, M.</span></span> <span> </span><span class="NLM_article-title">Busulfan</span>. <i>Ann. Pharmacother.</i> <span class="NLM_year" style="font-weight: bold;">1994</span>,  <span class="NLM_volume"><i>28</i></span>,  <span class="NLM_fpage">1055</span>– <span class="NLM_lpage">1062</span>, <span class="refDoi"> DOI: 10.1177/106002809402800911</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02008&amp;key=10.1177%2F106002809402800911" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02008&amp;key=7803883" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02008&amp;key=1%3ACAS%3A280%3ADyaK2M7gt1Wrsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=1994&pages=1055-1062&author=I.+Buggiaauthor=F.+Locatelliauthor=M.+B.+Regazziauthor=M.+Zecca&title=Busulfan&doi=10.1177%2F106002809402800911"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Busulfan</span></div><div class="casAuthors">Buggia I; Locatelli F; Regazzi M B; Zecca M</div><div class="citationInfo"><span class="NLM_cas:title">The Annals of pharmacotherapy</span>
        (<span class="NLM_cas:date">1994</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1055-62</span>
        ISSN:<span class="NLM_cas:issn">1060-0280</span>.
    </div><div class="casAbstract">OBJECTIVE:  To review the current published studies evaluating the pharmacokinetics, clinical efficacy, safety, and toxicity of busulfan in pediatric and adult patients.  DATA SOURCES:  English-language literature published between 1953 and 1993 was analyzed; pertinent literature was reviewed.  STUDY SELECTION:  Emphasis was placed on pharmacologic studies and clinical trials involving busulfan therapy both in myeloproliferative disorders and in conditioning regimens for autologous or allogeneic bone marrow transplantation.  DATA EXTRACTION:  Data from both pediatric and adult studies were evaluated; emphasis was placed on the relationship between plasma concentrations of busulfan and its efficacy and toxicity.  DATA SYNTHESIS:  Busulfan has been used widely at conventional dosages (1-12 mg/d) for the treatment of patients with chronic myelogenous leukemia (CML).  Busulfan at high doses (usually 16 mg/kg) given with other cytotoxic drugs (especially cyclophosphamide) is a common preparative regimen in patients undergoing allogeneic or autologous bone marrow transplantation (BMT) for acute or chronic leukemia and other nonmalignant disorders (e.g., hemoglobinopathies, inborn error of immune system, congenital metabolic disorders).  Pharmacokinetics of high-dose busulfan are age-dependent.  Busulfan systemic exposure and, thus, tissue and tumor exposure are lower in children than with adults.  Relationships between toxicity (principally neutropenia, hepatic veno-occlusive disease, incidence of seizures) and drug exposure were found for busulfan.  CONCLUSIONS:  Busulfan is a useful, sufficiently safe drug in the treatment of patients with CML.  At higher dosages, busulfan is a fundamental part of myeloablative therapies for patients undergoing BMT.  As the pharmacokinetics and metabolism of busulfan is further understood, there is great potential for improving treatment outcome.  An assessment of maximal tolerated exposure determined by therapeutic drug monitoring may decrease the incidence and lethality of regimen-related toxicities.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRCKXIcmdY-TrGbPKh4T9eAfW6udTcc2eakMf_iukAvj7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaK2M7gt1Wrsg%253D%253D&md5=e1a5b38f4f075cdd625936805c555c53</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1177%2F106002809402800911&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F106002809402800911%26sid%3Dliteratum%253Aachs%26aulast%3DBuggia%26aufirst%3DI.%26aulast%3DLocatelli%26aufirst%3DF.%26aulast%3DRegazzi%26aufirst%3DM.%2BB.%26aulast%3DZecca%26aufirst%3DM.%26atitle%3DBusulfan%26jtitle%3DAnn.%2520Pharmacother.%26date%3D1994%26volume%3D28%26spage%3D1055%26epage%3D1062%26doi%3D10.1177%2F106002809402800911" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Haapala, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hakala, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jokipelto, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vilpo, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hovinen, J.</span></span> <span> </span><span class="NLM_article-title">Reactions of N,N-Bis(2-chloroethyl)-p-aminophenylbutyric acid (Chlorambucil) with 2′-Deoxyguanosine</span>. <i>Chem. Res. Toxicol.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">988</span>– <span class="NLM_lpage">995</span>, <span class="refDoi"> DOI: 10.1021/tx000249u</span> </span><div class="citationLinks">[<a href="/doi/10.1021/tx000249u" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02008&amp;key=1%3ACAS%3A528%3ADC%252BD3MXkvFSjtbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2001&pages=988-995&author=E.+Haapalaauthor=K.+Hakalaauthor=E.+Jokipeltoauthor=J.+Vilpoauthor=J.+Hovinen&title=Reactions+of+N%2CN-Bis%282-chloroethyl%29-p-aminophenylbutyric+acid+%28Chlorambucil%29+with+2%E2%80%B2-Deoxyguanosine&doi=10.1021%2Ftx000249u"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Reactions of N,N-bis(2-chloroethyl)-p-aminophenylbutyric acid (chlorambucil) with 2'-deoxyguanosine</span></div><div class="casAuthors">Haapala, Elina; Hakala, Kristo; Jokipelto, Eeva; Vilpo, Juhani; Hovinen, Jari</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Research in Toxicology</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">988-995</span>CODEN:
                <span class="NLM_cas:coden">CRTOEC</span>;
        ISSN:<span class="NLM_cas:issn">0893-228X</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">N,N-Bis(2-chloroethyl)-p-aminophenylbutyric acid (chlorambucil, 1) was allowed to react in the presence of 2'-deoxyguanosine (16 mM) at physiol. pH (cacodylic acid, 50% base), and the reactions were followed by HPLC/MS/MS techniques.  Although the predominant reaction obsd. was chlorambucil hydrolysis, ca. 24% of 1 reacted with different heteroatoms of the nucleoside.  As expected, the principal site of 2'-deoxyguanosine alkylation was N7.  Alkylation of N7 caused spontaneous depurination, and N-(7-guaninylethyl)-N-hydroxyethyl-p-aminophenylbutyric acid (5) and the corresponding N7,N7-bis-adduct (6) were the major stable dGuo derivs.  Also several other adducts were detected and tentatively identified by means of MS/MS and UV.  From them, the O6-, N1-, N2-, and O5'-derivs. can be biol. significant.  Our results shed new light on DNA modifications caused by chlorambucil, which is an important chemotherapeutic drug and a known carcinogen.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqQow-dkNtGVbVg90H21EOLACvtfcHk0ljRrsYFSomNng"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXkvFSjtbg%253D&md5=c9ecd19ed88c6710e40fe80eb6e9e5a7</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1021%2Ftx000249u&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Ftx000249u%26sid%3Dliteratum%253Aachs%26aulast%3DHaapala%26aufirst%3DE.%26aulast%3DHakala%26aufirst%3DK.%26aulast%3DJokipelto%26aufirst%3DE.%26aulast%3DVilpo%26aufirst%3DJ.%26aulast%3DHovinen%26aufirst%3DJ.%26atitle%3DReactions%2520of%2520N%252CN-Bis%25282-chloroethyl%2529-p-aminophenylbutyric%2520acid%2520%2528Chlorambucil%2529%2520with%25202%25E2%2580%25B2-Deoxyguanosine%26jtitle%3DChem.%2520Res.%2520Toxicol.%26date%3D2001%26volume%3D14%26spage%3D988%26epage%3D995%26doi%3D10.1021%2Ftx000249u" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Puyo, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Montaudon, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pourquier, P.</span></span> <span> </span><span class="NLM_article-title">From old alkylating agents to new minor groove binders</span>. <i>Crit. Rev. Oncol. Hematol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>89</i></span>,  <span class="NLM_fpage">43</span>– <span class="NLM_lpage">61</span>, <span class="refDoi"> DOI: 10.1016/j.critrevonc.2013.07.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02008&amp;key=10.1016%2Fj.critrevonc.2013.07.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02008&amp;key=23972663" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02008&amp;key=1%3ACAS%3A280%3ADC%252BC3sbjvVegsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=89&publication_year=2014&pages=43-61&author=S.+Puyoauthor=D.+Montaudonauthor=P.+Pourquier&title=From+old+alkylating+agents+to+new+minor+groove+binders&doi=10.1016%2Fj.critrevonc.2013.07.006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">From old alkylating agents to new minor groove binders</span></div><div class="casAuthors">Puyo Stephane; Montaudon Daniele; Pourquier Philippe</div><div class="citationInfo"><span class="NLM_cas:title">Critical reviews in oncology/hematology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">89</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">43-61</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Alkylating agents represent the oldest class of anticancer agents with the approval of mechloretamine by the FDA in 1949.  Even though their clinical use is far beyond the use of new targeted therapies, they still occupy a major place in the treatment of specific malignancies, sometimes representing the unique option for the treatment of refractory tumors.  Here, we are reviewing the major classes of alkylating agents, with a particular focus on the latest generations of compounds that specifically target the minor groove of the DNA.  These naturally occurring derivatives have a unique mechanism of action that explains the recent regain of interest in developing new classes of alkylating agents that could be used in combination with other anticancer drugs to enhance tumor response in the clinic.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRG8YhZZYBEXukdrW1FkXG-fW6udTcc2eakMf_iukAvj7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3sbjvVegsA%253D%253D&md5=dd2ca22a19a6618b83baeaa677efac54</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1016%2Fj.critrevonc.2013.07.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.critrevonc.2013.07.006%26sid%3Dliteratum%253Aachs%26aulast%3DPuyo%26aufirst%3DS.%26aulast%3DMontaudon%26aufirst%3DD.%26aulast%3DPourquier%26aufirst%3DP.%26atitle%3DFrom%2520old%2520alkylating%2520agents%2520to%2520new%2520minor%2520groove%2520binders%26jtitle%3DCrit.%2520Rev.%2520Oncol.%2520Hematol.%26date%3D2014%26volume%3D89%26spage%3D43%26epage%3D61%26doi%3D10.1016%2Fj.critrevonc.2013.07.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Iwamoto, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hiraku, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oikawa, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mizutani, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kojima, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kawanishi, S.</span></span> <span> </span><span class="NLM_article-title">DNA intrastrand cross-link at the 5′-GA-3′ sequence formed by busulfan and its role in the cytotoxic effect</span>. <i>Cancer Sci.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>95</i></span>,  <span class="NLM_fpage">454</span>– <span class="NLM_lpage">458</span>, <span class="refDoi"> DOI: 10.1111/j.1349-7006.2004.tb03231.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02008&amp;key=10.1111%2Fj.1349-7006.2004.tb03231.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02008&amp;key=15132775" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02008&amp;key=1%3ACAS%3A528%3ADC%252BD2cXltlaitbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=95&publication_year=2004&pages=454-458&author=T.+Iwamotoauthor=Y.+Hirakuauthor=S.+Oikawaauthor=H.+Mizutaniauthor=M.+Kojimaauthor=S.+Kawanishi&title=DNA+intrastrand+cross-link+at+the+5%E2%80%B2-GA-3%E2%80%B2+sequence+formed+by+busulfan+and+its+role+in+the+cytotoxic+effect&doi=10.1111%2Fj.1349-7006.2004.tb03231.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">DNA intrastrand cross-link at the 5'-GA-3' sequence formed by busulfan and its role in the cytotoxic effect</span></div><div class="casAuthors">Iwamoto, Takuya; Hiraku, Yusuke; Oikawa, Shinji; Mizutani, Hideki; Kojima, Michio; Kawanishi, Shosuke</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Science</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">95</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">454-458</span>CODEN:
                <span class="NLM_cas:coden">CSACCM</span>;
        ISSN:<span class="NLM_cas:issn">1347-9032</span>.
    
            (<span class="NLM_cas:orgname">Japanese Cancer Association</span>)
        </div><div class="casAbstract">Busulfan (1,4-butanediol dimethanesulfonate) has been used widely for the treatment of patients with chronic myelogenous leukemia.  Busulfan is bifunctional and thus may effectively induce DNA damage, which may play an important role in the cytotoxicity.  In this study, we compared the cytotoxicity of bifunctional busulfan with that of monofunctional Et methanesulfonate (EMS) in human promyelocytic leukemia HL-60 cells.  Busulfan showed a significant inhibitory effect on cell growth, whereas the cells grew in the presence of EMS.  To clarify the mechanism of cytotoxicity of busulfan, we investigated DNA damage induced by busulfan using 32P-5'-end-labeled DNA fragments obtained from the human p16 tumor suppressor gene.  Busulfan induced DNA damage dose-dependently, whereas EMS caused little DNA damage.  DNA-sequencing expts. using piperidine and 3-methyladenine DNA glycosylase indicated that busulfan caused double-base lesions mainly at 5'-GA-3' and, to a lesser extent, at 5'-GG-3' sequences.  Time of flight mass spectrometry confirmed that busulfan forms an intrastrand cross-link at the 5'-GA-3' sequence, in addn. to mono-alkylation.  The mechanism and the role of crosslinking at the 5'-GA-3' sequence are discussed in relation to the cytotoxicity induced by busulfan.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp3npiNdSFXBrVg90H21EOLACvtfcHk0ljRrsYFSomNng"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXltlaitbk%253D&md5=037bf5d6f984e4a8b68a4674bfbbadd8</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1111%2Fj.1349-7006.2004.tb03231.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1349-7006.2004.tb03231.x%26sid%3Dliteratum%253Aachs%26aulast%3DIwamoto%26aufirst%3DT.%26aulast%3DHiraku%26aufirst%3DY.%26aulast%3DOikawa%26aufirst%3DS.%26aulast%3DMizutani%26aufirst%3DH.%26aulast%3DKojima%26aufirst%3DM.%26aulast%3DKawanishi%26aufirst%3DS.%26atitle%3DDNA%2520intrastrand%2520cross-link%2520at%2520the%25205%25E2%2580%25B2-GA-3%25E2%2580%25B2%2520sequence%2520formed%2520by%2520busulfan%2520and%2520its%2520role%2520in%2520the%2520cytotoxic%2520effect%26jtitle%3DCancer%2520Sci.%26date%3D2004%26volume%3D95%26spage%3D454%26epage%3D458%26doi%3D10.1111%2Fj.1349-7006.2004.tb03231.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schmitt, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goodfellow, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gomes, I. N. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosa, M. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reis, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Titi, H. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jean-Claude, B. J.</span></span> <span> </span><span class="NLM_article-title">Comparative analysis of the dual EGFR-DNA targeting and growth inhibitory properties of 6-mono-alkylamino- and 6,6-dialkylaminoquinazoline-based type II combi-molecules</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>192</i></span>,  <span class="NLM_fpage">112185</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2020.112185</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02008&amp;key=10.1016%2Fj.ejmech.2020.112185" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02008&amp;key=32145644" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02008&amp;key=1%3ACAS%3A528%3ADC%252BB3cXksFelsrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=192&publication_year=2020&pages=112185&author=J.+Schmittauthor=E.+Goodfellowauthor=S.+Huangauthor=C.+Williamsauthor=I.+N.+F.+Gomesauthor=M.+N.+Rosaauthor=R.+M.+Reisauthor=R.+Yangauthor=H.+M.+Titiauthor=B.+J.+Jean-Claude&title=Comparative+analysis+of+the+dual+EGFR-DNA+targeting+and+growth+inhibitory+properties+of+6-mono-alkylamino-+and+6%2C6-dialkylaminoquinazoline-based+type+II+combi-molecules&doi=10.1016%2Fj.ejmech.2020.112185"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Comparative analysis of the dual EGFR-DNA targeting and growth inhibitory properties of 6-mono-alkylamino- and 6,6-dialkylaminoquinazoline-based type II combi-molecules</span></div><div class="casAuthors">Schmitt, Julie; Goodfellow, Elliot; Huang, Shanlong; Williams, Christopher; Gomes, Izabela N. F.; Rosa, Marcela N.; Reis, Rui M.; Yang, Richard; Titi, Hatem M.; Jean-Claude, Bertrand J.</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">192</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">112185</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">Over the past decade, we described a novel tumor targeted approach that sought to design "combi-mols." to hit two distinct targets in tumor cells.  Here, to generate small combi-mols. with strong DNA damaging potential while retaining EGFR inhibitory potency, we developed the first synthetic strategy to access the 6-N, N-disubstituted quinazoline scaffold and designed JS61 to possess a nitrogen mustard function directly attached to the 6-position of the quinazoline ring.  We compared its biol. activity with that of structures contg. either a hemi mustard or a non-alkylating substituent.  Surprisingly, the results showed that JS61, while capable of inducing strong DNA damage, exhibited moderate EGFR inhibitory potency.  In contrast, "combi-mols." with no bulky substituent at the N-6 position (e.g. ZR2002 and JS84) showed stronger EGFR and growth inhibitory potency than JS61 in a panel of lung cancer cells.  To rationalize these results, X-ray crystallog. and mol. modeling studies were undertaken, and the data obtained indicated that bulkiness of the 6-N,N-disubstituted moieties hinder its binding to the ATP site and affects binding reversibility.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpUx5ebf6KJdLVg90H21EOLACvtfcHk0lhp9mllDjiw1g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXksFelsrg%253D&md5=f6b6fc11a474179932ec6b16db1db7fe</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2020.112185&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2020.112185%26sid%3Dliteratum%253Aachs%26aulast%3DSchmitt%26aufirst%3DJ.%26aulast%3DGoodfellow%26aufirst%3DE.%26aulast%3DHuang%26aufirst%3DS.%26aulast%3DWilliams%26aufirst%3DC.%26aulast%3DGomes%26aufirst%3DI.%2BN.%2BF.%26aulast%3DRosa%26aufirst%3DM.%2BN.%26aulast%3DReis%26aufirst%3DR.%2BM.%26aulast%3DYang%26aufirst%3DR.%26aulast%3DTiti%26aufirst%3DH.%2BM.%26aulast%3DJean-Claude%26aufirst%3DB.%2BJ.%26atitle%3DComparative%2520analysis%2520of%2520the%2520dual%2520EGFR-DNA%2520targeting%2520and%2520growth%2520inhibitory%2520properties%2520of%25206-mono-alkylamino-%2520and%25206%252C6-dialkylaminoquinazoline-based%2520type%2520II%2520combi-molecules%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2020%26volume%3D192%26spage%3D112185%26doi%3D10.1016%2Fj.ejmech.2020.112185" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Avendaño, C.</span>; <span class="NLM_string-name">Menéndez, J. C.</span></span> <span> </span><span class="NLM_article-title">Chapter 5 - DNA alkylating agents</span>. In  <i>Medicinal Chemistry of Anticancer Drugs</i>; <span class="NLM_contrib-group"><span class="NLM_string-name">Avendaño, C.</span>; <span class="NLM_string-name">Menéndez, J. C.</span></span>, Eds. <span class="NLM_publisher-name">Elsevier</span>: <span class="NLM_publisher-loc">Amsterdam</span>, <span class="NLM_year">2008</span>; pp  <span class="NLM_fpage">139</span>– <span class="NLM_lpage">176</span>.</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02008&amp;key=10.1016%2FB978-0-444-52824-7.00005-6" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2008&pages=139-176&author=C.+Avenda%C3%B1o&author=J.+C.+Men%C3%A9ndezauthor=C.+Avenda%C3%B1o&author=J.+C.+Men%C3%A9ndez&title=Medicinal+Chemistry+of+Anticancer+Drugs"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1016%2FB978-0-444-52824-7.00005-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26id%3Ddoi%3A10.1016%252FB978-0-444-52824-7.00005-6%26sid%3Dliteratum%253Aachs%26aulast%3DAvenda%25C3%25B1o%26aufirst%3DC.%26atitle%3DChapter%25205%2520-%2520DNA%2520alkylating%2520agents%26btitle%3DMedicinal%2520Chemistry%2520of%2520Anticancer%2520Drugs%26aulast%3DAvenda%25C3%25B1o%26aufirst%3DC.%26pub%3DElsevier%26date%3D2008%26spage%3D139%26epage%3D176" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Müller, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eisenbrand, G.</span></span> <span> </span><span class="NLM_article-title">The influence of N7 substituents on the stability of N7-alkylated guanosines</span>. <i>Chem.-Biol. Interact.</i> <span class="NLM_year" style="font-weight: bold;">1985</span>,  <span class="NLM_volume"><i>53</i></span>,  <span class="NLM_fpage">173</span>– <span class="NLM_lpage">181</span>, <span class="refDoi"> DOI: 10.1016/S0009-2797(85)80094-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02008&amp;key=10.1016%2FS0009-2797%2885%2980094-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02008&amp;key=3995651" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02008&amp;key=1%3ACAS%3A528%3ADyaL28XovV2huw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=1985&pages=173-181&author=N.+M%C3%BCllerauthor=G.+Eisenbrand&title=The+influence+of+N7+substituents+on+the+stability+of+N7-alkylated+guanosines&doi=10.1016%2FS0009-2797%2885%2980094-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">The influence of N7 substituents on the stability of N7-alkylated guanosines</span></div><div class="casAuthors">Mueller, Norbert; Eisenbrand, Gerhard</div><div class="citationInfo"><span class="NLM_cas:title">Chemico-Biological Interactions</span>
        (<span class="NLM_cas:date">1985</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">1-2</span>),
    <span class="NLM_cas:pages">173-81</span>CODEN:
                <span class="NLM_cas:coden">CBINA8</span>;
        ISSN:<span class="NLM_cas:issn">0009-2797</span>.
    </div><div class="casAbstract">Guanosine alkylated at the 7-position readily decompd. by imidazole ring opening and depurination.  There is a direct correlation between the electron-withdrawing effects, expressed as the Taft substituent const. σ*, of alkyl substituents in 7-position and the resp. acid dissocn. consts. and chem. stabilities of 7-alkylated guanosines.  The resp. values for the slopes of the regression lines were ρ* = +1.89 for imidazole ring opening and ρ* = +0.175 for the depurination reaction.  Unknown Taft consts. can be detd. from the σ*/pKa regression line.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoUzxIbXqrqNbVg90H21EOLACvtfcHk0lhp9mllDjiw1g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL28XovV2huw%253D%253D&md5=0f759a4808a45082779f20aeb9adea16</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1016%2FS0009-2797%2885%2980094-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0009-2797%252885%252980094-6%26sid%3Dliteratum%253Aachs%26aulast%3DM%25C3%25BCller%26aufirst%3DN.%26aulast%3DEisenbrand%26aufirst%3DG.%26atitle%3DThe%2520influence%2520of%2520N7%2520substituents%2520on%2520the%2520stability%2520of%2520N7-alkylated%2520guanosines%26jtitle%3DChem.-Biol.%2520Interact.%26date%3D1985%26volume%3D53%26spage%3D173%26epage%3D181%26doi%3D10.1016%2FS0009-2797%2885%2980094-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wee, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Z.</span></span> <span> </span><span class="NLM_article-title">Epidermal growth factor receptor cell proliferation signaling pathways</span>. <i>Cancers (Basel)</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">52</span>, <span class="refDoi"> DOI: 10.3390/cancers9050052</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02008&amp;key=10.3390%2Fcancers9050052" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02008&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhvVemtL%252FK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2017&pages=52&author=P.+Weeauthor=Z.+Wang&title=Epidermal+growth+factor+receptor+cell+proliferation+signaling+pathways&doi=10.3390%2Fcancers9050052"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Epidermal growth factor receptor cell proliferation signaling pathways</span></div><div class="casAuthors">Wee, Ping; Wang, Zhixiang</div><div class="citationInfo"><span class="NLM_cas:title">Cancers</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">52/1-52/45</span>CODEN:
                <span class="NLM_cas:coden">CANCCT</span>;
        ISSN:<span class="NLM_cas:issn">2072-6694</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">The epidermal growth factor receptor (EGFR) is a receptor tyrosine kinase that is commonly upregulated in cancers such as in non-small-cell lung cancer, metastatic colorectal cancer, glioblastoma, head and neck cancer, pancreatic cancer, and breast cancer.  Various mechanisms mediate the upregulation of EGFR activity, including common mutations and truncations to its extracellular domain, such as in the EGFRvIII truncations, as well as to its kinase domain, such as the L858R and T790M mutations, or the exon 19 truncation.  These EGFR aberrations over-activate downstream pro-oncogenic signaling pathways, including the RAS-RAF-MEK-ERK MAPK and AKT-PI3K-mTOR pathways.  These pathways then activate many biol. outputs that are beneficial to cancer cell proliferation, including their chronic initiation and progression through the cell cycle.  Here, we review the mol. mechanisms that regulate EGFR signal transduction, including the EGFR structure and its mutations, ligand binding and EGFR dimerization, as well as the signaling pathways that lead to G1 cell cycle progression.  We focus on the induction of CYCLIN D expression, CDK4/6 activation, and the repression of cyclin-dependent kinase inhibitor proteins (CDKi) by EGFR signaling pathways.  We also discuss the successes and challenges of EGFR-targeted therapies, and the potential for their use in combination with CDK4/6 inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpti1TbuQ7GPrVg90H21EOLACvtfcHk0lhp9mllDjiw1g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhvVemtL%252FK&md5=5d5a81e10b147d1a74957dfa293e75c3</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.3390%2Fcancers9050052&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fcancers9050052%26sid%3Dliteratum%253Aachs%26aulast%3DWee%26aufirst%3DP.%26aulast%3DWang%26aufirst%3DZ.%26atitle%3DEpidermal%2520growth%2520factor%2520receptor%2520cell%2520proliferation%2520signaling%2520pathways%26jtitle%3DCancers%2520%2528Basel%2529%26date%3D2017%26volume%3D9%26spage%3D52%26doi%3D10.3390%2Fcancers9050052" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Isakoff, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Puhalla, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Domchek, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Friedlander, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaufman, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robson, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Telli, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diéras, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, H. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garber, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, E. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maag, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qin, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giranda, V. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shepherd, S. P.</span></span> <span> </span><span class="NLM_article-title">A randomized Phase II study of veliparib with temozolomide or carboplatin/paclitaxel versus placebo with carboplatin/paclitaxel in BRCA1/2 metastatic breast cancer: design and rationale</span>. <i>Future Oncol</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">307</span>– <span class="NLM_lpage">320</span>, <span class="refDoi"> DOI: 10.2217/fon-2016-0412</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02008&amp;key=10.2217%2Ffon-2016-0412" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02008&amp;key=27739325" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02008&amp;key=1%3ACAS%3A528%3ADC%252BC2sXosF2lsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2017&pages=307-320&author=S.+J.+Isakoffauthor=S.+Puhallaauthor=S.+M.+Domchekauthor=M.+Friedlanderauthor=B.+Kaufmanauthor=M.+Robsonauthor=M.+L.+Telliauthor=V.+Di%C3%A9rasauthor=H.+S.+Hanauthor=J.+E.+Garberauthor=E.+F.+Johnsonauthor=D.+Maagauthor=Q.+Qinauthor=V.+L.+Girandaauthor=S.+P.+Shepherd&title=A+randomized+Phase+II+study+of+veliparib+with+temozolomide+or+carboplatin%2Fpaclitaxel+versus+placebo+with+carboplatin%2Fpaclitaxel+in+BRCA1%2F2+metastatic+breast+cancer%3A+design+and+rationale&doi=10.2217%2Ffon-2016-0412"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">A randomized Phase II study of veliparib with temozolomide or carboplatin/paclitaxel versus placebo with carboplatin/paclitaxel in BRCA1/2 metastatic breast cancer: design and rationale</span></div><div class="casAuthors">Isakoff, Steven J.; Puhalla, Shannon; Domchek, Susan M.; Friedlander, Michael; Kaufman, Bella; Robson, Mark; Telli, Melinda L.; Dieras, Veronique; Han, Hyo Sook; Garber, Judy E.; Johnson, Eric F.; Maag, David; Qin, Qin; Giranda, Vincent L.; Shepherd, Stacie P.</div><div class="citationInfo"><span class="NLM_cas:title">Future Oncology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">307-320</span>CODEN:
                <span class="NLM_cas:coden">FOUNBN</span>;
        ISSN:<span class="NLM_cas:issn">1479-6694</span>.
    
            (<span class="NLM_cas:orgname">Future Medicine Ltd.</span>)
        </div><div class="casAbstract">Veliparib is an orally administered poly(ADP-ribose) polymerase inhibitor that is being studied in Phase I-III clin. trials, including Phase III studies in non-small-cell lung cancer, ovarian cancer and breast cancer.  Tumor cells with deleterious BRCA1 or BRCA2 mutations are deficient in homologous recombination DNA repair and are intrinsically sensitive to platinum therapy and poly(ADP-ribose) polymerase inhibitors.  We describe herein the design and rationale of a Phase II trial investigating whether the addn. of veliparib to temozolomide or carboplatin/paclitaxel provides clin. benefit over carboplatin/paclitaxel with placebo in patients with locally recurrent or metastatic breast cancer harboring a deleterious BRCA1 or BRCA2 germline mutation (Trial registration: EudraCT 2011-002913-12, NCT01506609).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpMicV7820PzLVg90H21EOLACvtfcHk0ljhfyBxihCs_A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXosF2lsQ%253D%253D&md5=8a6fb6b2b50603229645617d68f54154</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.2217%2Ffon-2016-0412&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2217%252Ffon-2016-0412%26sid%3Dliteratum%253Aachs%26aulast%3DIsakoff%26aufirst%3DS.%2BJ.%26aulast%3DPuhalla%26aufirst%3DS.%26aulast%3DDomchek%26aufirst%3DS.%2BM.%26aulast%3DFriedlander%26aufirst%3DM.%26aulast%3DKaufman%26aufirst%3DB.%26aulast%3DRobson%26aufirst%3DM.%26aulast%3DTelli%26aufirst%3DM.%2BL.%26aulast%3DDi%25C3%25A9ras%26aufirst%3DV.%26aulast%3DHan%26aufirst%3DH.%2BS.%26aulast%3DGarber%26aufirst%3DJ.%2BE.%26aulast%3DJohnson%26aufirst%3DE.%2BF.%26aulast%3DMaag%26aufirst%3DD.%26aulast%3DQin%26aufirst%3DQ.%26aulast%3DGiranda%26aufirst%3DV.%2BL.%26aulast%3DShepherd%26aufirst%3DS.%2BP.%26atitle%3DA%2520randomized%2520Phase%2520II%2520study%2520of%2520veliparib%2520with%2520temozolomide%2520or%2520carboplatin%252Fpaclitaxel%2520versus%2520placebo%2520with%2520carboplatin%252Fpaclitaxel%2520in%2520BRCA1%252F2%2520metastatic%2520breast%2520cancer%253A%2520design%2520and%2520rationale%26jtitle%3DFuture%2520Oncol%26date%3D2017%26volume%3D13%26spage%3D307%26epage%3D320%26doi%3D10.2217%2Ffon-2016-0412" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Burke, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ali, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Connell, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sullivan, F. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Glynn, S. A.</span></span> <span> </span><span class="NLM_article-title">Sensitivity profiles of human prostate cancer cell lines to an 80 Kinase inhibitor panel</span>. <i>Anticancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>36</i></span>,  <span class="NLM_fpage">633</span>– <span class="NLM_lpage">641</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02008&amp;key=26851018" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02008&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtFalsLbE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=2016&pages=633-641&author=A.+J.+Burkeauthor=H.+Aliauthor=E.+O%E2%80%99Connellauthor=F.+J.+Sullivanauthor=S.+A.+Glynn&title=Sensitivity+profiles+of+human+prostate+cancer+cell+lines+to+an+80+Kinase+inhibitor+panel"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Sensitivity profiles of human prostate cancer cell lines to an 80 kinase inhibitor panel</span></div><div class="casAuthors">Burke, Amy J.; Ali, Husnain; O'Connell, Enda; Sullivan, Francis J.; Glynn, Sharon A.</div><div class="citationInfo"><span class="NLM_cas:title">Anticancer Research</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">36</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">633-642</span>CODEN:
                <span class="NLM_cas:coden">ANTRD4</span>;
        ISSN:<span class="NLM_cas:issn">0250-7005</span>.
    
            (<span class="NLM_cas:orgname">International Institute of Anticancer Research</span>)
        </div><div class="casAbstract">Background: Taxanes and anti-androgen therapies are routinely used for the treatment of metastatic prostate cancer, however the majority of patients eventually develop resistance.  Materials and Methods: Eighty kinase inhibitors were screened regarding their ability to inhibit cell viability in CWR22, 22Rv1, PC-3 and DU145 prostate cancer cells using automated toxicity assays.  Four kinase inhibitors were selected for further investigation.  Results: No significant difference in sensitivity patterns was found between the androgen receptor wild-type CWR22 and its androgen receptor mutant variant 22Rv1, indicating that androgen receptor mutation did not impact on kinase inhibitor sensitivity in this model.  Metastatic PC-3 and DU145 prostate cancer cell lines were less sensitive to kinase inhibitors than the non-metastatic CWR22 and 22Rv1.  All four cell lines responded to GSK-3 inhibitor BIO, and MEK inhibitor PD198306.  DU145 cells were resistant to p75NTR/TrkA and CHK4 inhibitors, RO-082750 and Ryuvidine.  Conclusion: Kinase inhibition may be an appropriate strategy for the treatment of prostate cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrdh-H_JcuOj7Vg90H21EOLACvtfcHk0ljhfyBxihCs_A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtFalsLbE&md5=6688d5c15abed4a9cb078efbcd35ac3a</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBurke%26aufirst%3DA.%2BJ.%26aulast%3DAli%26aufirst%3DH.%26aulast%3DO%25E2%2580%2599Connell%26aufirst%3DE.%26aulast%3DSullivan%26aufirst%3DF.%2BJ.%26aulast%3DGlynn%26aufirst%3DS.%2BA.%26atitle%3DSensitivity%2520profiles%2520of%2520human%2520prostate%2520cancer%2520cell%2520lines%2520to%2520an%252080%2520Kinase%2520inhibitor%2520panel%26jtitle%3DAnticancer%2520Res.%26date%3D2016%26volume%3D36%26spage%3D633%26epage%3D641" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Skehan, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Storeng, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scudiero, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Monks, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McMahon, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vistica, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Warren, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bokesch, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kenney, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boyd, M. R.</span></span> <span> </span><span class="NLM_article-title">New colorimetric cytotoxicity assay for anticancer-drug screening</span>. <i>J. Natl. Cancer Inst.</i> <span class="NLM_year" style="font-weight: bold;">1990</span>,  <span class="NLM_volume"><i>82</i></span>,  <span class="NLM_fpage">1107</span>– <span class="NLM_lpage">1112</span>, <span class="refDoi"> DOI: 10.1093/jnci/82.13.1107</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02008&amp;key=10.1093%2Fjnci%2F82.13.1107" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02008&amp;key=2359136" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02008&amp;key=1%3ACAS%3A528%3ADyaK3cXltVylsL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=82&publication_year=1990&pages=1107-1112&author=P.+Skehanauthor=R.+Storengauthor=D.+Scudieroauthor=A.+Monksauthor=J.+McMahonauthor=D.+Visticaauthor=J.+T.+Warrenauthor=H.+Bokeschauthor=S.+Kenneyauthor=M.+R.+Boyd&title=New+colorimetric+cytotoxicity+assay+for+anticancer-drug+screening&doi=10.1093%2Fjnci%2F82.13.1107"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">New colorimetric cytotoxicity assay for anticancer-drug screening</span></div><div class="casAuthors">Skehan, Philip; Storeng, Ritsa; Scudiero, Dominic; Monks, Anne; McMahon, James; Vistica, David; Warren, Jonathan T.; Bokesch, Heidi; Kenney, Susan; Boyd, Michael R.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the National Cancer Institute</span>
        (<span class="NLM_cas:date">1990</span>),
    <span class="NLM_cas:volume">82</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">1107-12</span>CODEN:
                <span class="NLM_cas:coden">JNCIEQ</span>;
        ISSN:<span class="NLM_cas:issn">0027-8874</span>.
    </div><div class="casAbstract">A rapid, sensitive, and inexpensive method was developed for measuring the cellular protein content of adherent and suspension cultures in 96-well microtiter plates.  The method is suitable for ordinary lab. purposes and for very large-scale applications, such as the National Cancer Institute's disease-oriented in vitro anticancer-drug discovery screen, which requires the use of several million culture wells per yr.  Cultures fixed with trichloroacetic acid were stained for 30 min with 0.4% (wt/vol) sulforhodamine B (SRB) dissolved in 1% acetic acid.  Unbound dye was removed by four washes with 1% acetic acid, and protein-bound dye was extd. with 10 mM unbuffered Tris base [tris(hydroxymethyl)aminomethane] for detn. of optical d. in a computer-interfaced, 96-well microtiter plate reader.  The SRB assay results were linear with the no. of cells and with values for cellular protein measured by both the Lowry and Bradford assays at densities ranging from sparse subconfluence to multilayered supraconfluence.  The signal-to-noise ratio at 564 nm was approx. 1.5 with 1,000 cells per well.  The sensitivity of the SRB assay compared favorably with sensitivities of several fluorescence assays and was superior to those of both the Lowry and Bradford assays and to those of 20 other visible dyes.  The SRB assay provides a colorimetric end point that is nondestructive, indefinitely stable, and visible to the naked eye.  It provides a sensitive measure of drug-induced cytotoxicity, is useful in quantitating clonogenicity, and is well suited to high-vol., automated drug screening.  SRB fluoresces strongly with laser excitation at 488 nm and can be measured quant. at the single-cell level by static fluorescence cytometry.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrA1MIZ3rkcqLVg90H21EOLACvtfcHk0ljhfyBxihCs_A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3cXltVylsL8%253D&md5=d7bc1784a1f181842d2999efa7fa870c</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1093%2Fjnci%2F82.13.1107&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fjnci%252F82.13.1107%26sid%3Dliteratum%253Aachs%26aulast%3DSkehan%26aufirst%3DP.%26aulast%3DStoreng%26aufirst%3DR.%26aulast%3DScudiero%26aufirst%3DD.%26aulast%3DMonks%26aufirst%3DA.%26aulast%3DMcMahon%26aufirst%3DJ.%26aulast%3DVistica%26aufirst%3DD.%26aulast%3DWarren%26aufirst%3DJ.%2BT.%26aulast%3DBokesch%26aufirst%3DH.%26aulast%3DKenney%26aufirst%3DS.%26aulast%3DBoyd%26aufirst%3DM.%2BR.%26atitle%3DNew%2520colorimetric%2520cytotoxicity%2520assay%2520for%2520anticancer-drug%2520screening%26jtitle%3DJ.%2520Natl.%2520Cancer%2520Inst.%26date%3D1990%26volume%3D82%26spage%3D1107%26epage%3D1112%26doi%3D10.1093%2Fjnci%2F82.13.1107" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Matheson, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McNamee, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alaoui-Jamali, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tari, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jean-Claude, B. J.</span></span> <span> </span><span class="NLM_article-title">The combi-targeting concept: dissection of the binary mechanism of action of the combi-triazene SMA41 in vitro and antitumor activity in vivo</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>311</i></span>,  <span class="NLM_fpage">1163</span>– <span class="NLM_lpage">1170</span>, <span class="refDoi"> DOI: 10.1124/jpet.104.071977</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02008&amp;key=10.1124%2Fjpet.104.071977" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02008&amp;key=15358812" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02008&amp;key=1%3ACAS%3A528%3ADC%252BD2cXhtVKmtLjF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=311&publication_year=2004&pages=1163-1170&author=S.+L.+Mathesonauthor=J.+P.+McNameeauthor=T.+Wangauthor=M.+A.+Alaoui-Jamaliauthor=A.+M.+Tariauthor=B.+J.+Jean-Claude&title=The+combi-targeting+concept%3A+dissection+of+the+binary+mechanism+of+action+of+the+combi-triazene+SMA41+in+vitro+and+antitumor+activity+in+vivo&doi=10.1124%2Fjpet.104.071977"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">The combi-targeting concept: Dissection of the binary mechanism of action of the combi-triazene SMA41 in vitro and antitumor activity in vivo</span></div><div class="casAuthors">Matheson, Stephanie L.; McNamee, James P.; Wang, Taiqui; Alaoui-Jamali, Moulay A.; Tari, Ana M.; Jean-Claude, Bertrand J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">311</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1163-1170</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">We have previously reported the synthesis of SMA41, a unimol. combination of an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) of the quinazoline class and a DNA-damaging monomethyltriazene termed "combimol.".  Hydrolysis of 1-[4-(m-tolylamino)-6-quinazolinyl]-3-methyltriazene (SMA41) gives rise to an intact TKI [6-amino-4-(3-methylanilino)quinazoline; SMA52] capable of inhibiting epidermal growth factor (EGF)-induced EGFR autophosphorylation and a DNA-targeting methyldiazonium species.  Herein, we showed that SMA41 blocked EGF-induced EGFR autophosphorylation by an irreversible mechanism, suggesting that it may covalently damage the receptor in these cells.  More importantly, this was assocd. with significant inhibition of mitogen-activated protein kinase activation in A431 cells.  In cells treated with [14C]SMA41, radio-high-performance liq. chromatog. detection of both N7- and O6-methylguanine revealed an almost complete repair of the O6-methylguanine lesions and a greater tolerance of the N7-methylguanine adducts 24 h post-treatment.  In contrast to temozolomide (a cyclic triazene used in the clinic) and the reversible inhibitor SMA52, SMA41 induced significant cell cycle arrest in S, G2, and M phases 24 h after a 2-h drug exposure.  Furthermore, in vivo studies demonstrated that SMA41 was well tolerated.  At 200 mg/kg, it showed approx. 2-fold greater antiproliferative activity than SMA52 in A431 cells implanted in immunocompromised SCID mice.  These results suggest that the binary targeting properties of SMA41 are assocd. with a binary cascade of events in the cells that seem to culminate into significant growth inhibition in vitro and in vivo.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqkhi3W-ADWZLVg90H21EOLACvtfcHk0ljb9dGFWH_IOw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXhtVKmtLjF&md5=e4d1a0bfe3202e961e7e2a1f2ecb8d21</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1124%2Fjpet.104.071977&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.104.071977%26sid%3Dliteratum%253Aachs%26aulast%3DMatheson%26aufirst%3DS.%2BL.%26aulast%3DMcNamee%26aufirst%3DJ.%2BP.%26aulast%3DWang%26aufirst%3DT.%26aulast%3DAlaoui-Jamali%26aufirst%3DM.%2BA.%26aulast%3DTari%26aufirst%3DA.%2BM.%26aulast%3DJean-Claude%26aufirst%3DB.%2BJ.%26atitle%3DThe%2520combi-targeting%2520concept%253A%2520dissection%2520of%2520the%2520binary%2520mechanism%2520of%2520action%2520of%2520the%2520combi-triazene%2520SMA41%2520in%2520vitro%2520and%2520antitumor%2520activity%2520in%2520vivo%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2004%26volume%3D311%26spage%3D1163%26epage%3D1170%26doi%3D10.1124%2Fjpet.104.071977" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i32"><a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.9b02008">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_13475"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acs.jmedchem.9b02008?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acs.jmedchem.9b02008</a>.<ul id="rightTab-silist" class="NLM_list-list_type-label"><li><p class="inline">Supplementary figures, molecular modeling, and NMR and HRMS spectra and HPLC chromatograms of the final compound <b>JS230</b> (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.9b02008/suppl_file/jm9b02008_si_001.pdf">PDF</a>)</p></li><li><p class="inline">Molecular strings of compounds <b>1</b>–<b>6</b> and <b>JS230</b> (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.9b02008/suppl_file/jm9b02008_si_002.csv">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.9b02008/suppl_file/jm9b02008_si_001.pdf">jm9b02008_si_001.pdf (3.4 MB)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.9b02008/suppl_file/jm9b02008_si_002.csv">jm9b02008_si_002.csv (0.52 kb)</a></li></ul></div></div><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.9b02008&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bwgroup%3Astring%3AACHS+website+Group%3Bwebsite%3Awebsite%3Aacspubs%3BpageGroup%3Astring%3APublication+Pages%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.9b02008%3BsubPage%3Astring%3AFull+Text%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2020.63.issue-11" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.9b02008" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                5MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"677a6a818f783c1c","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
